2016N272781_11 CONFIDENTIA L
GlaxoSmithKline group of companies 205646
1TITLE PA GE
Protocol Title: A Phase 3, Multi -Center, Randomized, Double -Blind, Placebo -
Controlled, 104 -Week Study  to Evaluate the Efficacy  and Safet y of Belimumab 
Administered in Combination with Rituximab to Adult Subjects with Sy stemic L upus 
Erythematosus (SLE)
Protocol Number : 205646 Amendment 04(Global )
Short Title : A Phase 3 Study  to Evaluate the Efficacy  and Safet y of Belimumab 
Administered in Combination with Rituximab to Adult Subjects with Sy stemic L upus 
Erythematosus (SL E)–BLISS -BELIEV E
Compound Number: [COMPANY_004]1550188
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_658596] Information can be found in the Study  Reference 
Manual .
Regulatory Agency Identifying Number(s):
[LOCATION_002] Food and Drug Administration I dentify ing Number(s): IND 009970 ; 
EudraCT number: 2016 -003050 -32
Approval Date: 30-APR -2020
Copy right 2020the GlaxoSmithKline group of companies. All rights reserved.   
Unauthorised cop ying or use of this information is prohibited.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N272781_11 CONFIDENTIA L
205646
3PROTOCOL AMENDMENT SUMMARYOFCHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 4 (Global) 30-Apr-2020
Amendment 3 (Global) 15-Aug-2019
Amendment 2 / KOR -1 02-Feb-2019
Amendment 2 / ARG -1 11-Dec-2018
Amendment 2 / DEU -2 28-Nov-2018
Amendment 2 (Global) 17-Nov-2018
Amendment 1 /ARG -1 02-Jul-2018
Amendment 1/DEU -2 27-Nov-2017
Amendment 1/DEU -[ADDRESS_658597]-2017
Amendment 1/KOR -1 22-Jun-2017
Amendment 1 (Global) 17-Apr-2017
Original Protocol 16-Jan-2017
Amendment 0 4(Global) :30-APR -2020
Rationale for the Amendment: In response to the COVID -[ADDRESS_658598] patient safet y and data integrity .1) Visit windows are 
being conditionally  extended for all subject visits for the study .2) Clarification that the 
independent blinded assessor can be called upon to perform the S2K efficacy  assessment 
at an unscheduled visit. 3 ) In the event that subjects are unable to visit the site, i t is 
acceptable for sites to supply  investigational product (belimumab) to subjects by  
[CONTACT_509436] .4) Clarification rega rding acceptable use and dosage of anti-
malarial treatment s(e.g. hydroxychloroquine ).5)Change to the language describing the 
timing of the primary  analy sis.6)Recommendations for safety  contact [CONTACT_509437] s.7) Guidance for stud y treatment discontinuation 
if a subject has suspected or confirmed COVID -[ADDRESS_658599] been made which are unrelated to 
the COVID -19 pandemic .
Section # and Name [CONTACT_62578] o f Change Brief Rationale
1. Synopsis, Table of 
endpointsSecondary endpoint “ Time to 
clinical remission sustained to 
Week 64, defined as Clinical 
SLEDAI -2K score =0, achieved 
without immunosuppressants 
and with corticosteroids at a 
prednisone equivalent do se of 
0 mg/day.”
changed to Correction of error and 
alignm ent of the protocol with 
the reporting and analysis plan.
2016N272781_11 CONFIDENTIA L
205646
4Section # and Name [CONTACT_62578] o f Change Brief Rationale
“Time to clinical remission 
sustained to Week 104, 
defined as Clinical SLEDAI -2K 
score =0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone 
equivalent dose of 0 mg/day.”
2: Sch edule of Activities 
(SoA) Table 1,Table 2,Table 
3and Table 4Visit windows. Footnote a–if 
the COVID -[ADDRESS_658600] visits within 
the p rotocol defined windows 
(±7 days), then it is permissible 
to use an expanded visit 
window (±28 days).
Unscheduled visit. The column 
for this visit in Table [ADDRESS_658601] key efficacy 
and safety data.
Provides greater flexibility to 
sites for obtaining the blinded 
assessor’s S2K assessment if 
subjects are unable to attend 
protocol defined visits.
Correction. It is not essential for 
the interviews to be conducted 
prior to clinical assessments.
4:Objectives and Endpoints Secondary endpoint “ Time to 
clinical remission sustained to 
Week 64, defined as Clinical 
SLEDAI -2K score =0, achieved 
without immunosuppressants 
and with corticosteroids at a 
prednisone equivalent dose of 
0 mg/day.”Correction of error and 
alignment of protocol with 
reporting a nd analysis plan.
2016N272781_11 CONFIDENTIA L
205646
5Section # and Name [CONTACT_62578] o f Change Brief Rationale
changed to 
“Time to clinical remission 
sustained to Week 104, 
defined as Clinical SLEDAI -2K 
score =0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone 
equivalent dose of 0 mg/day.”
7.[ADDRESS_658602] them.Allow subjects to continue 
treatment w ith belimumab if 
unable to visit the site, for 
example, as a consequence of 
the COVID -19 pandemic.
7.7.1 Allowable medications Subsection [IP_ADDRESS] (Anti -
malarials) has been amended 
to include provision for subjects 
to have short term treatment 
with hydroxy chloroquine for 
reasons other than lupus, for 
example, experimental 
treatment of COVID -19.Response to potential change in 
use of anti -malarials as a 
consequence of the COVI D-[ADDRESS_658603] upon the timing and the 
estimands of the statistical 
analysis.
2016N272781_11 CONFIDENTIA L
205646
6Section # and Name [CONTACT_62578] o f Change Brief Rationale
A correction has been made in 
Section 10.4.1 to clarify that 
the MITT population (and not 
the ITT population) will be used 
to conduct the analysis of the 
primary and key secondary 
endpoints.Correction and alignment of 
protocol with the reporting and 
analysis plan.
Appendix 9. Clinical 
Laboratory TestsLanguage added to clarify that 
local laboratory tests are 
recommended if disruption as a 
consequence of COVID -19 
prevents or delays central 
laboratory tests.Support continued safety and 
efficacy assessment in response 
to COVID -19.
Appendix 13. Protocol 
Amendment HistoryHas been fully updated with 
details of all global and country 
specific amendment s.Provide complete history of 
amendments.
Throughout protocol Minor editorial revisions Corrections of typographical 
errors and minor revisions for 
clarity.
2016N272781_11 CONFIDENTIA L
205646
7TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE................................ .....3
1.SYNOPSIS ................................ ................................ ................................ ............. 10
2.SCHEDULE OF ACTIVITI ES (SOA) ................................ ................................ .......19
3.INTRODUCTION ................................ ................................ ................................ ....34
3.1. Study Rationale ................................ ................................ .......................... 34
3.2. Background ................................ ................................ ................................ 34
3.3. Benefit/Risk Assessment ................................ ................................ ............ 36
3.3.1. Risk Assessment ................................ ................................ ......... 37
3.3.2. Benefit Assessment ................................ ................................ .....44
3.3.3. Overall Benefit: Risk Conclusion ................................ .................. 44
4.OBJECTIVES AND ENDPO INTS ................................ ................................ ........... 44
5.STUDY DESIGN ................................ ................................ ................................ ....50
5.1. Overall Design ................................ ................................ ............................ 50
5.2. Number of Participants ................................ ................................ ............... 54
5.3. Participant and Study Completion ................................ ............................... 54
5.4. Scientific Rationale for Study Design ................................ .......................... 54
5.4.1. Selection of Contro ls................................ ................................ ....54
6.STUDY POPULATION ................................ ................................ ........................... 55
6.1. Inclusion Criteria ................................ ................................ ......................... 55
6.2. Exclusion Criteria ................................ ................................ ........................ 57
6.3. Lifestyle Restrictions ................................ ................................ ................... 60
6.4. Screen Failures ................................ ................................ ........................... 60
7.TREATMENTS ................................ ................................ ................................ .......60
7.1. Treatments Administered ................................ ................................ ............ 61
7.1.1. Medical Devices ................................ ................................ ........... 62
7.2. Dose Modification ................................ ................................ ....................... 63
7.3. Method of Treatment Assignment ................................ ............................... 63
7.4. Blinding ................................ ................................ ................................ .......63
7.5. Preparation/Handling/Storage/Accountability ................................ .............. 64
7.6. Treatment Compliance ................................ ................................ ................ 65
7.7. Concomitant Therapy ................................ ................................ .................. 66
7.7.1. Allowable Medications ................................ ................................ .66
[IP_ADDRESS]. Anti-malarials ................................ .............................. 67
[IP_ADDRESS]. Corticosteroids ................................ ........................... 67
[IP_ADDRESS]. Corticosteroids for Reasons Other Than SLE 
Disease Activity ................................ .......................... 69
[IP_ADDRESS]. Other Immunosuppressant Agents ............................. 69
[IP_ADDRESS]. Nonsteroidal Anti -inflammatory Drugs 
(NSAIDs), Aspi[INVESTIGATOR_248], and Acetaminophen ...................... [ADDRESS_658604] to Follow Up ................................ ................................ ........................ 77
9.STUDY ASSESSMENTS AN D PROCEDURES ................................ ..................... 77
9.1. Screening Assessments ................................ ................................ ............. 78
9.2. Assessments at Baseline ................................ ................................ ............ 80
9.3.Assessments at Scheduled Visits ................................ ............................... 80
9.4. Assessments at Unscheduled Visits ................................ ........................... 80
9.5. Assessments at Early W ithdrawal Visits and Follow -up Visits ..................... 81
9.6. Efficacy Assessme nts................................ ................................ ................. 81
9.6.1. Patient -Reported Outcomes Assessments ................................ ...82
9.7. Adverse Events ................................ ................................ ........................... 83
9.7.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................ ................................ ................... 84
9.7.2. Method of Detecting AEs and SAEs ................................ ............. 84
9.7.3. Follow -up of AEs and SAEs ................................ ......................... 84
9.7.4. Regulatory Reporting Requirements for SAEs ............................. 84
9.7.5. Cardiovascular and Death Events ................................ ................ 85
9.7.6. Pregnancy ................................ ................................ ................... 85
9.7.7. Medical Device Incidents ................................ ............................. 85
[IP_ADDRESS]. Time Period for Detecting Medical Device 
Incidents ................................ ................................ .....86
9.7.7 .2. Follow -up of Medical Device Incidents ........................ 86
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents 
to Sponsor ................................ ................................ ..86
9.7.8. Device Malfunction ................................ ................................ ......87
9.8. Treatment of Overdose ................................ ................................ ............... 87
9.9. Safety Assessments ................................ ................................ ................... 88
9.9.1. Physical Examinations ................................ ................................ .88
9.9.2. Vital Signs ................................ ................................ .................... 88
9.9.3. Electrocardiograms ................................ ................................ ......88
9.9.4. Clinical Safety Laboratory Assessments ................................ ......88
9.9.5. Neurological Assessment ................................ ............................ 89
9.9.6. Suicidal Risk Monitoring ................................ ............................... 89
9.10. Pharmacokinetics ................................ ................................ ....................... 90
9.11. Pharmacodynamics ................................ ................................ .................... 90
9.12. Genetics ................................ ................................ ................................ .....91
9.13. Biomarkers ................................ ................................ ................................ .91
9.13.1. Immunogenicity Assessments ................................ ...................... 91
9.13.2. RNA ................................ ................................ ............................. 91
9.13.3. B Cell Receptors ................................ ................................ .......... 91
9.13.4. BLyS Protein ................................ ................................ ................ 91
9.14. Medical Resource Utilization and Health Economics ................................ ..92
2016N272781_11 CONFIDENTIA L
205646
910.STATISTICAL CONSIDER ATIONS ................................ ................................ ........ 92
10.1. Hypotheses ................................ ................................ ................................ .92
10.1.1. Analysis for Marketing Application ................................ ............... 93
10.2. Sample Size Determination ................................ ................................ ........ 93
10.3. Populations for Analyses ................................ ................................ ............ 94
10.4. Statistical Analyses ................................ ................................ ..................... 95
10.4.1. Efficacy Analyses ................................ ................................ ......... 95
10.4.2. Safety Analyses ................................ ................................ ........... 97
10.4.3. Other Analyses ................................ ................................ ............ 97
10.4.4. Interim Analyses ................................ ................................ .......... 98
11.REFERENCES ................................ ................................ ................................ .......99
12.APPENDICES ................................ ................................ ................................ ......101
12.1. Appendix 1:Abbreviations and Trademarks ................................ ............... 101
12.2. Appendix 2:Recommended Corticostero id Taper Schedule ...................... 103
12.3. Appendix 3: Contraceptive Guidance and Collection of Pregnancy 
Information ................................ ................................ ................................ 105
12.4. Appendix 4:Study Governance Considerations ................................ ......... 108
12.5. Appendix 5:Liver Safety: Required Actions and Follow -up 
Assessments ................................ ................................ ............................ 112
12.6. Appendix 6:Liver Safety Study Treatment Restart Guidelines ................... 115
12.7. Appendix 7:Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ................................ .....116
12.8. Appendix 8:Medical Device Incidents: Definition and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ................................ .....122
12.9. Appendix 9: Clinical Laboratory Tests ................................ ........................ 124
12.10. Appendix 10:Genetics ................................ ................................ ............... 127
12.11. Appendix 11: American College of Rheumatology (ACR) Criteria for 
SLE................................ ................................ ................................ ........... 128
12.12. Appendix 12:Country -specific requirements ................................ .............. 129
12.13. Appendix 13: Protocol Amendment History ................................ ............... 131
2016N272781_11 CONFIDENTIA L
205646
101. SYNOPSIS
Protocol Title: A Phase 3, Multi -Center, Randomized, Double -Blind, Placebo -
Controlled, 104 -Week Study  to Evalu ate the Efficacy  and Safet y of Belimumab 
Administered in Combination with Rituximab to Adult Subjects with Sy stemic L upus 
Erythematosus (SL E)
Short Title: A Phase 3 Study  to Evaluate the Efficacy  and Safet y of Belimumab 
Administered in Combination with Rit uximab to Adult Subjects with Sy stemic L upus 
Erythematosus (SL E)-BLISS -BELIEVE
Rationale:
SLE is characterized by  [CONTACT_221970], including antibodies to double -stranded DNA 
(dsDNA), and b y abnormal B cell activation and differentiation , indicating that therapi[INVESTIGATOR_509404] B cells could be beneficial in treating SL E. Belimumab and 
rituximab are monoclonal antibodies that achieve their expected pharmacology  through 
different but complementary  mechanisms; therefore, based on their mechanisms of 
action, sy nergistic effects when used in combination in the treatment of SLE are possible
compared to either treatment alone. Belimumab treatment increases peripheral memory  B 
cells potentially  by [CONTACT_509438] B cell 
compartment. This mobilization would expose these cells to more efficient depletion by  
[CONTACT_4124]. Continuing belimumab after a single course of rituximab would then suppress 
the B-lymphocy te stimulator ( BLyS)elevation observed after rituximab monotherap y, 
thus suppressing the signal which leads to rapid repopulation of B cells, including 
autoreactive B cells. This study  will assess whether co -administration of belimumab and 
a single cy cleof rituximab may  optimize treatment with belimumab, resu lting in 
improvements in clinical status with a favorable safety  profile. 
Objectives and Endpoints: 
The key  evaluations are based on comparing belimumab with or without a single cy cle of 
rituximab (the combination arm vs. the control arm). There are limi ted analy ses planned 
to compare the combination of belimumab with a single cy cle of rituximab (combination 
arm) to belimumab with standard therap y (reference arm) .Details of the analy ses to be 
conducted will be described in the Reporting and Analy sis Plan (RAP), including 
analysis of the combination arm vs. the control arm and the combination arm vs. the 
reference arm.
Objectives Endpoints
Primary: Efficacy
To evaluate the efficacy of belimumab and 
a single cycle of rituximab administered in a 
combinati on regimen to adult participants 
with SLE.Proportion of participants with a state of 
disease control defined as a Systemic 
Lupus Erythematosus Disease Activity 
Index (SLEDAI) -2K score 2, achieved 
without immunosuppressants and with 
2016N272781_11 CONFIDENTIA L
205646
11Objectives Endpoints
corticosteroids at a prednisone equivalent 
dose of 5mg/day at Week 52. 
Secondary: Efficacy (Major) Proportion of participants with a state of 
clinical remission defined as a Clinical 
SLEDAI -2K score =0, achieved without 
immunosuppressants and with 
corticosteroids at a pred nisone equivalent 
dose of 0 mg/day at Week 64. (Serological 
activity score , i.e., anti -dsDNA positivity 
and/or hypocomplementemia, is excluded 
from the Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
disease control defined as a SL EDAI -2K
score 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5mg/day at Week 104. 
Secondary: Efficacy (Other) Proportion of participants with a state of 
disease control, defined as a SLEDAI -2K 
score 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5 mg/day, by [CONTACT_765].
Proportion of participants with a state of 
clinical remission, defined as a Clinical 
SLEDAI -2K score =0, achieved without 
immunosuppre ssants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765]. (Serological 
activity score, i.e., anti -dsDNA positivity 
and/or hypocomplementemia, is excluded 
from the Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
complete remission, defined as SLEDAI -2K 
score=0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, su stained for at least 
24weeks .
Proportion of participants with a state of 
clinical remiss ion, defined as Clinical 
SLEDAI -2K score =0, achieved without 
2016N272781_11 CONFIDENTIA L
205646
12Objectives Endpoints
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, sustained for at least 24 
weeks. (Serological activity score, i.e., anti -
dsDNA positivity and/or 
hypocomp lementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
complete remission, defined as a SLEDAI -
2K score =0 ,achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765] 
Time to first severe flare (as measured by 
[CONTACT_509439])
Time to first flare (as measured by [CONTACT_509440])
Time to disease control sustained to Week 
104, defined as SLEDAI -2K score 2, 
achieved without imm unosuppressants and 
with corticosteroids at a prednisone 
equivalent dose of 5 mg/day.
Time to clinical remission sustained to 
Week 104, defined as Clinical SLEDAI -2K 
score =0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone eq uivalent 
dose of 0 mg/day. (Serological activity, i.e., 
anti-dsDNA positivity and/or 
hypocomplementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.)
Duration of disease control , defin ed as 
SLEDAI -2Kscore 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5 mg/ day
Duration of clinical remission , defined as 
Clinical SLEDAI -2K score =0, achieved 
without immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day. (Serological activity, i.e., 
anti-dsDNA positivity and/or 
2016N272781_11 CONFIDENTIA L
205646
13Objectives Endpoints
hypocomplementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.)
Change from baseline in SLEDAI -2K score 
by [CONTACT_765]
Proportion of participants with SLEDAI -2K 
organ improvement by [CONTACT_765]
Proportion of partic ipants with SLEDAI -2K 
organ worsening by [CONTACT_765]
Change from baseline in Physician Global 
Assessment (PGA) by [CONTACT_765]
Proportion of participants with any SLICC 
Damage Index worsening (change >0) 
compared with baseline at Week 52 and 
Week 104
Proportion of part icipants that meet the 
Lupus Low Disease Activity State (LLDAS) 
response criteria by [CONTACT_765] . The LLDAS 
incorporates multiple measures of disease 
activity, specifically: (1) SLEDAI -2K 4, with 
no activity in major organ systems (renal, 
CNS, cardiopulmonary, vasculitis, fever) 
and no hemolytic anemia or gastrointestinal 
activity; (2) no new features of lupus 
disease activity compared with the previous 
assessment; (3) PGA (scale 0 -3) 1; (4) 
current prednisolone (or equivalent) dose 
7.5 mg daily; and (5) well tolerated 
standard maintenance doses of 
immunosuppressive drugs and approved 
biological agents, excluding investigational 
drugs.
Proportion of participants with a state of 
disease control, defined as a SLEDAI -2K 
score 2, achieved without 
immunosuppressant s and with 
corticosteroids at a prednisone equivalent 
dose of 5 mg/day, by [CONTACT_765]; using the 
Principal Investigators assessment of 
SLEDAI -2K.
Proportion of participants with a state of 
clinical remission, defined as a Clinical 
SLEDAI -2K score =0, achieved without 
2016N272781_11 CONFIDENTIA L
205646
14Objectives Endpoints
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765]; using the 
Principal Investigators assessment of 
SLEDAI -2K. (Serological activity score, i.e. 
anti-dsDNA positivity and/or 
hypocomplementemia, is excl uded from the 
Clinical SLEDAI -2K endpoint.)
Secondary: Safety
To assess the safety and tolerability of 
belimumab and a single cycle of rituximab 
administered in a combination regimen to 
adult participants with SLEIncidence of adverse events (AEs) inclu ding 
serious AEs (SAEs) and AEs of special 
interest (AESIs)
Secondary: Patient Reported Outcomes 
(PROs)
To assess the impact of belimumab and a 
single cycle of rituximab administered in a 
combination regimen to adult participants 
with SLE on PROsChange from baseline in Patient Global 
Assessment (PtGA )by [CONTACT_765]
Change from baseline in LupusQoL domain 
summary score s (8 domains) by [CONTACT_765] 
Change from baseline in FACIT -Fatigue 
score by [CONTACT_765] 
Proportion of participants with improvement 
in FACIT -Fatigue scor e exceeding the 
Minimal Clinically Important Difference 
(MCID, 4) by [CONTACT_509441]: Pharmacokinetics and 
Biomarkers
To assess pharmacokinetics of and 
biomarker response to belimumab and a 
single cycle of rituximab administered in a 
combination regi men to adult participants 
with SLEBelimumab and rituximab concentrations by 
[CONTACT_765]
Change from baseline in autoantibodies by 
[CONTACT_765]
Change from baseline in peripheral blood 
leukocytes including B cell subsets by [CONTACT_765]
Change in BLyS levels from baseline by [CONTACT_765]
2016N272781_11 CONFIDENTIA L
205646
15Objectives Endpoints
Exploratory: Patient Reported Work 
Productivity
To explore the impact of belimumab and a 
single cycle of rituximab administered in a 
combination regimen to adult participants 
with SLE on patient experience and 
productivity Change from baseline in Work Productivity 
and Activity Impairment (WPAI): Lupus 
percent o verall work productivity impairment 
by [CONTACT_765] 
Change from baseline in WPAI: Lupus 
percent activity impairment score by [CONTACT_509442]:
This is a Phase 3, multi -center, 3 -arm, randomi zed, double -blind, placebo -controlled, 
104week superiority  study  to evaluate the efficacy  and safet y of belimumab administered 
in combination with a single cy cle of rituximab to adult participants with SLE. 
Participants will be randomly  assigned to 1 of 3 treatment arms; belimumab plus 
rituximab -placebo (Arm A , control ), belimumab plus rituximab (Arm B , combination ), or 
open -label belimumab plus standard therapy  (Arm C , reference ). Blinded independent 
assessors will conduct the SL EDAI -2K at key  time points . An I ndependent Data 
Monitoring Committee (IDMC) will review the safety  data on a regular basis.
Number of Participant s:
A total of approximately 560participants are expected to be screened, with a goal of 
randomizing at least 280participants ( 50% scree n failure rate).
The sample size may  be increased up to a maximum of [ADDRESS_658605] conclusions can be drawn. The decisi on to increase the 
sample size will be made without unblinding the trial.
Treatment Groups and Duration:
Overview
At least 280participants will be randomized in a 1:2:1 ratio to 1 of 3 arms: belimumab 
plus rituximab -placebo (Arm A, control, target N= 70),belimumab plus rituximab (Arm 
B, combination, target N= 140), or belimumab plus standard therapy  (Arm C, reference, 
target N= 70). Arms A and B are double -blind; participants will receive belimumab 200 
mg/week for 51 weeks. Arm C (reference) is an open -label arm with belimumab 
subcutaneous (SC) 200 mg/week and standard therapy  for 104 weeks. Arm C (reference)
will provide a qualitative reference to assess the relative performance of Arm A (control) 
and Arm B (combination) vs. currently  available standard SLE therapy  (Arm C). The 
concomitant medication rules and definitions of treatment failure are the same for the 
2016N272781_11 CONFIDENTIA L
[ADDRESS_658606] therapy  
at entry . At randomization, participants will be stratified by  [CONTACT_509443] -2K 
score ( 9 vs. 10),by [CONTACT_509444] (immunosuppressant use vs. 
no use) and b y screening corticosteroid dose (prednisone equivalent 10 mg/day  vs. 
>10mg/day ). Belimumab will be administered SC on Day  1 and then weekly  (i.e., every  
7 day s 1 day ) through Week 51 for Arms A and B, and through Week 103 for Arm C . 
SC injections will be administered at alternating injection sites between the left or right 
thighs and the abdomen. Rituximab -placebo or rituximab will be administered b y 
intravenous (IV) infusions at Weeks [ADDRESS_658607] all 
efficacy  and safet y assessments.
Participants randomized to Arms A or B who enter the study  on immunosuppressants will 
discontinue immunosuppressants prior to or on the day  of the Week 4 visit. Continuing 
the stable immunosuppressant dose until Week 4 allows participants to receive 3 weeks 
ofbelimumab SC prior to discontinuing their immunosuppressants. Corticosteroids may  
be adjusted as necessary  during this transition period. If participants in Arms A and B 
receive immunosuppressants after the Week 4 visit they will be deemed treatment 
failures. Participants in Arm C will continue their stable immunosuppressants throughout 
the study  at the discretion of the investigator. If participants in Arm C require an 
increased dose of their stable immunosuppressant after Week 1 2or addition of a new 
immunosuppressant they  will be considered a treatment failure .
After the initial 12 weeks of study  treatment, a protocol -specified corticosteroid taper will 
be initiated and conducted under the direction of the investigator for participants in all 
3arms. Th e taper will proceed with a target of reaching a prednisone equivalent dose of 
5mg/day  by [CONTACT_10585] 26. If the investigator believes the participant would benefit from 
continued steroid taper and, if tolerated, a prolonged corticosteroid taper should continue 
after Week 26 with the goal of corticosteroid discontinuation. Participants who are able to 
tolerate the final taper will be withdrawn from corticosteroids. If a participant is unable to 
tolerate the final stage of the corticosteroid taper, the investigato r may  reinitiate 
corticosteroids at a prednisone equivalent dose of up to and including 5 mg/day . If a 7-
day average prednisone equivalent dose of >5 mg/day  is required at any  time after 
Week 26visit (i.e., beginning first day  of Week 27) , the participant will be considered a 
treatment failure for the efficacy  endpoints. 
Anti-malarial therapi[INVESTIGATOR_509405] E may not be initiated during the study , but may  be 
continued or dose -adjusted during the study , and will be allowed within the definitions of 
2016N272781_11 CONFIDENTIA L
205646
17the efficacy  endpoints .  Switching of anti -malarial due to toxicity  or lack of availabili tyis 
permitted
Non-Steroidal Anti -Inflammatory  drugs ( NSAIDs )(for 7 day s) may  not be initiated 
during the stud y, but may be continued and dose adjusted as clinicall y indicated un til the 
Week 44 visit. After the Week 44 visit any  increase in the NSAID dose above the 
baseline (Day  1) or Week 44 dose, whichever is higher, will declare the participant as a 
treatment failure unless the NSAID is given for <7 day s.
During the 52 -week dou ble-blind portion of the study , participants in Arms A and B who 
cannot tolerate discontinuation of immunosuppressants or taper of corticosteroids or, in 
the opi[INVESTIGATOR_871], require added therapy , will be considered treatment 
failures for the efficacy  endpoints. Blinding to the treatment assignments in Arms A and 
B will be maintained. At the investigator's discretion, these participants may continue 
treatment with belimumab, and/or be treated with additional SL E therapi[INVESTIGATOR_509406] , 
includin g corticosteroids and/or immunosuppressants. Participants in Arm C who are 
unable to tolerate the corticosteroid taper or, in the opi[INVESTIGATOR_871], require 
increased doses of their baseline immunosuppressants or addition of a new 
immunosuppressa nt will be considered treatment failures for the efficacy  endpoints. 
Participants in Arms A and B will enter into the 52 -week treatment -free, observational 
phase of the stud y after completing Week 52 (Weeks 53 through 104). “Treatment -free” 
refers to no a ctive treatment with study  treatment (i.e., belimumab and/or rituximab). 
Participants in Arm C will continue to receive belimumab SC and their stable 
immunosuppressants during Weeks 53 through 104. For participants in all three treatment 
arms, treatment wi th anti -malarials, NSAIDs, and/or corticosteroids with a prednisone 
equivalent dose of 5 mg/day  will be allowed in Weeks 53 to 104. 
During Weeks 53 to 104, additional treatment may be given if the investigator believes 
the participant would benefit becau se he/she: a) responded to study  treatment but did not 
meet the primary  efficacy  endpoint, or b) responded to study  treatment but subsequently  
experienced increasing disease activity  which requires additional therap y. Additional 
treatment may  include open -label belimumab, corticosteroids (>5 mg/day ), and/or 
immunosuppressants, and will be administered at the discretion of the investigator. 
Treatment with open -label rituximab is allowed within the protocol, but is not 
encouraged. Belimumab will be provided b y the sponsor for those participants who 
reinitiate treatment with belimumab, but additional treatment with rituximab and/or other 
medications will not be provided b y the sponsor . NOTE: These participants will be 
considered treatment failures for the Week 64 efficacy  anal yses if the additional 
treatment (see above) occurs before theWeek 64visit, and for the Week [ADDRESS_658608] 
dose of study  treatment.
2016N272781_11 CONFIDENTIA L
205646
192. SCHEDULE OF ACTIVITI ES (SOA )
Table 1 Double -blind Treatment Phase Procedures: Year 1, A rms A  and B
Double -Blind Treatment Phase 
Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before 
D1)Treatment Period –Arms A and B (a) Unsched -
uled VisitEarly 
Withdrawal
Visit (b)Follow -
up visit 
([ADDRESS_658609] 
dose)D1
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32,
W36W40 W44, 
W48W52 (l)
Informed consent X
Inclusion and exclusion criteria X X (m)
Genetics Informed consent X(r)
Randomization X
Assessments : Clinic
Full physical exam including 
height and weight X
12-lead ECG X
Demography X
Medical history 
(includes substance usage)X
Past and current medical 
conditions including 
cardiovascular medical historyX
Vital signs X
Symptom -driven physical exam, 
vital signsX X X X X X X X X X X X X X X
Weight X X X X
Assessments: Independent Assesso r
SLEDAI -2K: Blinded Assessor (t) X X X X X X X
Assessments: Principal Investigator
[CONTACT_257441] -2K: Investigator X X X X X X X X X X X X X X
C-SSRS Baseline/Screening X
C-SSRS Since Last Visit X X X X X X X X X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
20Double -Blind Treatment Phase 
Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before 
D1)Treatment Period –Arms A and B (a) Unsched -
uled VisitEarly 
Withdrawal
Visit (b)Follow -
up visit 
([ADDRESS_658610] 
dose)D1
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32,
W36W40 W44, 
W48W52 (l)
Neur ological Assessment X X X X X X X X X X X X X X X X
SLE Flare Index (n) X X X X X X X X X X X X X
SLICC -ACR Damage Index X X X
Physician Global Assessment 
(PGA)X X X X X X X X X X X X X
Survival Assessment (d) X
Asse ssments: Patient Reported Outcomes (PROs)
Patient Global Assessment (c) X X X X X X X
FACIT -Fatigue (c) X X X X X X X
Lupus QoL (c) X X X X X X X
WPAI: Lupus (c) X X X X X X X
Post-treatment interview (o) X X
Central Laboratory Tests
Drug and alcohol screen X
HIV, Hep B and Hep C screen X
Pregnancy test (WCBP) (e) X X X X X X X X X X X X X X X X
Laboratory assessments (include 
liver chemistries)X X X X X X X X X X X X X X X X
Serum immunoglobulin 
(IgA, IgM, IgG)X X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X X X
Anti-dsDNA/ANA, 
Complement C3/C4X X X X X X X X X X X X X X X
Extractable nuclear antigens 
(ENAs)X X X X X
PT/PTT X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
21Double -Blind Treatment Phase 
Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before 
D1)Treatment Period –Arms A and B (a) Unsched -
uled VisitEarly 
Withdrawal
Visit (b)Follow -
up visit 
([ADDRESS_658611] 
dose)D1
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32,
W36W40 W44, 
W48W52 (l)
Antiphospholipid antibodies (aCL, 
lupus anticoagulant, beta-2-
glycoprotein -1)X X X X X X
Labs and Biomarkers
B cells subsets X X X X X X X X
BLyS Protein X X X
RNA for Interferon Signature X
Immunogenicity: Belimumab X X(f) X(f) X X X X X X
Immunogenicity: Rituximab X X(f) X(f) X X X X X
Pharmacokinetics: Belimumab X(f) X X X X X X
Pharmacokinetics: Rituximab X(g) X(g) X X X(h) X X X
Genetic sample X
Further Research
Blood Leukocyte Analysis 
(PBMC) (p)X X X
B cell receptor (q) X X X
B cells subsets (u) X X X X
Study Treatment
Training on use of Autoinjector X X
Dispense /Train or Collect 
Electronic DiaryX X
Dispense Belimumab for weekly 
dosing (SC)X (i) X(s) X X X X X X X
Rituximab or Rituximab -Placebo 
(IV)X 
(j)X 
(j)X
(j)
Discontinue immunosuppressants X
Initia te corticosteroid taper X (k)
2016N272781_11 CONFIDENTIA L
205646
22Double -Blind Treatment Phase 
Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before 
D1)Treatment Period –Arms A and B (a) Unsched -
uled VisitEarly 
Withdrawal
Visit (b)Follow -
up visit 
([ADDRESS_658612] 
dose)D1
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32,
W36W40 W44, 
W48W52 (l)
Target for steroid corticosteroid 
dose to reach prednisone 
equivalent 5 mg/dayX
Study Visit Review Procedures
AE/SAE review X X X X X X X X X X X X X X X
Concomitant medication review 
(including SLE medications)X X X X X X X X X X X X X X X X
Review HCRU and Patient Diary X X X X X X X X X X X X X
a. Starting at Week 4and throughout the study period including follow -up, a study visit time window 7 days is acceptable . Note: Every effo rt should be made to schedule the visit in 
this window , however if the COVID -19 pandemic situation affects the ability to achieve this then ,for those COVID -19 specific instances ,the visit window can be expanded to ±[ADDRESS_658613] at Screening; Urine pregnancy test at all oth er visits, including pregnancy test [ADDRESS_658614] requirements .
f. At Week 4 and Week 6 pre-rituximab/ rituximab -placebo dose.
g. At Week [ADDRESS_658615]-rituximab/rituximab -placebo dose and at Week [ADDRESS_658616] -rituximab/rituximab -placebo dose.
h. At Week [ADDRESS_658617] dose for observation.
j. Premedication administration will be given 30 minutes prior to each Rituximab / rituximab -placebo dose and the subject needs to stay in clini c for 1hour post dose for observation
(i.e., Clinical monitoring including vital signs ).If the subject misses the Week [ADDRESS_658618] rituximab dose . 
NOTE: Contact [CONTACT_509445] a) first dose is more than [ADDRESS_658619] week 4, and b) if the date o f the second dose of rituximab would exceed [ADDRESS_658620]
dose . During unscheduled visits, procedures for Immunogenicity and PK will follow the schedule for Week 4 and Week 6. 
k. It is recommended that the steroid taper be initiated on Week 12 to r each the target prednisone equivalent of 5 mg/day at Week 26, but the taper schedule is at the discretion of 
the investigator.
2016N272781_11 CONFIDENTIA L
205646
23l.Procedures to be performed at Unscheduled Visits are based on reason for Unscheduled Visit, including adverse event or discon tinuation of study agent. Please refer to Section 
9.4and to the g uidance provided in the Study Reference Manual.
m. The interim medical history, including SLE medications, should be reviewed prior to randomization to assure that the participant's eligibility has not changed.
n. Blood samples for a B cell receptor analysis should be obtained in the event of a suspected SLE Flare (refer to footnote q) .
o. To be conducted at US sites only . 
p. To be c onducted only at USstudy sites.
q. To be conduc ted only at US study sites. B-cell receptor samples are also collected at US sites when subjects experience a suspected SLE Flare.
r. Separate Genetics informed consent as needed per country specific requirements. Genetics informed consent and sample can be o btained any time after baseline .
s. If a subject happens to be scheduled for an infusion (week 4 and/or 6) on the same day of the week as their normally schedule d belimumab injection, whenever possible, the day 
of the belimumab injection should be altered wit hin the dosing window to separate the day of the injection from the day of the infusion to allow for appro priate safety monitoring of 
the infusion. If subject has already self -administered the belimumab dose on the day of IV infusion, contact [CONTACT_509446]/rituximab -placebo dose.
t. Independent assessor will perform symptom -driven physical examination to include, at a minimum, assessments of eyes, mouth, skin, lungs, cardiovascular system, abdomen, 
and extrem ities (including joints). Independent assessors must have a source document (paper record in the study file) where the findings in the clinical exam an d laboratory 
analyses supporting the scoring of S2K are described.
u. To be conducted only at select E uropean sites
2016N272781_11 CONFIDENTIA L
205646
24Table 2 Double -blind Observational Phase Procedures: Year 2, A rms A  and B
Observational Period –Arms A and B (a)
Arms A and B 
Double -blind Observational Phase Procedures
(W=Week)W60 W64 W72 W80 W88, 
W96W104 Unscheduled 
Visit (e)Early 
Withdrawal
Visit (f)Follow -up visit 
([ADDRESS_658621] dose) (j)
Assessments : Clinic
Symptom -driven physical exam, vital signs X X X X X X X X X
Weight X X
Assessments: Independent Assessor
SLEDAI -2K: Blinded Ass essor (m) X X X X X
Assessments: Principal Investigator
[CONTACT_257441] -2K: Investigator X X X X X X X X
C-SSRS Since Last Visit X X X X X X X X X
Neurological assessment X X X X X X X X X
SLE Flare Index (g) X X X X X X X X
SLICC -ACR Damage Index X X
Physician's Global Assessment (PGA) X X X X X X X X
Survival assessment (c) X
Assessments: Patient Reported Outcomes (PROs)
Patient Global Assessment (b) X X X X
FACIT -Fatigue ( b) X X X X
Lupus QoL ( b) X X X X
WPAI: Lu pus ( b) X X X X
Exit Interview (h) X X
Central Laboratory Tests
Urine pregnancy test (WCBP) (d) X X X X X X X X X
Laboratory assessments 
(include liver chemistries) X X X X X X X X X
Serum immunoglobulin (IgA, IgM, IgG) X X X X X X X X X
Urinalysis X X X X X X X X X
Anti-dsDNA/ANA, Complement C3/C4 X X X X X X X X X
Extractable nuclear antigens (ENAs) X X X X
PT/PTT X X X X
2016N272781_11 CONFIDENTIA L
205646
25Observational Period –Arms A and B (a)
Arms A and B 
Double -blind Observational Phase Procedures
(W=Week)W60 W64 W72 W80 W88, 
W96W104 Unscheduled 
Visit (e)Early 
Withdrawal
Visit (f)Follow -up visit 
([ADDRESS_658622] dose) (j)
Antiphospholipid antibodies (aCL, lupus 
anticoagulant, beta-2-glycoprotein -1)X X X X X
Labs and Biomarkers
B cells subsets X X X X X
BLyS Protein X X X X X X X
Immunogenicity: Belimumab X X X X X
Immunogenicity: Rituximab X X
Pharmacokinetics: Belimumab X X X X X X X
Pharmacokinetics: Rituximab X X X
Further Resea rch
Blood Leukocyte Analysis (PBMC) (k) X X X
B cell receptor (l) X X X
B cell subsets (n) X X X X X
Study Treatment
Collect Electronic Diary X X
Study Visit Review Procedures
AE/SAE review X X X X X X X X X
Concomitant medic ation review (including SLE 
medications)X X X X X X X XX
Review HCRU and P atient Diary(i) X X X X X X X X
a. During this study period including follow -up, a study visit time window 7 days is acceptable. Note: Every effort should be made to schedule t he visit in this window, however if the 
COVID -19 pandemic situation affects the ability to achieve this then, for those COVID -19 specific instances, the visit window can be expanded to ±[ADDRESS_658623] dose of rituximab / rituximab -placeb o(Week 58) and [ADDRESS_658624] dose of belimumab (Week 6 8) may be done at home, 
with the results repo rted by [CONTACT_509447]. See Section 9for pregnancy test requirements for participants that withdraw .(Argentina only: In addition to pregnancy 
testing at the specified clinic visits, a urine pregnan cy test is to be performed at home at Week 56, Week 68, Week 76, Week 84, Week 92, and Week 100, with the results 
reported by [CONTACT_509447].)
e. Procedures to be performed at Unscheduled Visits are based on reason for Unscheduled Visit, includi ng adverse event or discontinuation of study agent. Please refer to Section 
2016N272781_11 CONFIDENTIA L
205646
269.4and to the g uidance is provided in the Study Reference Manual.
f. Participants who withdraw from the study are required to complete an Early Withdrawal Visit 1 -4 weeks after withdrawal from the study.
g. Blood samples for a B cell receptor analysis should be obtained in the event of a suspected SLE Flare (refer to footnote l) .
h. To be conducted at US sites only. 
i. Diary review is only necessary if the patient receive Belimumab rescue therapy. 
j. Follow up visit is required only for subjects who receive belimumab rescue therapy at any time between Week 52 and Week 104.
k. To be conducted only at USstudy sites.
l. To be conducted only at US study sites. B-cell receptor samples are also collected when subjects at USsites experience a suspected SLE Flare.
m. Independent assessor will perform symptom -driven physical examination to include, at a minimum, assessments of eyes, mouth, skin, lungs, cardiovascular system, abdomen , 
and extrem ities (including joints). Independent assessors must have a source document (paper record in the study file) where the findings in the clinical exam an d laboratory 
analyses supporting the scoring of S2K are described.
n. To be conducted atselect Eu ropean centers.
2016N272781_11 CONFIDENTIA L
205646
27Table 3 Open -Label Treatment Phase Procedures: Year 1, A rm C
Treatment Phase Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before D1 )Treatment Period –Arm C (a)
D1, 
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32, 
W36W40 W44, 
W48W52 Unsched -
uled Visit
(h)Early 
Withdrawal
Visit (b)Follow -up 
Visit ([ADDRESS_658625] 
dose)
Informed consent X
Inclusion and exclusion criteria X X (i)
Genetics Informed consent X (m)
Randomization X
Assessments : Clinic
Full physical exam including 
height and weightX
12-lead ECG X
Demography X
Medical history 
(includes substance usage)X
Past and current medical 
conditions including 
cardiovascular medical historyX
Vital signs X
Symptom -driven physical 
exam, vital signsX X X X X X X X X X X X X X X
Weight X X X X
Assessments: Independent Assesso r
SLEDAI -2K: Blinded Assessor
(n)X X X X X X X
Assessments: Principal Investigator
[CONTACT_257441] -2K: Investigator X X X X X X X X X X X X X X
C-SSRS Baseline/Screening X
C-SSRS Since Last Visit X X X X X X X X X X X X X X X
Neuro logical Assessment X X X X X X X X X X X X X X X X
SLE Flare Index (j) X X X X X X X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
28Treatment Phase Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before D1 )Treatment Period –Arm C (a)
D1, 
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32, 
W36W40 W44, 
W48W52 Unsched -
uled Visit
(h)Early 
Withdrawal
Visit (b)Follow -up 
Visit ([ADDRESS_658626] 
dose)
SLICC -ACR Damage Index X X X
Physician Global Assessment 
(PGA)X X X X X X X X X X X X X
Survival Assessment (d) X
Asses sments: Patient Reported Outcomes (PROs)
Patient Global Assessment (c) X X X X X X X
FACIT -Fatigue (c) X X X X X X X
Lupus QoL (c) X X X X X X X
WPAI: Lupus (c) X X X X X X X
Treatment Interview (k) X X
Central Laboratory Tests
Drug and alcohol screen X
HIV, Hep B and Hep C screen X
Pregnancy test (WCBP) (e) X X X X X X X X X X X X X X X X
Laboratory assessments 
(include liver chemistries)X X X X X X X X X X X X X X X X
Serum immunoglobulin 
(IgA, IgM, IgG)X X X X X X X X X X X X X X X X
Urinalysis X X X X X X X X X X X X X X X X
Anti-dsDNA/ANA, 
Complement C3/C4X X X X X X X X X X X X X X X
Extractable nuclear antigens 
(ENAs)X X X X X
PT/PTT X X X X X X X
Antiphospholipid antibodies 
(aCL, lupus anticoagulant, 
beta-2-glycoprotein -1)X X X X X X
Labs and Biomarkers
B cells subsets X X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
29Treatment Phase Procedures
(D=Day, W=Week)Screening 
(35 to 
1day(s) 
before D1 )Treatment Period –Arm C (a)
D1, 
(Base -
line)W4 W6 W8 W12 W16 W20, 
W24W26 W28, 
W32, 
W36W40 W44, 
W48W52 Unsched -
uled Visit
(h)Early 
Withdrawal
Visit (b)Follow -up 
Visit ([ADDRESS_658627] 
dose)
BLyS Protein X X X
RNA for interferon signature X
Immunogenicity: Belimumab X X X X X X X X X
Pharmacokinetics: Belimumab X X X X X X X
Genetic sample X
Further Research
B cell subsets (o) X X X X
B-cell Receptor (l) X X X
Study Treatmen t
Training on use of Autoinjector X X
Dispense /Train or Collect 
Electronic patient diaryX X
Dispense Belimumab for 
weekly dosing (SC)X
(f)X X X X X X X X X
Initiate corticosteroid taperX 
(g)
Target for corticosteroid dose 
to reach prednisone equivalent 
5 mg/dayX
Study Visit Review Procedures
AE/SAE review X X X X X X X X X X X X X X X
Concomitant medication review 
(including SLE medications)X X X X X X X X X X X X X X X X
Review HCRU and P atient 
DiaryX X X X X X X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
30a. Starting at Week 4and throughout the study period including follow -up, a study visit time window 7 days is acceptable .Note: Every effort should be made to schedule the visit in
this window, however if the COVID -19 pandemic situation affects the ability to achieve this then, for those COVID -19 specific instances, the visit window can be expanded to ±[ADDRESS_658628] at Screening; Urine pregnancy test at all other visits, including pregnancy test [ADDRESS_658629] dose for observ ation.
g. It is recommended that the steroid taper be initiated on Week 12 to reach the target predniso ne equivalent of 5 mg/day at Week 26, but the taper schedule is at the discretion of
the investigator.
h. Procedures to be performed at Unscheduled Visits are based on reason for Unscheduled Visit, including adverse event or discont inuation of study agent. Please refer to Section
9.4and to the guidance provided in the Study Reference Manual.
i. The interim medical history, including SLE medications, should be reviewed prior to randomization to assure that the particip ant's eligibility has not changed.
j. Blood samples for a B cell receptor analysis should be obtained in the event of a suspected SLE Flare (refer to footnote l) .
k. To be conducted at US sites only.
l. To be conducted only at US study sites as part of further research . B-cell r eceptor samples are also collected at US sites when subjects experience a suspected SLE Flare.
m. Separate Genetics informed consent as needed per cou ntry specific requirements. Genetics informed c onsent and sample can be obtained any time after baseline.
n. Independent assessor will perform symptom -driven physical examination to include, at a minimum, assessments of eyes, mouth, skin, lungs, cardiovascular system, abdomen ,
and extrem ities (including joints). Independent assessors must have a source document (pap er record in the study file) where the findings in the clinical exam and laboratory
analyses supporting the scoring of S2K are described.
o. To be conducted at select European centers .
2016N272781_11 CONFIDENTIA L
205646
31Table 4 Open -Label Treatment Phase Procedures: Year 2, A rm C
Treatment Period –Arm C (a)
Arm C
Treatment Phase Procedures
(W=Week)W60 W64 W72 W80 W88, 
W96W104 Unscheduled 
Visit (e)Early 
Withdrawal
VisitFollow -up 
Visit ([ADDRESS_658630] 
dose)
Assessments : Clinic
Symptom -driven physical e xam, 
vital signsX X X X X X X X X
Weight X X
Assessments: Independent Assessor
SLEDAI -2K: Blinded Assessor (i) X X X X X
Assessments: Principal Investigator
[CONTACT_257441] -2K: Investigator X X X X X X X X
C-SSRS Since Last Visit X X X X X X X X X
Neurological assessment X X X X X X X X X
SLE Flare Index (f) X X X X X X X X
SLICC -ACR Damage Index X X
Physician Global Assessment ( PGA ) X X X X X X X X
Survival assessment (c) X
Assessments: Patient Reported Outcomes (PROs)
Patient Global Assessment (b) X X X X
FACIT -Fatigue ( b) X X X X
Lupus QoL ( b) X X X X
WPAI: Lupus ( b) X X X X
Exit Interview (g) X X
Central Laboratory Tests
Urine pregnancy test (WCBP) (d) X X X X X X X X X
Laboratory asses sments 
(include liver chemistries) X X X X X X X X X
Serum immunoglobulin (IgA, IgM, IgG) X X X X X X X X X
Urinalysis X X X X X X X X X
Anti-dsDNA/ANA, Complement C3/C4 X X X X X X X X X
2016N272781_11 CONFIDENTIA L
205646
32Treatment Period –Arm C (a)
Arm C
Treatment Phase Procedures
(W=Week)W60 W64 W72 W80 W88, 
W96W104 Unscheduled 
Visit (e)Early 
Withdrawal
VisitFollow -up 
Visit ([ADDRESS_658631] 
dose)
Extractable nuclear antigens (ENAs) X X X X
PT/PTT X X X X
Antiphospholipid antibodies (aCL, lupus 
anticoagulant, beta-2-glycoprotein -1)X X X X X
Labs and Biomarkers
B cells subsets X X X X X
Immunogenicity: Belimumab X X X X X
Pharmacokinetics: Belimumab X X X X X
Further Research
B cell recepto r(h) X X X
Study Treatment
Collect Electronic Diary X X
Dispense Belimumab for weekly dosing 
(SC)X X X X X
Study Visit Review Procedures
AE/SAE review X X X X X X X X X
Concomitant medication review 
(including SLE medications)X X X X X X X X X
Review HCRU and P atient Diary X X X X X X X X
2016N272781_11 CONFIDENTIAL
205646
33 a. During this study period including follow-up, a study visit time window ± 7 days is acceptable. Note: Every effort should be made to schedule the visit in this window, however if the  
COVID-19 pandemic situation affects the ability to achieve this then, for those COVID-19 specific instances, the visit window can be expanded to ±[ADDRESS_658632] dose of belimumab may be done at home, with the results reported by [CONTACT_509447]. .(Argentina only: In addition to  
pregnancy testing at the specified clinic visits, a urine pregnancy test is to be performed at home at Week 56, Week 68, Week 76, Week 84, Week 92, and Week 100, with the  
results reported by [CONTACT_509447].)
e. Procedures to be performed at Unscheduled Visits are based on reason for Unscheduled Visit, including adverse event or discontinuation of study agent. Please refer to Section  
9.4 and to the guidance provided in the Study Reference Manual.
f. Blood samples for a B cell receptor analysis should be obtained in the event of a suspected SLE Flare (refer to footnote h).
g. To be conducted at US sites only.
h. To be conducted only at US study sites. B-cell receptor samples are also collected at US sites only when subjects experience a suspected SLE Flare.
i. Independent assessor will perform symptom-driven physical examination to include, at a minimum, assessments of eyes, mouth, skin, lungs, cardiovascular system, abdomen, and 
extremities (including joints). Independent assessors must have a source document (paper record in the study file) where the findings in the clinical exam and laboratory analyses 
supporting the scoring of S2K are described.
2016N272781_11 CONFIDE NTIA L
205646
343. INTRODUCTION
3.1. Stud y Rationale
Systemic Lupus Ery thematosus ( SLE)is characterized by  [CONTACT_221970], including 
antibodies to double -stranded DNA (dsDNA), and by  [CONTACT_88086] B cell activation and 
differentiation [ Davidson , 2001], indicating that therapi[INVESTIGATOR_509407]. Belimumab and rituximab ar e monoclonal 
antibodies that achieve their expected pharmacology  through different but 
complementary  mechanisms; therefore, based on their mechanisms of action, sy nergistic 
effects in the treatment of SL E are possible .Belimumab treatment increases periphe ral 
memory  B cells potentially  by [CONTACT_509448]. This study  will assess whether co -administration of belimumab and 
a single cy cle of rituximab may  optimize treatment with belimumab ,resulting in 
improvements in clinical status with a favorable safety  profile, by  [CONTACT_509449]. belimumab plus rituximab -placebo. An 
open -label arm is included to provide a qualitative reference to standard therapy .
3.2. Background
Belimumab is an important treatment option for patients with SL E, but significant 
numbers of patients do not achieve a state of low disease activity , and are still left with 
moderate level of residual disease activit y. There is a large unmet m edical need for 
additional effective treatment which could meaningfull y reduce disease -related morbidity  
and mortality  and limit the toxicity  associated with traditional treatment regimens such as 
corticosteroids and immunosuppressants.
Rituximab treatment results in nearly  complete depletion of CD20+ B cells in the 
peripheral blood within hours of treatment. In contrast, relativel y high numbers of CD20+ 
B cells persist in the bone marrow following initial treatment with rituximab [ Boumans , 
2011]. Belimumab treatment increases peripheral memory  B cells potentially  by 
[CONTACT_509450] B cell compartment from 
tissues into the periphery. This mobilization would expose these cells to more efficient 
depletion by  [CONTACT_4124]. Continuing belimumab after a single course of rituximab would 
suppress the B-lymphocyte stimulator ( BLyS)elevation observed after rituximab 
monotherap y, thus suppressing the signal which leads to potential repopu lation of 
autoreactive B cells.
A treatment regimen which could reliabl y and effectively  achieve and maintain low 
disease activity  or remission, including patients with earlier and potentially  more 
reversible disease prior to the development of permanent d isability  or end -organ damage, 
would change the paradigm b y which SLE is treated today. This patient population has a 
large unmet medical need as 50% of SLE patients develop end -organ damage within the 
first 5 years of diagnosis [ Urowitz , 2012]. Recent scientific research suggests that a 
combination treatment with anti -BLyS and anti -CD20 may  potentially  address this need. 
Anti-BLyS and anti -CD20 therapeutics operate through different but complementary  
mechanisms and t he addition of a single cy cle of rituximab treatment may  optimize the 
effect of belimumab treatment in SLE.
2016N272781_11 CONFIDE NTIA L
205646
35Synergy  may  emerge through the following mechanisms:
Belimumab may  cause redistribution of memory  and germinal center B cells 
from ly mphoid tissue i nto blood, where they  are exposed to higher rituximab 
concentrations in the absence of local tissue factors that protect the B cells in 
their niches, which is likely  to increase B cell depletion.
Neutralization of serum BLy S level increases seen after ritu ximab monotherapy , 
preventing rapid B cell repopulation which is associated with SL E disease flares.
Increased stringency  of B cell reconstitution in the presence of anti -BLyS 
therap y with belimumab, resulting in fewer auto -reactive cells being formed 
after B cell depletion with rituximab.
Preclinical data supporting the h ypothesis that a combination of belimumab and 
rituximab may  provide additional efficacy  over either agent alone were generated in a 
human -CD20 expressing mouse model. Experiments using thi s model demonstrated 
relative resistance of the marginal zone (MZ) B cell compartment to anti -CD20 antibody  
monotherap y. Approximately 50% of these cells remained following anti -CD20 mAb as 
compared to complete depletion of circulating mature B cells. MZ B cells were rendered 
sensitive to anti -CD20 mAb depletion when they  were effectivel y mobilized from tissues 
into the vasculature with anti -L and anti -4 integrand mAbs. Thus, the tissue B cells 
were not inherentl y resistant to anti -CD20 mAb treatment: tre atment response was 
enhanced b y prior mobilization of the MZ B cells into the vasculature [ Gong , 2005]. 
Additionally , when mouse BLy S receptor (BR3) -Fc and anti -hCD20 were combined in 
this model, there was more effectiv e tissue B cell depletion of MZ B cells and follicular 
(FO)B cells than with either agent alone. Similar observations were made in murine SL E 
models [ Lin, 2015] in which dual targeting resulted in greater efficacy  with increased 
tissue B cell depletion, greater reduction in a range of auto -antibody  levels, and 
significant decreases in total IgG1, IgG2b, IgG3, IgM, and IgA when compared to BLy S 
inhibition and CD20 B cell depletion alone.
There have been 4 recent case repo rts of patients with SL E and Sjogren’s Sy ndrome 
demonstrating the ability of the combination to induce remission or states of disease 
control for prolonged periods [ Kraaij , 2014; De Vita , 2014; Simonetta , 2016]. I n one case 
a 32-year-old woman with a [ADDRESS_658633] therapy  and 
induction regimens. Initiation of rituximab led to only  partial response and a full relapse 
occurred while the patient was still B cell depleted but B cells began to repopulate , at 
which point belimumab was started. The patient entered a prolonged (>12 months) state 
of disease control on no steroids or immunosuppressants but on belimumab. The third 
case involved a [ADDRESS_658634] 
therap y and the addition of belimumab only resulted in transient partial reduction of 
proteinuria. Belimumab was stopped and the patient received one cy cle of rituximab with 
no significant or sustained effects on disease activity , and a rebound increa se in serum B-
2016N272781_11 CONFIDE NTIA L
205646
36cell activating factor of the TNF ligand family  (BAFF )levels was detected. Belimumab 
was reintroduced and the patient experienced “rapid and dramatic” improvements in 
clinical and biological parameters including proteinuria. After more than 18 months no 
disease flares or proteinuria relapses were observed. I n the fourth case, a patient with 
severe, refractory  (including to prior courses of rituximab) Sjogren’s Sy ndrome with 
associated Mucosa associated ly mphoid tissue ( MAL T)lymphoma and cryg lobulinemic 
vasculitis was treated with belimumab. The patient did not respond and so, as a last 
resort, rituximab was tried again, while there was still ongoing exposure to belimumab. 
This was followed b y complete and persistent regression of the l ymphoma , skin ulcers 
and vasculitis. Cry oglobulins and rheumatoid factor became persistentl y negative and the 
patient is in remission after three and a half years.
A detailed description of the chemistry , pharmacology , efficacy  and safet y of belimumab 
is provided in the most recent version of the Belimumab I nvestigator’s Brochure . Refer to 
the local rituximab approved product label for description of the chemistry , 
pharmacology , efficacy , and safet y of rituximab.
3.3. Benefit/Risk A ssessment
More det ailed information about the established benefits and risks of belimumab and 
rituximab, including expected adverse events (AEs), may  be found in the Belimumab 
Investigator’s Brochure and local rituximab approved product label, respectivel y.
There are no published clinical trial data for the co -administration of belimumab with 
rituximab ; however, the following data were reviewed and no new safety risks bey ond 
what would be expected for either agent alone is suggested from the limited data 
available from patients who may  have had overlappi[INVESTIGATOR_509408]:
The [COMPANY_004] Safet y Database of AEs from clinical trials and post -marketing 
experience
An insurance claims database (Safety  Works)
In-stream, blinded data from an ongoing [COMPANY_004] study  of belimumab in subjects 
with vasculitis who were induced with high dose corticosteroids and either 
rituximab or cy clophosphamide
In stream, blinded data from an ongoing [COMPANY_004] study  of belimumab co -
administered with rituximab in the treatment of pr imary  Sjögren’ s syndrome
Given that the experience of co -administration of anti -CD20 and anti -BLyS therapi[INVESTIGATOR_509409], robust safety  monitoring and stoppi[INVESTIGATOR_509410] . The key  risk assessment an d mitigation strategy  for this 
protocol is outlined below and in Section 8.2.
2016N272781_11 CONFIDENTIA L
205646
373.3.1. Risk A ssessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
Infections:
Prolonged B cell suppression and more complete 
B cell depletion expected; potential for more 
profound hypogammaglobulinemia with 
increased risk for se rious infections including 
opportunistic infections (OIs), Progressive 
multifocal leukoencephalopathy ( PML), and 
Hepatitis B virus ( HBV)reactivation. Rituximab: The rate of serious infections with 
rituximab in the rheumatoid arthritis ( RA)
population is 4% per year.
Reactivation of hepatitis B has also been very 
rarely reported in RA patients receiving 
rituximab.
Late onset neutropenia occurs rarely in patients 
treated with rituximab.
Belimumab: The rate of serious infections for 
SLE is 5% of subjects rec eiving either 
belimumab or placebo.
Belimumab and Rituximab Coadministration:
Infections are expected events for both 
belimumab and rituximab. Cases of PML have 
been very rarely reported, including fatal events, 
for both rituximab and belimumab in autoimmu ne 
diseases.
There is preclinical evidence for prolonged B cell 
suppression and more complete B cell depletion 
as well as effect on IgG1+ plasma cells in the 
long-lived bone marrow niche thought to be less Exclusions based on significant infection history, 
serologic evidence of past or present HBV or 
Hepatitis C virus (HCV) infection; IgG 
<250 mg/dL (note: <400mg/dL for [LOCATION_013]) , IgA 
deficiency (IgA level <10 mg/dL), neutrophils 
<1.5X 109/L.
A PML management plan including neurologic 
questionnaire, patient alert card, and stoppi[INVESTIGATOR_509411]. An independent PML 
Panel is also available for consultations.
A diagnosis of PML should be considered in any 
subject presenting with new -onset or 
deteriorating neurological signs and symptoms. 
The subject should be referred to a neurologist 
or other appropriate specialist for evaluation. If 
PML is confirmed, study agent should be 
discontinued and consideration should be given 
to stoppi[INVESTIGATOR_53097]. If PML 
is suspected, this should be reported to the 
Medical Monitor within 24 hrs. The 
2016N272781_11 CONFIDENTIA L
205646
38Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
sensitive to immunotherapy [ Lin, 2015] with dual 
B cell immunotherapy. Assessment of the 
translatability of the IgG reductions to humans is 
difficult to make due to species differences in B 
cell biology and different treatments; however, 
the mouse data raises the hypoth etical risk that 
immunoglobulin levels may reduce more with 
coadministration treatment.
Neutropenia:
SLE disease related neutropenia and Rituximab 
induced neutropenia may result in further
reduction in circulating neutrophils and/or 
influence timing of thi s neutropenia onset as 
compared to when Rituximab is administered 
alone.appropriateness of continuing study agent, while 
the case is being assessed, should be 
discussed.
Monitor patients for signs and symptoms of 
infection, monitor laboratory values, request that 
patients report signs of infection. Treat infections 
immediately and appropriately.
Neutropenia :
Individual subject’s treatment with belimumab 
and rit uximab/rituximab -placebo will be 
discontinued for (a) life threatening infection; (b) 
IgG <400 mg/dL if associated with a serious 
infection. 
Subjects should be monitored for neutropenia 
throughout the study. Neutropenia should be 
managed appropriately acc ording to local 
practice and clinical judgement should be applied 
with regard to the appropriateness of continuing 
study treatment in these subjects.
•Study treatment with rituximab/rituximab -
placebo (infusions Week 4 and/or Week 
6) must be temporarily with held and the 
[COMPANY_004] medical monitor consulted about 
2016N272781_11 CONFIDENTIA L
205646
39Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
continued dosing if a subject 
experiences a neutrophil count <1x 109/L.
•Study treatment with belimumab (Arms 
A/B and C) must be temporarily withheld 
and the [COMPANY_004] medical monitor consulted 
about continued dosin g if a subject 
experiences a neutrophil count 
<0.5x 109/L.
Systemic Infusion / Injection -Related Reactions, Hypersensitivity Reactions and Immunogenicity:
Serum Sickness: Serum sickness has been 
associated with rituximab in autoimmune 
indications [ Meijer , 2010].
There is a potential risk for increased 
immunogenicity due to cross reactivity which 
could lead to increased frequency of 
hypersensitivity reactions, particularly of the 
delayed type.Rituximab: The incidenc e of serum sickness 
associated with rituximab in pSS studies has 
ranged from 6 -38% [ Carubbi , 2014].
Administration of belimumab and rituximab may 
result in infusion and hypersensitivity reactions, 
which can be severe and can be fatal. Delay in 
the onset of serious hypersensitivity reactions 
can occur. Both rituximab and belimumab have 
been associated with delayed type non -acute 
Hypersensitivity reaction ( HSR )/serum sickness, 
although no relationship to Anti-drug Antib ody 
(ADA)has been established.
Belimumab and Rituximab Coadministration : 
Incidences of hypersensitivity and infusion 
reactions have been noted to be higher with co -
administration vs. mono -biologic therapy but no Immunogenicity will be evaluated with periodic 
assessment over the course of the study. 
A pre -medication regimen will be given before 
each rituximab/rituximab placebo infusion: 
methylprednisolone [ADDRESS_658635] belimumab injection and the 
rituximab/placebo infusions. Should symptoms of 
acute hypersensitivity oc cur, an extended period 
of monitoring may be appropriate, based on 
clinical judgement. If subjects are to receive 
belimumab after [ADDRESS_658636] 
2016N272781_11 CONFIDENTIA L
205646
40Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
association with ADA has been established 
[Weinblatt , 2006].should remain under clinical supervision for [ADDRESS_658637] for HSR and 
delayed HSR/serum sickness.
Malignancy:
There is an increased risk of malignancy, 
including Non -Hodgkin’s lymphoma, in SLE.
There is a theoretical increased risk of 
malignancy with combination 
immunosuppressive mechanisms.Belimumab and Rituximab: Immunomodulatory 
drugs like rituximab and belimumab may 
increase the risk of malignancy. To date, no 
causal relationship between be limumab or 
rituximab and malignancy, including B cell 
lymphoma, has been detected, both of which 
have been administered long term and in 
combination with other immunosuppressants of 
various mechanisms.Subjects with a history of malignancy in the [ADDRESS_658638] 
that pati ents report signs and symptoms. Treat 
appropriately.
Interaction with Vaccinations:
There is a risk of reduced antibody titers with 
mono and dual B cell immunotherapy. The 
potential synergistic effect of rituximab and 
belimumab may result in a prolonged B cell 
depletion that could have a similar inhibitory 
impact on vaccine responses as administering 
repeated doses of rituximab.Rituximab: As described in the label [ Rituxan
package insert, 2016], the response to 
pneumococcal vaccination (a T cell independent 
antigen) as measured by [CONTACT_509451] 6 of 12 serotypes was lower in 
patients treated with rituximab plus methotrexate 
(MTX) as compared to patients treated with MTX 
alone (19% vs. 61 %). Additionally, a lower 
proportion of patients in the rituximab plus MTX Immunization with live vaccines is prohibited 
from 30 days prior to Day 1 and during 
belimumab use.
Subjects’ v accination status should be assessed 
and current immunization guidelines followed; all 
necessary vaccinations should be administered if 
possible no later than 30 days prior to Day 1.
2016N272781_11 CONFIDENTIA L
205646
41Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
group developed detectable levels of anti -
keyhole limpet hemocyanin antibodies (a novel 
protein antigen) after vaccination compared to 
patients on MTX alone (47% vs. 93%).
In a comb ination study, median antibody titers 
(tetanus, diphtheria, pneumococcus) at Week 32 
were reduced from baseline in atacicept 
(recombinant fusion protein which inhibits BLyS 
and APRIL) but not placebo -treated patients who 
had been previously treated with ri tuximab. 
However, these values recovered close to 
baseline by [CONTACT_10585] [ADDRESS_658639] to the 
frequency of shifts.
Belimumab: The efficacy of concurrent 
vaccin ation in patients receiving belimumab is 
not known; however, in the belimumab 
vaccination trial, evaluation of the impact of 
belimumab treatment on response to on -
treatment vaccination with 23 -valent 
pneumococcal vaccine revealed that immune 
responses to t he different serotypes were similar 
in SLE patients receiving belimumab compared 
with those not receiving treatment at the time of 
vaccination.
2016N272781_11 CONFIDENTIA L
205646
42Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
Psychiatric Events:
There is anidentified risk of psychiatric events 
with belimumab and rituximab.Rituximab: Depression and anxiety were 
common AEs in rituximab RA trials.
Belimumab: There have been reports of 
depression and suicidality in patients receiving 
belimumab. Subjects who, in the investigator’s opi[INVESTIGATOR_1649], pose 
a significant suicide risk will be excluded.
The Columbia -Suicide Severity Rating Scale ( C-
SSRS )will be completed at each visit 
Subjects will be monitored closely for signs and 
symptoms of psychiatric illness including 
depression and suicidal ideation. Subje cts 
displaying such signs and symptoms will be 
treated appropriately and referred as necessary 
to specialty psychiatric care.
Cardiac Disorders:
Rituximab: Angina pectoris, cardiac arrhythmias 
such as atrial flutter and fibrillation, heart failure 
and/o r myocardial infarction have occurred in 
patients treated with rituximab. There is no data 
on the safety of rituximab in patients with 
moderate to severe heart failure or severe, 
uncontrolled Cardiovascular ( CV)disease.
Belimumab and Rituximab: Hypotensio n may 
accompany infusion/postinjection systemic 
reactions with both rituximab and belimumab.Exclude subjects with severe heart failure (New 
York Heart Association, Class IV) or other 
severe, uncontrolled cardiac disease.
Closely monitor any patients with cardiac history 
or those who have experienced prior 
cardiopulmonary adverse reactions during 
administration of rituximab/rituximab placebo. 
Consider withholding antihypertensive 
medications 12 hours prior to rituximab/rituximab 
placebo infusion.
2016N272781_11 CONFIDENTIA L
205646
43Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Investigational Pr oduct (IP): Belimumab ([COMPANY_004]1550188), Rituximab, and Belimumab and Rituximab Coadministration
Severe Sk in reactions:
Rituximab: Severe skin reactions such as Toxic 
Epi[INVESTIGATOR_509412] -Johnson 
syndrome; some with fatal outcome, have been 
reported with rituximab.Permanently discontinue treatment in the case of 
such an event with suspected rela tionship to 
treatment.
Posterior Reversible Encephalopathy Syndrome (PRES):
Rituximab: Cases of Posterior reversible 
encephalopathy syndrome ( PRES )/ reversible 
posterior leukoencephalopathy syndrome 
(RPLS) have been reported. Signs and 
symptoms include d visual disturbance, 
headache, seizures and altered mental status, 
with or without associated hypertension. A 
diagnosis of PRES/RPLS requires confirmation 
by [CONTACT_14548]. The reported cases had 
recognized risk factors for PRES/RPLS, 
including the patien ts’ underlying disease, 
hypertension, immunosuppressive therapy 
and/or chemotherapy.Medical monitor will be notified of any new 
neurologic symptoms. Medical monitor and 
investigator will consider the possibility of PRES 
in differential diagnosis.
2016N272781_11 CONFIDENTIA L
205646
443.3.2. Benef it Assessment
The primary  data supporting efficacy  of intravenous ( IV)belimumab were the Phase 3 
trials (C1056 and C1057) in which 1684 subjects were treated for up to 52 weeks 
(C1057) or 76 weeks (C1056) ( Belimumab Investigator’s Brochure , Section [IP_ADDRESS]). 
Belimumab produced significant improvements in the SL E Responder Index as well as in 
the individual component Safety  of Estrogen in Lupus National Assessment Trial 
(SEL ENA) -Systemic Lupus Ery thematosus Disease Activit y Index (SL EDAI) score in 
both studies. Pooled analyses demonstrated steroid sparing and decreased risk of severe 
flares over 52 weeks. Clinical trial data for belimumab since approval continue to show 
efficacy  in the treatment of SL E through decreased SL Eflares and decreased disease 
activity  across multiple organ s ystems ( Belimumab I nvestigator’s Brochure , Section 
[IP_ADDRESS]). Similar results were observed in the pi[INVESTIGATOR_9205] 3 trial of belimumab SC 200 
mg/week (BEL112341) , with significant improvements in the SL E Responder Index and 
time to first severe flare endpoints. The inclusion of rituximab provides an opportunity  
for subjects with active SLE despi[INVESTIGATOR_509413] y to benefit from potentially  
disease modify ing regimen that may  include induction of disease control or clinical 
remission and a reduction in or complete discontinuation of corticosteroids and 
immunosuppressant therapy .
3.3.3. Overall Benefit: Risk Conclusion
Taking into account the measures that will be im plemented to minimize risk to subjects 
participating in this study, the potential risks associated with co -administration of 
belimumab and rituximab are justified b y the anticipated benefits that may be afforded to 
patients with SL E who choose to participa te in this trial.
4. OBJECTIVES A ND ENDPO INTS
The key  evaluations are based on comparing belimumab with or without a single cy cle of 
rituximab (the combination arm vs. the control arm). There are limited analy ses planned 
to compare the combination of belimuma b with a single cy cle of rituximab (combination 
arm) to belimumab with standard therap y (reference arm) .Details of the analy ses to be 
conducted will be described in the Reporting and Analy sis Plan (RAP), including 
analysis of the combination arm vs. the control arm and the combination arm vs. the 
reference arm.
Objectives Endpoints
Primary: Efficacy
To evaluate the efficacy of belimumab and 
a single cycle of rituximab administered in a 
combination regimen to adult participants 
with SLE.Proportion of pa rticipants with a state of 
disease control defined as a SLEDAI -2K 
score 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5mg/day at Week 52. (Serological 
activity, i.e., anti -dsDNA positivity and/or 
2016N272781_11 CONFIDENTIA L
205646
45Objectives Endpoints
hypo complementemia, is scored in the 
SLEDAI -2K endpoint.)
Secondary: Efficacy (Major) Proportion of participants with a state of 
clinical remission defined as a Clinical 
SLEDAI -2K score =0, achieved without 
immunosuppressants and with 
corticosteroids at a pre dnisone equivalent 
dose of 0 mg/day at Week 64. (Serological 
activity score , i.e., anti -dsDNA positivity 
and/or hypocomplementemia, is excluded 
from the Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
disease control defined as a S LEDAI -2K 
score 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5mg/day at Week 104. 
Secondary: Efficacy (Other) Proportion of participants with a state of 
disease control, defined as a SLEDAI -2K 
score 2, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 5 mg/day, by [CONTACT_765].
Proportion of participants with a state of 
clinical remission, defined as a Clinical 
SLEDAI -2K score =0, achieved without 
immunosuppre ssants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765]. (Serological 
activity score, i.e., anti -dsDNA positivity 
and/or hypocomplementemia, is excluded 
from the Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
complete remission, defined as SLEDAI -
2K=0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, sustained for at least 24 
weeks.
Proportion of participants with a state of 
clinical remission at Week 104, defined as 
2016N272781_11 CONFIDENTIA L
205646
46Objectives Endpoints
Clinical SLEDAI -2K score=0, achieved 
without immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, sustained for at least 24 
weeks. (Serological activity score, i.e., anti -
dsDNA positivity and/or 
hypocomplementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.)
Proportion of participants with a state of 
complete remission, defined as a SLEDAI -
2K score =0, achieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765] 
Time to first severe flare (as measured by 
[CONTACT_509439])
Time to first flare (as measured by [CONTACT_509440])
Time to disease control sustained to Week 
104, defined as SLEDAI -2K score 2, 
achieved withou t immunosuppressants and 
with corticosteroids at a prednisone 
equivalent dose of 5 mg/day 
Time to clinical remission sustained to 
Week 104, defined as Clinical SLEDAI -2K 
score =0, achieved without 
immunosuppressants and with 
corticosteroids at a predniso ne equivalent 
dose of 0 mg/day. (Serological activity, i.e., 
anti-dsDNA positivity and/or 
hypocomplementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.) 
Duration of disease control, defined as 
SLEDAI -2K score 2, achieved without 
immunosuppressant s and with 
corticosteroids at a prednisone equivalent 
dose of 5 mg/day
Duration of clinical remission, defined as 
Clinical SLEDAI -2K score =0, achieved 
2016N272781_11 CONFIDENTIA L
205646
47Objectives Endpoints
without immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day. (Serol ogical activity, i.e., 
anti-dsDNA positivity and/or 
hypocomplementemia, is excluded from the 
Clinical SLEDAI -2K endpoint.)
Change from baseline in SLEDAI -2K score 
by [CONTACT_765]
Proportion of participants with SLEDAI -2K 
organ improvement by [CONTACT_765]
Proportion of p articipants with SLEDAI -2K 
organ worsening by [CONTACT_765]
Change from baseline in Physician Global 
Assessment (PGA) by [CONTACT_765]
Proportion of participants with any SLICC 
Damage Index worsening (change >0) 
compared with baseline at Week 52 and 
Week 104
Proportion of participants that meet the 
Lupus Low Disease Activity State (LLDAS) 
response criteria by [CONTACT_765]. The LLDAS 
incorporates multiple measures of disease 
activity, specifically: (1) SLEDAI -2K 4, with 
no activity in major organ systems (renal, 
CNS, cardiopulmon ary, vasculitis, fever) 
and no hemolytic anemia or gastrointestinal 
activity; (2) no new features of lupus 
disease activity compared with the previous 
assessment; (3) PGA (scale 0 -3), 1; (4) 
current prednisolone (or equivalent) dose 
7.5 mg daily; and (5) well tolerated 
standard maintenance doses of 
immunosuppressive drugs and approved 
biological agents, excluding investigational 
drugs.
Proportion of participants with a state of 
disease control, defined as a SLEDAI -2K 
score 2, achieved without 
immunosuppr essants and with 
2016N272781_11 CONFIDENTIA L
205646
48Objectives Endpoints
corticosteroids at a prednisone equivalent 
dose of 5 mg/day, by [CONTACT_765]; using the 
Principal Investigators assessment of 
SLEDAI -2K.
Proportion of participants with a state of 
clinical remission, defined as a Clinical 
SLEDAI -2K score =0, ach ieved without 
immunosuppressants and with 
corticosteroids at a prednisone equivalent 
dose of 0 mg/day, by [CONTACT_765]; using the 
Principal Investigators assessment of 
SLEDAI -2K. (Serological activity score, i.e. 
anti-dsDNA positivity and/or 
hypocomplementemia, i s excluded from the 
Clinical SLEDAI -2K endpoint.)
Secondary: Safety
To assess the safety and tolerability of 
belimumab and a single cycle of rituximab 
administered in a combination regimen to 
adult participants with SLEIncidence of adverse events (AEs) including 
serious AEs (SAEs) and AEs of special 
interest (AESIs)
2016N272781_11 CONFIDENTIA L
205646
49Objectives Endpoints
Secondary: Patient Reported Outcomes 
(PROs)
To assess the impact of belimumab and a 
single cycle of rituximab administered in a 
combination regimen to adult participants 
with SLE on PROsChange from baseline in Patient Global 
Assessment (PtGA) by [CONTACT_765]
Change from baseline in LupusQoL domain 
summary score s (8 domains) by [CONTACT_765]
Change from baseline in FACIT -Fatigue 
score by [CONTACT_765] 
Proportion of subjects with improvement in 
FACIT -Fatigue sco re exceeding the Minimal 
Clinically Important Difference (MCID, 4) 
by [CONTACT_509441]: Pharmacokinetics and 
Biomarkers
To assess pharmacokinetics of and 
biomarker response to belimumab and a 
single cycle of rituximab administered in a 
combination reg imen to adult participants 
with SLEBelimumab and rituximab concentrations by 
[CONTACT_765]
Change from baseline in autoantibodies by 
[CONTACT_765]
Change from baseline in peripheral blood 
leukocytes including B cell subsets by [CONTACT_765]
Change in BLyS levels from baseline by
[CONTACT_509441]: Patient Reported Work 
Productivity
To explore the impact of belimumab and a 
single cycle of rituximab administered in a 
combination regimen to adult participants 
with SLE on patient experience and 
productivity Change from baseline i n Work Productivity 
and Activity Impairment (WPAI): Lupus 
percent overall work productivity impairment 
score by [CONTACT_765] 
Change from baseline in WPAI: Lupus 
percent activity impairment score by [CONTACT_765]
2016N272781_11 CONFIDENTIA L
205646
505. STUDY DESIGN
5.1. Overall Design
This is a Phase 3, multi -center, 3 -arm, randomized, double -blind, placebo -controlled, 
104week superiority  study  to evaluate the efficacy  and safet y of belimumab administered 
in combination with a single cy cle of rituximab to adult participants with SLE. 
Participants will be randomly assigned to 1 of 3 treatment arms; belimumab plus 
rituximab -placebo (Arm A, control), belimumab plus rituximab (Arm B, combination), or 
belimumab plus standard therap y (Arm C, reference). Arms A and B are double -blind; 
Arm C is open -label. In order to min imize bias given that Arm C is open -label, blinded 
independent assessors will conduct SL EDAI -2K evaluations at key  time points, including 
the primary  and key  secondary  efficacy  endpoints. An Independent Data Monitoring 
Committee (I DMC) will review the safe ty data periodically  to ensure external medical 
and statistical review of safet y issues (Section 10.4.4 ).
Randomization and the first dose of belimumab should be completed within [ADDRESS_658640] therapy  
at entry . At randomization, participants will be stratified by  [CONTACT_509443] -2K 
score ( 9 vs. 10), b y immunosuppressant use at screening (immunosuppressant use vs. 
no use), an d by [CONTACT_509452] (prednisone equivalent 10 mg/day  vs. 
>10mg/day ). Belimumab will be administered subcutaneousl y (SC)on Day  1 and then 
weekl y (i.e., every 7 days 1 day ) through Week [ADDRESS_658641] all efficacy and safet y 
assessments.
Participants randomized to Arms A and B who enter the study  on immunosuppressants 
will discontinue immunosuppressants at or prior to the Week 4 visit. Continuing the 
stable immunosuppressant dose until Week 4 allows participants to receive 3 weeks of 
belimumab SC prior to discontinuing their imm unosuppressants. Corticosteroids may  be 
adjusted as necessary  during this transition period. If participants in Arms A and B 
receive immunosuppressants after the Week 4 visit they  will be deemed treatment failures 
for the efficacy  endpoints. Participants i n Arm C who enter the stud y on stable 
immunosuppressants may continue their stable immunosuppressants throughout the study  
at the discretion of the investigator. If participants in Arm C require an addition of a new 
immunosuppressant after Week 1 2they will be considered a treatment failure. See 
Section [IP_ADDRESS] for additional details on management of immunosuppressants.
2016N272781_11 CONFIDENTIA L
205646
51After the initial 12 weeks of study  treatment, a protocol -specified corticosteroid taper will 
be initiated and conducted under the direction of the investigator for participants in all 
3arms. The taper will proceed with a target of reaching a prednisone equivalent dose of 
5mg/day  by [CONTACT_10585] 26. If the investigator believes the participant would ben efit from 
continued steroid taper and, if tolerated, a prolonged corticosteroid taper should continue 
after Week 26 with the goal of corticosteroid discontinuation. Participants who are able to 
tolerate the final taper will be withdrawn from corticosteroid s. If a participant is unable to 
tolerate the final stage of the corticosteroid taper, the investigator may  reinitiate 
corticosteroids at a prednisone equivalent dose of up to and including 5 mg/day . If a 7-
day average prednisone equivalent dose of >5 mg/d ay is required at any  time after Week 
26, the participant will be considered a treatment failure for the efficacy  endpoints. The 
recommended corticosteroid taper scheme is described in Appendix 2.
Anti-malarial therap ies for SLEmay not be initiated during the study , but may  be 
continued or dose -adjusted during the study , and will be allowed within the definitions of 
the efficacy  endpoints. 
During the 52 -week double -blind phase, participants in Arms A and B who cannot
tolerate discontinuation of immunosuppressants or taper of corticosteroids or, in the 
opi[INVESTIGATOR_871], require added therap y, will be considered treatment failures 
for the efficacy  endpoints. Blinding to the treatment assignments in Arms A and B will be 
maintained. At the investigator's discretion, these participants may  continue treatment 
with belimumab, and/or be treated with additional SL E therapi[INVESTIGATOR_509406] , including 
corticosteroids and/or immunosuppressants. Participants in Arm C who are unable to 
tolerate the corticosteroid taper or, in the opi[INVESTIGATOR_871], require increased 
doses of their baseline immunosuppressants or addition of a new immunosuppressant will 
be considered treatment failures for the efficacy  endpoints.
Participants in Arms A and B will enter into the 52 -week treatment -free, observational 
phase of the stud y after completing Week 52 (Weeks 53 through 104). “Treatment -free” 
refers to no active treatment with study  treatment (i.e., belimumab and/or rituximab).
Participants in Arm C will continue to receive belimumab SC and their stable 
immunosuppressants during Weeks 53 through 104. Treatment with anti -malarials, 
NSAIDs, and/or corticosteroids with a prednisone equivalent dose of 5mg/day  will be 
allowed in We eks 53 through 104 in all three arms. 
During Weeks 53 to 104, additional treatment may be given if the investigator believes 
the participant would benefit because he/she: a) responded to study  treatment but did not 
meet the primary  efficacy  endpoint; or b ) responded to study  treatment but subsequently  
experienced increasing disease activity  which requires additional therap y. Additional 
treatment may  include open -label belimumab, corticosteroids (>5 mg/day ), and/or 
immunosuppressants, and will be administer ed at the discretion of the investigator. 
Additional treatment with rituximab is allowed, but not encouraged. Belimumab will be 
provided b y the sponsor to those participants who reinitiate treatment with belimumab, 
but additional treatment with rituximab a nd/or other SL E medications will not be 
provided b y the study. These participants will be considered treatment failures for the 
Week 104 efficacy  anal yses. Participants who are deemed treatment failures will be 
encouraged to continue in the study  and to ha ve all efficacy  and safet y assessments.
2016N272781_11 CONFIDENTIA L
205646
52Additional information on management of participants who receive open -label 
belimumab and/or rituximab, including the schedule for obtaining immunogenicity  
samples, is provided in the Study  Reference Manual (SRM).
Participants who discontinue study  therapy  but remain in the study  will follow the study  
visit schedule.
Participants who discontinue study  treatment andwithdraw from the stud y up to Week 52 
are required to complete an Early Withdrawal Visit and a Follow -up Visit; the Early 
Withdrawal Visit is scheduled [ADDRESS_658642] dose of belimumab. Participants in 
Arms A or B who withdraw from the study after Week 52 are required to complete an 
Early Withdrawal Visit 1 -4 weeks after withdrawal from the study . Participants in Arm C 
who discontinue study  treatment and withdraw from the study  after Week 52 are required 
to complete an Early Withdrawal Visit and a Follow -up Visit; the Early Withdrawal Visit 
is scheduled [ADDRESS_658643] dose of belimumab and/or or monthly  for1 year after the last dose of 
rituximab or rituximab -placebo, whichever is later. 
In the event that a participant withdraws from the study  or withdraws consent, an attempt 
will be made to ascertain surviva l status at approximately  [ADDRESS_658644] 280participants ( 50% screen failure rate).
The sample size may  be increased up to a maximum of [ADDRESS_658645] completed the study  if he/she has completed all 
phases of the stud y, including the Week 104 Visit, as defined in the SoA (Section 2).
Participants who discontinue study  therapy  but remain in the study  will follow the study  
visit schedule . 
Participants who discontinue study  treatment and withdraw from the study  up to Week 52 
are required to complete an Early Withdrawal Visit and a Follow -up Visit; the Early 
Withdrawal Visit is scheduled [ADDRESS_658646] dose of belimumab. Participants in 
Arms A or B who withdraw from the stud y after We ek 52 are required to complete an 
Early Withdrawal Visit 1 -4 weeks after withdrawal from the study . Participants in Arm C 
who discontinue study  treatment and withdraw from the study  after Week 52 are required 
to complete an Early Withdrawal Visit and a Fol low-up Visit; the Early Withdrawal Visit 
is scheduled [ADDRESS_658647] dose of belimumab and/or monthly  until [ADDRESS_658648] participant in the 
study .
5.4. Scientific Rationale for Study  Design
5.4.1. Selection of Controls
The belimumab p lus rituximab -placebo arm (Arm A) will be used as the study control 
arm because belimumab has demonstrated efficacy in 4 large, controlled, Phase 3 
controlled clinical trials, HGS1006 -C1056 (referred to hereafter as C1056), HGS1006 -
2016N272781_11 CONFIDENTIA L
205646
55C1057 (C1057), BEL113750 , and BEL112341, and remains the onl y biologic approved 
for the treatment of SLE. An open -label reference arm of belimumab plus standard 
therap y, including immunosuppressants (Arm C) is included to provide a qualitative 
reference to assess the relative per formance of Arm A (control) and Arm B (combination) 
vs. belimumab plus standard SLE therapy  in current practice (Arm C, reference).
Belimumab SC 200 mg weekl y will be dosed for 51 weeks for Arms A and B since this 
was the dose and duration of therap y for t he primary  endpoint in the positive Phase 3 
study  of SC belimumab (BEL112341). The SC 200 mg weekl y dose was selected for 
study  BEL112341 because it provides steady -state average belimumab concentrations 
similar to those in the 10 mg/kg every  4 weeks dose groups, which were positive for the 
primary  endpoint in the pi[INVESTIGATOR_9205] 3 studies of IV belimumab (C1056 and C1057). 
Arm B will explore the combination of rituximab (2 doses of 1000 mg IV at Weeks 4 and 
6) and [ADDRESS_658649] dosing 
regimen is established. In this study , rituximab dosing will follow 1 cy cle of the approved 
dosing recommendation for rheumatoid arthritis (RA) which is 2 IV doses of 1000 mg 
given in a 2 -week interval. This rituximab regimen demonstrated rapid B cell depletion of 
CD19 -positive cells (<5 cells/ L) in approximately 90% of subjects b y 2 weeks after the 
infusions in a large Phase 3 SL E trial [ Merrill , 2010].
Rituximab or rituximab -placebo will be dosed at Weeks [ADDRESS_658650] these medications discontinued at or prior to 
the Week 4 visit. The jus tification for dosing at Week 4 and Week 6 includes: 1) 
separation of start times for belimumab and rituximab, thereb y allowing for observation 
of safet y events which may be attributable to starting treatment with the individual 
agents, and b) evidence tha t belimumab may  mobilize B cells into the periphery  making 
them available targets for anti -CD20 treatment, thus starting belimumab prior to 
rituximab may  allow more efficient peripheral B cell depletion by  [CONTACT_4124] [ Stohl , 
2012].
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
Age
1.Participant must be 18years of age at the time of signing the informed consent.
2016N272781_11 CONFIDENTIA L
205646
56Type of Participant and Disease Characteristics
Participants who:
2.Have a clinical diagnosis of SLEbased on 4 or more of the 11 American College of 
Rheumatology  (ACR) criteria (see Appendix 11).
3.Have a screening SL EDAI -2K score 6 (This refers to the total score . Serological 
activity , i.e., anti -double stranded deox yribonucleic acid [dsDNA]) po sitivity  and/or 
hypocomplementemia is not required to be present in SLEDAI -2K assessment , but 
are scored if present ).
4. Have unequivocall y positive autoantibody test results defined as an anti -nuclear 
(ANA) titer 1:80 and/or a positive anti -dsDNA ( 30 IU/mL) serum antibody  test 
from 2 independent time points as follows:
Positive test results from [ADDRESS_658651] be based on the study's central laboratory results
OR
One positive historical t est result and [ADDRESS_658652] result during the screening 
period.
NOTE: Historical documentation of a positive test of ANA (e.g., ANA b y HEp-2 
titer) and anti -dsDNA (e.g., anti -dsDNA by  [CONTACT_509453] ) that must include the 
date and t ype of the test, the name [CONTACT_509487] , andnumerical 
reference range , whenever available . Onl y unequivocally positive values as 
defined in the laboratory 's reference range are acceptable; borderline values 
will not be accepted.
Concomitant Medications
5.Are on a stable SLE treatment regimen consisting of any  of the following 
medications (alone or in combination) for a period of at least 30 day s prior to Day 1
(i.e., day  of first dose of study  treatment) with the exception that switching one agent 
for another of the same class for tolerability  or availability  reasons, which will be 
allowed within 30 day s of Day  1.
Corticosteroids (prednisone or prednisone equivalent)
For those subjects on alternating daily doses of steroids, use the average of 2 
daily  doses to calculate t he average daily  steroid dose.
Any immunosuppressant or immunomodulatory  agents including methotrexate, 
azathioprine, leflunomide, my cophenolate (including m ycophenolate mofetil, 
mycophenolate mofetil hy drochloride, and m ycophenolate sodium), calcineurin 
inhibitors (e.g. tacrolimus, cy closporine), sirolimus, cy clophosphamide, 6 -
mercaptopurine, mizoribine, or thalidomide. (Note: oral cy clophosphamide use 
is exclusionary  in [LOCATION_013] )
Anti-malarials (e.g., h ydroxychloroquine, chloroquine, quinacrine).
Non-stero idal anti -inflammatory  drugs (NSAIDs).
2016N272781_11 CONFIDENTIA L
205646
57NOTES:
Corticosteroids may  be added as a new medication or their doses adjusted up to 
30 day s prior to Day  1.
New SLE therap y other than corticosteroids must not be added within 60 days 
prior to Day  1.
6.Male and/or fem ale
A female participant is eligible to participate if she is not pregnant (see Appendix 3 ), 
not breastfeeding, and at least one of the following conditions applies:
(i) Not a woman of childbearing potential (WOCBP) as de fined in Appendix 3
OR
(ii) A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_658653] dose of rituximab or rituximab -
placebo, whichever is later.
Informed Consent
7.Capable of giving signed informed consent as described in Appendix 4 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF) and in this protocol.
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Symptomatic herpes zoster within 3 mont hs prior to screening. 
2.Evidence of active or latent tuberculosis (TB ). Documentation may  include medical 
history  and examination, chest X -rays (posterior, anterior, and lateral), and TB 
testing: either a positive tuberculin skin test (TST; defined as a sk in induration ≥5 
mm at 48 to 72 hours, regardless of Baccillus Calmette -Guerin (BCG) or other 
vaccination history ) or a positive ( not indeterminate ) QuantiFERON -TB Gold Plus
test.
NOTE: The choice to perform a TST or a QuantiFERON -TB Gold Plus test will be 
made b y the i nvestigator according to local licensing and standard of care. The 
QuantiFERON -TB Gold Plus test can only  be used in countries where it is 
licensed, and the use of this test is dependent on previous treatment(s). This 
test may  not be suitable if previous t reatment(s) produced significant 
immunosuppression.
3.Significant allergies to humanized monoclonal antibodies.
4.History  of hypersensitivity  to belimumab and/or rituximab or known to have titers of 
human anti -mouse antibody  or history  of hypersensitivity  reac tions when treated 
with other diagnostic or therapeutic monoclonal antibodies. 
2016N272781_11 CONFIDENTIA L
[ADDRESS_658654] been resected with no 
evidence of me tastatic disease for 3 y ears.
6.Alanine transferase (ALT) >2x upper limit of normal (ULN).
7.Bilirubin >1.5xUL N (isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).
8.IgA deficiency  (IgA level < 10 mg/dL).
9.IgG < 250 mg/dL. (Note: <400 mg/dL for [LOCATION_013]  only )
10.Neutrophils < 1.5 x 109.
11.Current unstable liver or biliary  disease per investigator assessment defined by  [CONTACT_90985], encephalopathy , coagulopathy , hypoalbuminemia, esophageal or 
gastric varices, per sistent jaundice, or cirrhosis.
12.Severe heart failure ( [LOCATION_001] Heart Association Class I V) or other severe, 
uncontrolled cardiac disease.
13.QTc >450 msec or QTc >480 msec in participants with bundle branch block. 
NOTES: 
The QTc is the QT interval corrected for heart rate according to Bazette's 
formula (QTcB), Fridericia's formula (QTcF), and/or another method. It is either 
machine -read or manually  overread. 
14.Have a history  of a major organ transplant (e.g., heart, lung, kidney , liver) or 
hematopoietic stem cell/marrow transplant.
15.Have clinical evidence of significant unstable or uncontrolled acute or chronic 
diseases not due to SL E (i.e., cardiovascular, pulmonary , hematologic, 
gastrointestinal, hepatic, renal, neurological, psychiatric, malignancy , or infec tious 
diseases) which, in the opi[INVESTIGATOR_14371], could confound the 
results of the study  or put the subject at undue risk.
16.Have an acute or chronic infection requiring management as follows: 
Currently  on any  suppressive therap y for a c hronic infection such as 
pneumocy stis, cy tomegalovirus, herpes simplex virus, herpes zoster, or at ypi[INVESTIGATOR_356539]. 
Hospi[INVESTIGATOR_53039] 60 days of Day  1. 
Have had infection requiring treatment with parenteral (IV or IM) a ntibiotics 
(antibacterials, antivirals, anti -fungals, or anti -parasitic agents) within [ADDRESS_658655] severe lupus kidney disease (defined b y proteinuria >6 g/24 hour or equivalent 
using spot urine protein to creatinine ratio, or serum creatinine >2.5 mg/dL), or have 
severe active nephritis requiring induction therap y not permitted by [CONTACT_990] (e.g., IV 
cyclophosphamide), or have required hemodial ysis or high dose prednisone or 
equivalent (>100 mg/da y) within 90 days of Day 1.
2016N272781_11 CONFIDENTIA L
[PHONE_10562].Have severe active central nervous s ystem (CNS) lupus (including seizures, 
psychosis, organic brain sy ndrome, cerebrovascular accident (CVA), cerebritis, or 
CNS vasculitis) requiring therapeutic intervention within [ADDRESS_658656] a planned surgical procedure, laboratory  abnormality , or condition (e.g., poor 
venous access) that, in the opi[INVESTIGATOR_14371], makes the subject 
unsuitable for the stud y.
20.Have evidence of serious suicide risk, including any  history of suicidal behavior in 
the last 6 months and/or any  suicidal ideation of ty pe [ADDRESS_658657] 2 months or who, in the investigator's opi[INVESTIGATOR_1649], pose a significant suicide risk.
21.Have a history  of an anaphy laxis reaction to parenteral ad ministration of contrast 
agents, human or murine proteins, or monoclonal antibodies.
Prior/Concomitant Therapy
22.Live vaccine(s) within [ADDRESS_658658] receiv ed an y of the following within 364 days of Day  1:
Belimumab. 
Rituximab. 
Abatacept. 
Any B cell targeted therapy  (anti -CD20 agents other than rituximab, anti CD22 
[epratuzumab], anti -CD52 [alemtuzumab], BLyS -receptor fusion protein [BR3], 
TACI  Fc, anti -BAFF (LY2127399), anti -Interferon alpha agents or anti -BLyS 
other than belimumab). 
A biologic investigational agent other than B cell targeted therap y (e.g., 
abetimus sodium, anti CD40L  antibody  [BG9588/ I DEC 1311]). (Investigational 
agent applies to an y drug not approved for sale in the country  in which it is 
being used.)
24.Have required 3 or more courses of s ystemic corticosteroids (e.g., IV pulse therap y 
or high dose oral treatment) within 364 day s of Day 1. (Topi[INVESTIGATOR_509414].)
25.Have received any  of the following within 90 days of Day  1: 
Anti-TNF therap y (e.g., adalimumab, etanercept, infliximab) 
Interleukin -[ADDRESS_658659] (anakinra) 
Intravenous immunoglobulin (I VIG) 
High dose prednisone or equivalent (>100 mg/day) 
Plasmap heresis.
26.Have received an y of the following within 60 days of Day  1: 
A non -biologic investigational agent (Investigational agent applies to an y drug 
not approved for sale in the country  in which it is being used.)
2016N272781_11 CONFIDENTIA L
205646
60Intravenous (IV) cy clophosphamide and, for [LOCATION_013]  only, oral 
cyclophosphamide
Any steroid injection (e.g., intramuscular [I M], intraarticular, or IV).
NOTE : New inhaled and topi[INVESTIGATOR_509415] 
(e.g., ey e drops, topi[INVESTIGATOR_142739]) are allowed. Any  NSAID use for <1week is 
allowed.
Diagnostic assessments
27.Positive immunodeficiency  virus (HIV) antibody  test.
28.Positive serology  for Hepatitis B, defined as (i) HB surface antigen positive 
(HBsAg+) OR (ii) HB core antibody  positive (HBcAb+).
29.Positive Hepatitis C (HCV) an tibody  test.
Other Exclusions
30.Have current drug or alcohol dependence, or a history  of drug or alcohol abuse or 
dependence within 364 day s prior to Day  1.
31.Sensitivity  to an y of the study treatments, or components thereof, or drug or other 
allergy  that, in the opi[INVESTIGATOR_871], contraindicates participation in the 
study .
32.Unable to administer study  treatment (belimumab) by  [CONTACT_509454].
6.3. Lifest yle Restrictions
No restrictions are require d.
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y randomized in the study . A minimal set of screen failure 
information is required to ensure transparent reporting of scr een failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorities. Minimal information 
includes demograph y, screen failure details, and eligibility  criter ia. SAEs are collected 
during screening if they  are related to study  participation.
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may be rescreened one time; all screening procedures must be repeated. 
7. TREATMENTS
Study  treatment is defined as any  investigational treatment(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according 
to the study  protocol.
2016N272781_11 CONFIDENTIA L
205646
617.1. Treatments A dministered
Study Treatment Name: [CONTACT_509488] 
([COMPANY_004]1550188)Rituximab Rituximab -placebo
Dosage formulation: Sterile, liquid 
product.Sterile, liquid 
concentrate.
Unit dose 
strength(s)/Dosage 
level(s):200 mg/mL; 1mL 
(deliverable)500 mg/50 mL
(single -use vial)
Route of Administration SC injection IV infusion IV infusion
Dosing instructions: Once weekly SC 
injection via 
autoinjector in thigh 
or abdomen1000 mg IV 
infusion at Week 4 
and Week 6IV infusion at Week 4 
and Week 6
Packaging and Labeling: Belimumab will be 
provided in cartons 
(5 auto -
injectors/carton). 
Each carton will be 
labeled as required 
per country 
requirement.Rituximab will be 
provided as a 
single 50 mLvial in 
its original carton. 
Each carton will be 
labeled as required 
per country 
requirement.Placebo is saline in 
250mL bags, s ourced 
locally
2016N272781_11 CONFIDENTIA L
205646
62Study Treatment Name: [CONTACT_509488] 
([COMPANY_004]1550188)Rituximab Rituximab -placebo
Manufacturer: Prefilled syringe:
Prefilled syringe 
components are 
procured from 
Becton Dickinson. 
Prefilled syringe is 
filled with drug 
product and 
assembled at [COMPANY_004], 
Barnard Castle, 
[LOCATION_006].
Autoinjector: The 
autoinjector 
components are 
manufact ured by 
[CONTACT_509455] 
(SHL) and 
assembled with the 
prefilled syringe at 
[COMPANY_004], Barnard 
Castle, [LOCATION_006].Single -Use Vial:
Refer to local 
rituximab approved 
label.
Device: Single -use 
autoinjectorNot applicable Not applicable
7.1.1. Medical Devices
The G SK manufactured medical devices (or devices manufactured for [COMPANY_004] by  a 
third party ) provided for use in this study  are injection devices: a prefilled sy ringe 
contained within an autoinjector device.
Instructions for medical device use are provided to the pa rticipant upon enrollment. 
[COMPANY_004] medical device incidents, including those resulting from malfunctions of the 
device, must be detected, documented, and reported by  [CONTACT_496961] . (See Section 9.7).
2016N272781_11 CONFIDENTIA L
205646
637.2. Dose M odification
No dose modifications of belimumab or rituximab/rituximab -placebo are allowed.
7.3. Method of Treatment A ssignment
All participants will be assigned to study  treatment in accordance with the randomization 
schedule and randomization must occur before any investigational product is 
administered. Participants will be centrall y randomized using an Interactive Web 
Response Sy stem (IWRS). Before the study  is initiated, the log in information and 
directions for the IWRS will be provided to each site. A part icipant will be assigned a 
subject number at the time the informed consent is signed. Once a subject number has 
been assigned to a participant, it cannot be re -assigned to another participant.
A randomization schedule will be generated with the following t reatment assignments:
Arm Treatment Description
A Belimumab SC for 52 weeks + Rituximab IV Placebo at Weeks 4 and 6
B Belimumab SC for 52 weeks + Rituximab IV [ADDRESS_658660] therapy for 104 weeks 
Study  treatment will be dispensed at the study  visits summarized in the SoA (Section 2). 
Returned study  treatment should not be re -dispensed to the participants. In the event that 
a subject is unable to attend their planned st udy visit (see Section 2) to receive their 
carton of belimumab autoinjectors, if allowable under local regulations and approved b y 
the sponsor , the investigator may  with the agreement of the subject arrange to have the 
autoinje ctors dispensed and shipped direct lyto the subject.
At least 280participants will be randomized in a 1:2:1 ratio to 1 of 3 treatment groups: 
belimumab plus rituximab -placebo (Arm A, target N= 70), belimumab plus rituximab 
(Arm B, target N=1 40), or belimum ab plus standard therap y (Arm C, target N= 70). 
Randomization of participants will be stratified b y screening SLEDAI -2K score ( 9 vs. 
10), immunosuppressant use at screening (immunosuppressant use vs. no use), and 
screening corticosteroid dose (prednisone equivalent 10 mg/day  vs. >10mg/day ).
7.4. Blinding
The study  is double -blind with regard to whether participants are randomized to Arm A 
(belimumab plus rituximab -placebo) or Arm B (belimumab plus rituximab). 
Randomization to Arm C will not be blinded. I n ord er to minimize bias given that Arm C 
is open -label, independent assessors blinded to treatment group (A, B, or C) will conduct 
the SL EDAI -2K assessments at selected visits, including those that are components of the 
primary  and major secondary  endpoints, o n the schedule provided in the SoA (Section 2).
2016N272781_11 CONFIDENTIA L
205646
64Investigators and the Sponsor/Study  Team will remain blinded to the results of the B cells 
subsets because those data could potentially  unblind whether or not the participant 
received rituximab.
An unblinded pharmacist will be used at each study site to prepare rituximab and its 
placebo for IV administration. Unblinded monitors will be assigned to review all 
pharmacy  records, storage, and procedures.
The I WRS will b e programmed with blind -breaking instructions. In case of emergency , 
the investigator has the sole responsibility for determining if unblinding a participant’s 
treatment assignment is warranted . Participant safety  must alway s be the first 
consideration in making such a determination. If a participant ’s treatment assignment is 
unblinded , [COMPANY_004] must be notified within [ADDRESS_658661] be recorded in the source documentation and 
electronic Case Report Form ( eCRF ), as applicable.
An unblinded pharmacist at each site will be assigned to use the I WRS randomization 
software, to order and to receive all drug shipments and notifications.
A participant may  continue in the study  if that participant’s tr eatment assignment is 
unblinded by  [CONTACT_509456]. The event or condition which led to 
the unblinding will be recorded in the eCRF.
An Independent Data and Monitoring Committee (IDMC) will conduct periodic reviews 
of unblinded data to ensure external objective and/or statistical review of safety  issues 
(see Section 10.4.4 ). The composition, remit, and procedures of the IDMC are provided 
in the I DMC Charter.
Review and adjudication of treat ment failures, AEs of special interest and protocol 
deviations will be performed by  [CONTACT_509457] 52and 
end of study  data base locks (DBLs). Subject level data will not be shared with site 
personnel until after the end of study  reporting is complete. 
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  participant with a Serious Adverse Event (SAE) for 
purposes of regulatory  reporting .If the SAE requires that an exp edited regulatory  report 
be sent to one or more regulatory  agencies, a copy of the report, identify ing the 
participant’s treatment assignment, may  be sent to investigators in accordance with local 
regulations and/or [COMPANY_004] policy .
7.5. Preparation/Handling/Storage /Accountability
1.The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
2.Only  partic ipants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
2016N272781_11 CONFIDENTIA L
205646
65automated) area in accor dance with the labeled storage conditions with access 
limited to authorized unblinded site staff, e.g., unblinded pharmacist. 
3.The investigator, institution, the head of the medical institution or delegate (where 
applicable) is responsible for study  treatm ent accountability , reconciliation, and 
record maintenance (i.e., receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  treatment 
are provided in the SRM . 
Under normal condition s of handling and administration, study  treatment is not 
expected to pose significant safet y risks to site staff . Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unintentional occupation al exposure notify  the monitor, Medical Monitor and/or 
[COMPANY_004] study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this i s required b y local laws, or is available upon request from 
[COMPANY_004].
7.6. Treatment Compliance
The first dose of belimumab will be administered by  [CONTACT_509458]. (Participants may  be assisted in administration of 
their SC dose of belimumab at this first dose and with subsequent doses .) 
Participants will remain in the clinic for at least 3 hours for observation. The date 
and time of the dose administered in the clinic will be recorded in the Patient Diary .
NOTE -1: If a participant misses a dose of belimumab on the scheduled day  of 
administration , instruct the participant to self -admin ister the missed dose as soon as 
possible during that dosing week. If subject did not self -administer the dose by  [CONTACT_509459] y dosing period, SKIP that dose . The participant should not administer 
two doses on the same day and t wo doses should not be administered to make up for 
a dose missed for a full [ADDRESS_658662] can resume 
self-administering belimumab weekly on their usual day  of administration.
NOTE -2: If a participant has administered a partial dose or was unable to completely  
self-administer adose of belimumab due to malfunction of the autoinjector or user 
error , instruct the subject to SKI Padditio nal attempts and not re -inject for that 
week’s belimumab dose.Thereafter, the subject should resume self -administering 
belimumab weekl y on their usual day  of administration during the following weekl y 
dosing period . The participant should not self -adminis ter [ADDRESS_658663] 
administration attempt .(See Section 9.7.8 -Device Malfunction) .
NOTE 3: Participants who miss [ADDRESS_658664] the Medical Monitor if participants miss 8 or mo re 
consecutive doses of belimumab to evaluate continuation in the study .
2016N272781_11 CONFIDENTIA L
205646
66When participants self -administer study  treatment at home, compliance with 
belimumab will be assessed through review of the self -injection patient diary  with 
each participant during s ite visits and documented in the source. A record of the 
number of belimumab autoinjectors dispensed to and taken b y each participant must 
be maintained and reconciled with study  treatment and compliance records. 
Treatment start and stop dates, including d ates for treatment delay s will also be 
recorded in the eCRF.
Rituximab or rituximab -placebo will be administered IV to participants at the site or 
infusion center, following administration of the premedication regimen. 
Administration of the premedication r egimen and the rituximab or rituximab -placebo 
will be documented in the source documents and reported in the eCRF, including 
whether the full infusion was administered and over what period of time. Study  
participant identification will be confirmed at the time of dosing by  a member of the 
study  site staff other than the person administering the study  treatment.
7.7. Concomitant Therapy
This section reviews the medications and the doses allowed and prohibited during the 
course of the stud y.
Any medication or vacc ine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving from the start of 
treatment until the follow -up visit at the time points specified in the SoA must be 
recorded along with:
reason for use
dates of administration including start and end dates
dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_43205] y questions regarding 
concomitant or prior therapy .
7.7.1. Allowable Medications
Participants must be on a stable SL E treatment regimen for at least 30 day s prior to Day  1 
(see Section 6.1). These medications may  include corticosteroids, anti -malarial agents, 
immunosuppressant agents and nonsteroidal ant i-inflammatory  agents (NSAIDs).
New SLE therap y other than corticosteroids must not be added within [ADDRESS_658665] concurrent medications (ad d, eliminate, change dose 
level/frequency ) as clinically  required; however, changes in certain medications (as 
outlined below) may  result in the participant being defined as a treatment failure. Rules 
regarding declaring a participant as a treatment failur e may  vary  according to timing and 
are handled differentl y in Arms A and B vs. Arm C. Participants declared treatment 
2016N272781_11 CONFIDENTIA L
205646
67failures are encouraged to remain in the study  and receive all efficacy  and safet y 
assessments through Week 104.
[IP_ADDRESS]. Anti-malarials
Anti-malar ial therapi[INVESTIGATOR_509405] E may be continued or dose adjusted during the study , and 
will be allowed within the definitions of the efficacy  endpoints. A new anti -malarial (e.g., 
hydroxychloroquine, chloroquine, quinacrine) may  not be started during the course of the 
study for SLE . Starting any  new anti -malarial treatment for SL E after Day  1 will declare 
the participant a treatment failure.
For non -SLE reasons (e.g., for the experimental treatment of COVID -19) an anti -malarial 
may be initiated for a subject not pre viously  on an anti -malarial, or dose increased above 
the common allowable maximum doses ( defined below )according to the following 
guidelines ,for short -term treatment :
< 21 day s treatment duration
Not during the intervals within 8 weeks before the key  efficacy  visits (actual visit 
date) at Weeks 52, 64, and 104.
An anti -malarial may  be replaced by  [CONTACT_509460] -malarial due to documented toxicity  or 
lack of availability  at an y time during the stud y.
Thecommon allowable maximum doses of anti -malarial drugs are:
Hydroxy chloroquine –400 mg/day
Chloroquine –500 mg/day
Quinacrine –100 mg/day
For compounded anti -malarials, no individual component may  exceed the maximum dose 
above.
Clinical loading dose is permitted for initiation or replacement.
NOTE: The use of anti -malarials for anti -malarial prophy laxis is permitted.
[IP_ADDRESS]. Corticosteroids
Received dose for all s ystemic corticosteroids will be converted to prednisone equivalent 
dose. As such, when “prednisone” is used throughout this protocol, it refers to prednis one 
dose or equivalent.
Total sy stemic corticosteroid dose is defined as the average daily  dose of all 
corticosteroids taken SC, IV, IM, intradermally , and orally  for both SL E and non -SLE 
reasons.
At baseline, the average daily  dose of corticosteroids is t he sum of corticosteroid dose 
over 7consecutive days up to, but not including Day  1, divided by  7. While on study  
2016N272781_11 CONFIDENTIA L
[ADDRESS_658666] dose of study  agent on Day  1, the investigator may  add corticosteroid 
medication as clinicall y required (for example, in order to manage the transition period 
for discontinuing immunosuppressants b y Week 4) .Dosage of corticosteroids may  be 
adjusted as clinicall y necessary until Week 12. After the initial 12 weeks of the study, a 
protocol specified corticosteroid taper is recommended to begin and should be initiated 
and conducted under the direction of the investigator. The taper will proceed with a tar get 
of reaching a prednisone equivalent dose of 5mg/day  by [CONTACT_10585] 26. The recommended 
corticosteroid taper scheme is described in Appendix 2. Corticosteroids may be adjusted 
as clinically  necessary  through Week 26, pa rticipants will not be declared treatment 
failures unless they  are not able to successfull y taper to a 7 -day average prednisone 
equivalent dose of 5mg/day  after Week 26 . For purposes of defining treatment failure, 
after Week 26, the average daily  dose of corticosteroids is the sum of corticosteroid dose 
on the 7 day s immediately  following the Week 26 visit, divided by  7 (the corticosteroid 
dose on the day  of the Week 26 visit is not included in the calculation). After Week 26, if 
a participant’s average daily dose of corticosteroid exceeds a prednisone equivalent dose 
of 5mg/day  at any  time the participant will be declared a treatment failure. (The date of 
treatment failure will be the end of the 7 -day interval which meets the treatment failure 
rule.)
If the investigator believes the participant would benefit from continued corticosteroid 
taper after Week 26, and if it is tolerated, a prolonged corticosteroid taper should 
continue with the goal of discontinuing corticosteroids. Recommendations for the 
schedule of this taper are included in Appendix 2. Participants who are able to tolerate the 
final taper will be withdrawn from corticosteroids. If a participant is unable to tolerate the 
final stage of the corticosteroid taper, the investigator may  reinitiate corticosteroids at a 
prednisone equivalent dose of up to and including 5 mg/day . If a 7-day average 
prednisone equivalent dose of >5 mg/day is required at an y time after Week 26, the 
participant will be considered a treatment failure for the efficacy  endpoints. Participants 
who are declared treatment failures are encouraged to remain in the study  through Week 
104 and receive all safet y and efficacy assessments.
For purposes of assessing the major secondary  endpoint at Week 64 (the proportion of 
participants with a state of clinical remission, defined as a Clinical SLEDAI -2K score = 
0), achieved without immunosuppressants and with corticosteroids at a prednisone 
equivalent dose of 0 mg/day  at Week 64), participants must be on a dose of 0 mg/day  on 
the 7 day s immediately  following the Week 64 visit (the corticosteroid dose on the day  of 
the Week 64 visit is not included in the calculation).
Intraarticular Injections:
Participants may  receive intraarticular injections duri ng the stud y with the exception 
of within 8 weeks prior to the key  efficacy  endpoints (i.e., Weeks 52, 64, and 104). A 
2016N272781_11 CONFIDENTIA L
205646
69participant who receives any  intraarticular injection(s) within 8 weeks before the 
Week 52, 64, and/or 104 visits will be defined as a tr eatment failure .
[IP_ADDRESS]. Corticosteroids for Reasons Other Than SLE Disease A ctivity
Corticosteroids for non -SLE reasons (e.g., asthma, contact [CONTACT_8748], etc) may  be given 
short -term at higher doses than 5mg/day  according to the following guidelines:
Up to 750 mg (prednisone) for 1 day ,
and/or
Up to 60mg/day  (prednisone) for 2 -3 day s ,
and/or
Up to 40 mg/day  (prednisone) for [ADDRESS_658667] be tapered to 5 mg/day  within [ADDRESS_658668] dose of a course of high 
dose corticosteroids given for non -SLE reasons. In addition no new high dose 
corticosteroids for reasons other than SL E are allowed that result in an average
corticosteroid dose of >5 mg/day during the intervals starting 8 weeks before the key  
efficacy  visits at Weeks 52, 64, and 104. During the intervals of 8 weeks before these 
efficacy  endpoints, an y new high dose cortico steroid use will declare the participant as a 
treatment failure. The day of the Week 44, 56, and 96 visits will count as the start of 
these 3 intervals.
NOTE: Inhaled and topi[INVESTIGATOR_509416] .
[IP_ADDRESS]. Other Immuno suppressant A gents
Belimumab SC 200 mg/week will be initiated in all treatment arms on Day  1 of the study . 
Participants who enter the study  on immunosuppressant therapy  in Arms A and B will 
continue their stable immunosuppressant regimen until up to Week 4 . At or prior to the 
Week 4 visit, immunosuppressants will be discontinued. Corticosteroids may  be adjusted 
as necessary  during this transition period. Participants in Arm C may  continue their 
immunosuppressant agents throughout the stud y.
Starting an y new immunosuppressant agent after Day  1 for increased lupus disease 
activity  will cause the participant to be declared a treatment failure. An 
immunosuppressant agent may  however be replaced with one of the agents listed below 
due to documented toxicity  or la ck of availability .
For participants in Arms A and B, the dose of existing immunosuppressant agents may  be 
adjusted, as clinicall y required, up to the Week 4 visit. Any  existing immunosuppressant 
agents will be discontinued at or prior to the Week 4 visit for Arms A and B.
2016N272781_11 CONFIDENTIA L
205646
70Participants in Arm C may continue their existing immunosuppressant agents throughout 
the course of the study . Dosage of existing immunosuppressant agents may  be increased 
as clinically  necessary  until Week 1 2. After the Week 1 2visit, an y increase in dose over 
the baseline (Day  1) or Week 1 2visit dose, whichever is higher, will cause the participant 
to be declared a treatment failure.
The common allowable maximum doses for immunosuppressant agents at baseline (Day  
1) and during the stud yare listed below:
Azathioprine –300 mg/day
6-mercaptopurine –300 mg/day
Mycophenolate mofetil (PO)/ my cophenolate mofetil hy drochloride (IV) –
4g/day
Mycophenolate sodium (PO) –2.88 g/day
Methotrexate –25 mg/week
Oral cy clophosphamide –2.5 mg/kg/day (Note: use not permitted in [LOCATION_013] )
Cyclosporine –4 mg/kg/day *
Tacrolimus –0.2 mg/kg/day *
Sirolimus –2 mg/kg/day*
Thalidomide –200 mg/day
Leflunomide –40 mg/day *
Mizoribine –150 mg/day
*Clinical loading dose is permitted when replacing immunosuppre ssant agents. 
Monitor blood levels as clinically  indicated.
An immunosuppressant agent may  be replaced with one of the agents above due to 
documented toxicity  or lack of availability . For other immunosuppressant agents not 
listed above, the investigator mu st contact [CONTACT_272124].
New topi[INVESTIGATOR_152094] (e.g., ey e drops, topi[INVESTIGATOR_142739]) are allowed after 
Day 1.
[IP_ADDRESS]. Nonsteroidal A nti-inflammatory  Drugs (NSA IDs), A spi[INVESTIGATOR_248], and 
Acetaminophen
Since NSAIDs and aspi[INVESTIGATOR_509417] (e.g., arthritis) and may  affect 
renal function (NSAID nephropath y), the use of these agents should be initiated and 
stabilized prior to entry  into the trial.
NSAIDs may  be continued and dose adjusted as clinically  indicated until 8 weeks be fore 
efficacy  visits, i.e., Weeks 52, 64, and 104. During the intervals of 8 weeks before these 
efficacy  endpoints, an y increase in the NSAID dose above the dose at Day  1 or the visit 
day starting the interval of 8 weeks prior to these key  efficacy  visits, whichever is higher, 
will declare the participant as a treatment failure unless the NSAID is given for <7 day s.
The day  of the Week 44, 56, and 96 visits will count as the start of these 3 intervals.
2016N272781_11 CONFIDENTIA L
205646
71New NSAIDs may  not be added after Day  1 unless given fo r <7 day s. Initiation of an 
NSAID after Day  1 that is given 7 day s will declare the participant as a treatment 
failure.
An NSAID may  be replaced with another NSAID due to documented toxicity  or lack of 
availability .
Daily  doses of aspi[INVESTIGATOR_155752] 1000 mg/da y are allowed at an y time during the study . Daily  
doses of aspi[INVESTIGATOR_438949] 1000 mg/day  may  be initiated at any  time up to the Week 44 visit 
and may  continue through the end of the stud y. For participants who never received an 
aspi[INVESTIGATOR_509418] a dose >1000 mg/day  between the Day  1 and Week 44 visit, starting a 
new aspi[INVESTIGATOR_509418] a dose >1000 mg/day  after the Week 44 visit will declare the 
participant a treatment failure unless the aspi[INVESTIGATOR_509419] <7 day s.
Acetaminophen (paracetamol) is primarily  an analgesic and lacks the anti -inflammatory  
properties of other NSAIDs. The use of acetaminophen is recommended when possible to 
treat non -SLE related conditions, in the absence of a pre -existing hepatic function 
deficiency .
7.7.2. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_509420] y time during the stud y 
will be considered treatment failures for anal ysis (i.e., non -responders). The Medical 
Monitor must be contact[CONTACT_509461].
The following medications and therapi[INVESTIGATOR_509421] :
Other investigational agents (biologic or non -biologic). Investigational applies to any  
drug not approved for sale in the country  in which it is being used.
Co-enrollment into another study  of a different investigational agent or that may  
interfere with the conduct of this protocol.
Anti-TNF therap y (e.g., adalimumab, etanercept, infliximab).
Other biologics with effects on the immune sy stem (e.g., abata cept, interleukin -[ADDRESS_658669] [anakinra]).
IVIG.
IV cyclophosphamide and for German y onl y, oral cy clophosphamide
Plasmapheresis.
7.7.3. Live Vaccines
Live vaccines are not permitted in the study . Participants who require a live vaccine 
during the stud y should have study  agent discontinued prior to receiving the live vaccine.
7.7.4. Additional SLE Therapy
In the 52 -week, double -blind treatment phase, participants in Arms A or B who fail to 
adequatel y respond to study treatment or in the medical judgment of the i nvestigator 
2016N272781_11 CONFIDENTIA L
205646
72cannot meet the corticosteroid taper rules, tolerate immunosuppressant withdrawal at 
Week 4, or who will require additional therap y will be considered treatment failures. 
Participants who are treatment failures will be encouraged to remain in t he study  and 
receive all safety  and efficacy  assessments through Week 104. At the discretion of the 
investigator, the participant may  continue to receive belimumab SC 200 mg/week. If 
additional medical treatment is necessary  it will also be at the discreti on of the 
investigator and may  include corticosteroids and/or immunosuppressants. 
In the 52 -week observational phase (Weeks 53 to 104), participants in Arms A and B 
may continue or reinitiate open -label belimumab SC 200 mg weekl y treatment if (a) they  
responded clinically  in the 52 -week treatment phase of the study  but did not meet the 
primary  efficacy  endpoint, or (b) responded clinically  but subsequentl y experienced an 
increase in disease activity requiring treatment. If a participant requires rescue the rapy in 
addition to the re -initiation of treatment with belimumab, corticosteroids >5 mg/day  of a 
prednisone equivalent and/or immunosuppressants may  be given at the discretion of the 
investigator. Reason for rescue therap y and medication dosing requiremen ts should be 
documented in source records. Treatment with open -label rituximab is allowed, but not 
encouraged. Belimumab will be provided by  [CONTACT_1758] , but other SLE treatments, 
including rituximab, will not be provided b y the sponsor . In these situations the 
participants in Arms A or B would be considered treatment failures for the efficacy  
endpoints. Participants who are declared treatment failures will be encouraged to remain 
in the study  and continue to receive all safet y and efficacy  assessments. Addit ional 
information on management of participants who receive open -label belimumab and/or 
rituximab, including the schedule for obtaining immunogenicit y samples, is provided in 
the SRM.
Participants in Arm C will continue to receive belimumab during Weeks 53 to 104. 
Participants in Arm C who, in the opi[INVESTIGATOR_871], require additional 
treatment, may  receive rescue therapy  including corticosteroids >5 mg/day of a 
prednisone equivalent and/or new, additional or increased immunosuppressants at the 
investigator's discretion. Treatment with open -label rituximab is allowed, but not 
encouraged. Other SL E treatments, including rituximab, will not be provided by  [CONTACT_10748] . In these situations, the participants in Arm C would be considered treatment 
failures for the efficacy  endpoints. Participants who are declared treatment failures will 
be encouraged to remain in the study  and continue to receive all safet y and efficacy  
assessments.
Management of additional SL E therapy , including required laboratory  tests a nd other 
procedures, is described in the SRM .
7.8. Treatment after the End of the Study
At the end of the stud y, participants who wish to continue treatment with belimumab may 
do so by  [CONTACT_53231] y available belimumab.
2016N272781_11 CONFIDENTIA L
205646
738. DISCONTINUA TION CRIT ERIA
8.1. Withdrawal from the Study
Participants are free to withdraw from the stud y at any time, for any  reason. Participants 
may withdraw consent, including use and disclosure of research -related health 
information at an y time, for an y reason. Participants may be withdrawn/removed, if 
necessary , by [CONTACT_509462] y, behavioral, administrative, or 
other reasons. It is understood by  [CONTACT_509463]; therefore, unnecessa ry withdrawal of participants should 
be avoided.
If a participant withdraws from the study , he/she may  request destruction of any  samples 
taken, and the investigator must document this in the site study  records.
In addition, for participants who are WOCBP who receive rituximab or rituximab -
placebo at the Week [ADDRESS_658670] dose of 
rituximab or rituximab -placebo was administered.
8.2. Discontinuation of Study  Treatment
Participants who discontinue study  treatment should be encouraged to continue to 
participate in stud y visits in accordance with the SoA (Section 2), especially  all 
remaining safet y evaluations.
If a participant experiences a clinicall y significant AE that the investigator believes may  
be definitel y, possibly, or probably related to study treatment and could potentially  be 
exacerbated b y the next dose, the investigator may delay  study  treatment dosing by  [CONTACT_509464]. If a similar concern is present at the time of the next 
scheduled dose, the investigator should contact [CONTACT_509465] (or rituximab -placebo) should be 
postponed further or discontinued.
Participants may  be withdrawn from study  treatment for an y of the following reasons:
Prohibited conc urrent medication or therap y or prohibited dose of concurrent 
medication or therap y (see Section 7.7.2 ).
Unacceptable toxicity .
Pregnancy  willrequire withdrawal from stud y treatment , belimumab and/or 
rituximab when the pregnancy  is recognized. Maintenance of contraception and 
monthly  telephone calls for urine pregnancy  test results will be required until 
12months after the last dose of rituximab or rituximab -placebo was 
administered . Participants who become pre gnant during the stud y will be 
encouraged to remain in the study  to be followed for all efficacy  and safety  
assessments including the course and outcome of the pregnancy . If the outcome 
of the pregnancy  occurs after a subject completes or leaves the stud y,attempts 
2016N272781_11 CONFIDENTIA L
205646
74will be made to obtain follow up information, including the outcome of the 
pregnancy .
NOTE: (German y onl y): Whether rituximab is excreted in human milk is not 
known. However, because maternal IgG is excreted in human milk, and 
rituximab was detec table in milk from lactating monkey s, women should not 
breastfeed while treated with rituximab and for 12 months following rituximab 
treatment.
All participants should be monitored closel y for infection. Participants who develop IgG 
<250 mg/dL confirmed by [CONTACT_75481] 1 week (>2 day s) after the initial result, will have 
study  treatment withheld, and the investigator must contact [CONTACT_509466] y treatment should be continued. In addition, increased vigilance for 
infection is recomme nded in participants who develop IgG <550 mg/dL. Those with a 
decrease in IgG below 400 mg/dL that is associated with a serious infection (i.e., an 
infection reported as an SAE) will be withdrawn from study  treatment. In addition, if any  
participant develo ps a life -threatening infection regardless of IgG status, the investigator 
must contact [CONTACT_509467]. 
Severe skin reactions such as Toxic Epi[INVESTIGATOR_509422] -Johnson 
syndrome, so me with fatal outcome, have been reported with the use of rituximab. I n 
case of such an event, treatment should be permanently  discontinued.
A participant will be withdrawn from study  treatment if he or she meets liver stoppi[INVESTIGATOR_31732] (defined in Section 8.2.1 ), presents with suicidal ideation of ty pe 4 or 5 on the 
C-SSRS, or in the investigator's judgment, the participant is at risk for a suicide attempt. 
Participants who are withdrawn from study  treatment wil l remain in the study  for 
observation and continue to have all safety  and efficacy  assessments.
For an y stud y participants exhibiting symptoms consistent with COVI D-19, please 
consider holding dosing of investigational product (I P) and consult with the Medical 
Monitor. I f a participant tests positive for COVID -19, or if no testing is available, hold 
dosing of IP until sy mptoms resolve and contact [CONTACT_1689]. If a positive 
COVID -[ADDRESS_658671] been designed to 
assure participant safety and evaluate liver event etiology .
Discontinuation of study  treatment is required when :
a participant meets one of the conditions outlined in Algorithm A or Algorithm B
OR
2016N272781_11 CONFIDENTIA L
205646
75when in the presence of abnormal liver chemistries not meeting protocol -specified 
stoppi[INVESTIGATOR_004], the investigator believes study  treatment discontinuation it is in the 
best interest of the participant.
Algorithm A: Phase III -IV Liver Chemistry Stoppi[INVESTIGATOR_6926] I ncreased Monitoring 
Algorithm
See Appendix 5 for liver safet y required actions and follow -up assessments.
2016N272781_11 CONFIDENTIA L
205646
76Algorithm B: Phase III -IV Liver Chemistry Increased Monitoring Algorithm with 
Continued Therapy for ALT 3xUL N but <8xULN
See Appendix 5 for liver safet y required actions and follow -up assessments.
8.2.2. Study Treatment Restart
If participant meets liver chemistry  stoppi[INVESTIGATOR_509423]:
[COMPANY_004] Medical Governance approval is granted
Ethics and/or I RB approval is obtained, if required, and
Separate consent for treatment restart is signed b y the participant
Refer to Appendix 6 for full guidance. 
8.3. Temporary  Discontinuation and Re -Start of Belimumab
Study  treatment with belimumab (Arms A/B and C) must be temporarily  withheld and 
the [COMPANY_004] medical monitor consulted about continued dosing if a subject experiences a 
neutrophil count <0.5x109/L.
Withdrawal of study  treatment does not require withdrawal from the study ; participants 
who discontinue study  treatment should be encouraged to continue the study  with all 
safet y and efficacy assessments. Participants who miss [ADDRESS_658672] ha ve the next dose of belimumab in the clinic and stay  for observation for 3 hours.
2016N272781_11 CONFIDENTIA L
205646
778.4. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator or the 
sponsor for safet y, behavioral, compliance, administrative or other reasons.
If the participant withdraws consent for disclosure of future information, the 
sponsor may  retain and continue to use any  data collected before such a 
withdrawal of consent .
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
Refer to the SoA (Section 2) for data to be collected at the time of study  
discontinuation and follow -up and for an y further evaluations that need to be 
completed.
8.5. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066]. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_43207]/or should continue in the study .
Before a participant is deemed lost to follow up, the investig ator or designee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 
3telephone calls and, if necessary , a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact [CONTACT_78779]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedu res and their timing are summarized in the SoA (Section 2). 
Protocol waivers or exemptions are not allowed. 
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awarene ss to determine if the participant should continue or 
discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
2016N272781_11 CONFIDENTIA L
205646
78All screening evaluations must be completed an d reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening 
log to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable . 
Procedures conducted as part of the participant’s routine clinical management (e.g., 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA.
The maximum amount of blood collected from each participant over the two 
year duration of the study  for study  related assessments, including an y extra 
assessments that may  be required, will not exceed 1100 mL,with the exception 
of additional blood required for the Blood Leukocy te anal ysis as specified 
below .
Additional blood (2 samples of 40 mL  each in Year 1 and 2 samples of 40 
mL each in Year 2) for the Blood Leukocy te anal ysis will be collected from 
participants from US study  sites. If a participant in the Blood Leukocy te 
analysis withdraws from the study  and completes an Early Withdrawal Visit, 
a 40 mL  sample will be collected at the Early Withdrawal Visit.
Repeat or unscheduled samples may  be taken for safet y reasons or for 
technical issues with the samples.
9.1. Screening A ssessments
Information collected during the screening phase assessments represent key data that 
identify  and define participant baseline status. This information is critical for the 
evalua tion and comparison of subsequent safet y and efficacy assessments.
Informed Consent 
Informed consent will be obtained from the participant prior to the initiation of any  study  
procedures or stud y-specific data collection.
Participants who give written con sent will enter a screening period of up to [ADDRESS_658673] been completed and 
eligibility  criteria confirmed. 
Screening A ssessments
During the screening period the following assessments will be performed:
Demographic parameters will be captured: year of birth, sex, race, and ethnicity .
Medical history /medication will be assessed as related to the exclusion criteria listed in 
Section 6.2. A complete med ical history  will be taken at the Screening Visit. I nformation 
from the medical history  is important to establish the baseline condition of the 
participant, and will impact the safet y monitoring assessments during the study. An y 
significant medical conditi ons affecting the participant in the past 5 y earsshould be 
2016N272781_11 CONFIDENTIA L
205646
79recorded on the Medical conditions page of the eCRF. The history  should include the 
following:
Past or current conditions
Prior surgical procedures
Pharmacotherap y and chronic or current use of an y medication or herbal 
preparation
Prior use of belimumab and/or rituximab
Allergies and significant allergic reactions
Significant infections, or history  of recurrent infection, including urinary  and 
respi[INVESTIGATOR_36115]
Smoking history  (current o r previous smoker, number of cigarettes smoked per 
day)
Cardiovascular medical history /risk factors (as detailed in the eCRF).
Pregnancy  Test 
A serum pregnancy  test will be performed for women of child -bearing potential at the 
Screening Visit and a urine pregnancy  test will be performed during each subsequent 
clinic visit. Refer to the pregnancy section (Section 9.7.6 ). (Arge ntina only : Additional 
urine pregnancy  tests will be performed at specified study  weeks (i.e., non visit weeks) 
during stud y year 2 (see SoA in Section 2).
Full phy sical examination
The full phy sical examination will include complete assessment of all organ sy stems 
including assessments of the hea d and neck (including ey es, ears, nose, throat, and 
thyroid gland), skin, musculoskeletal (including evaluation of both small and large 
joints), neurological, respi[INVESTIGATOR_696] , and cardiovascular s ystems, gastrointestinal sy stem, and 
abdomen (including liver an d spleen), l ymph nodes and extremities.
Electrocardiogram
A single 12 -lead ECG will be obtained at screening using an ECG machine that 
automatically  calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
Laboratory  tests
The following labor atory tests will be performed at screening, as related to the eligibility  
criteria described in Section 6.2.
Autoantibodies and complement
HIV, hepatitis B and Hepatitis C screen
Immunoglobulin (IgG, IgA, IgM)
2016N272781_11 CONFIDENTIA L
205646
80Urinaly sis
Hematology  and blood chemistry
Drug and alcohol screen
PT/PTT
Repeat samples may  be taken for retesting for technical issues with the samples. I f the 
investigator decides to repeat a laboratory  test of an abnormal (exclusionary) value, it is 
recommended that the investigator contact [CONTACT_509468]. 
Sharing the relevant medical history  and current findings with the [COMPANY_004] Medical Monitor 
would help to determine if re -testing is warranted.
SLEDA I-2K
The SL EDAI -2K is a clinic al index for measuring SLE disease activit y in the previous 
10days.
9.2. Assessments at Baseline
Procedures at the Baseline Visit are listed in the SoA (Section 2). They  include clinical 
and efficacy  assessments, pa tient reported outcome (PRO) assessments, laboratory  tests, 
pharmacokinetics, pharmacogenetics, biomarkers and blood samples for immunogenicit y. 
The interim medical history , including SLE medications, should be reviewed to assure 
that the participant's eli gibility  for the study  has not changed. Additional information 
about these procedures are provided in Section 9.6(clinical and efficacy ), Section 9.6.1
(patient repo rted outcome assessments), Section 9.9.4 (laboratory  tests), Section 9.10
(pharmacokinetics), Section 9.11 (pharmacod ynam ics), Section 9.12 (genetics), Section 
9.13 (biomarkers) and blood samples for immunogenicity  (Section 9.13.1 ) and in the
SRM.
9.3. Assessments at Scheduled Visits
Procedures at the Scheduled Visits are listed in the SoA (Section 2). They  include clinical 
and efficacy  assessments, patient reported outcome assessments, laboratory tests, 
pharmacokineti cs, biomarkers, and blood samples for immunogenicity . Time windows 
are provided for each study  visit to allow flexibility  in site and participant scheduling. All 
study  visits should occur within the visit window of the scheduled study  visit. A dditional 
information about these procedures are provided in Section 9.6(clinical and efficacy ), 
Section 9.6.1 (patient reported outcome assessments), Section 9.9.4 (laboratory  tests), 
Section 9.10 (pharmacokinetics), Section 9.11 (pharmacod ynamics), Section 9.13
(biomarkers) and blood samples for immunogenicity  (Section 9.13.1 ) and in the SRM. 
Participants who are deemed treatment failure and/or discontinue study  treatment ,but 
remain in the study ,will follow the study  visit schedule.
9.4. Assessments at Unscheduled Visits
Unscheduled visits may  be performed for a variety  of reasons, including safety . The
specific procedures to be performed at an Unscheduled Visit depend on the reason for the 
2016N272781_11 CONFIDENTIA L
205646
81Unscheduled Visit. Add itional information on the procedures to be performed at an 
Unscheduled Visit isprovided in the SRM.
Note: if a subject is unable to attend their scheduled visit, for example as a consequence 
of restrictions related to the COVID -[ADDRESS_658674] b y telephone or video call to review adverse 
events ( including suicidal ideation/behavior and neurological s ymptoms ), concomitant 
medications and ongoing SLE treatments including belimumab . These reviews will be 
documented in the source records and the eCRF .Such telephone/video contacts may  be 
recorded as unscheduled visits. No attempt should be made to perform efficacy  
assessments at these telephone/video contacts.
9.5. Assessments at Early  Withdr awalVisits and Follow -up 
Visits
Participants who discontinue study  treatment and withdraw from the study  up to Week 52 
are required to complete an Early Withdrawal Visit and a Follow -up Visit; the Early 
Withdrawal Visit is scheduled [ADDRESS_658675] dose of belimumab. Participants in 
Arms A or B who withdraw from the stud y after Week 52 are required to complete an 
Early Withdrawal Visit 1 -4 weeks after withdrawal from the study . Participants in Arm C 
who discontinue study  treatment and withdraw from the study  after Week 52 are required 
to complete an Early  Withdrawal Visit and a Follow -up Visit; the Early Withdrawal Visit 
is scheduled [ADDRESS_658676] dose of belimumab. Procedures at the Early  Withdrawal
Visits and Follow -up Visits are listed in the SoA (Section 2).
9.6. Efficacy  Assessments
Overview
Planned time points for all efficacy  assessments are listed in the SoA (Section 2). At 
selected time points, the SL EDAI -2K is performed by  [CONTACT_509469] t group assignment. Time windows are provided for 
each stud y visit to allow flexibility  in site and participant scheduling. All study  visits 
should occur within the visit window of the scheduled study  visit. Details regarding the 
conduct of the efficacy  assessments described below are provided in the SRM . In 
addition, information from the SL EDAI -2K, PGA, laboratory  tests, use and doses of SL E 
medications, and clinical evaluations will be used to calculate the Lupus Low Disease 
Activity  State (LLDAS) [ Franklyn , 2016].
SLEDA I-2K
The SL EDAI -2K is a clinical index for measuring SLE disease activit y in the previous 
10days.
2016N272781_11 CONFIDENTIA L
205646
82Physician's Global A ssessment
The Phy sician's Global Assessment (PGA) is a phy sician -reported visual analogue scale 
that provides an overall measure of the participant's current disease activity . 
SLICC -ACR Damage Index
The Sy stemic Lupus International Collaborating clinics (SLICC) -American College of 
Rheumatology  (ACR) Damage Index measures irreversibl e changes occurring since the 
diagnosis of SLE.
SLE Flare Index
The SL E Flare Index identifies whether a participant has experienced a mild/moderate or 
severe flare.
Lupus Low  Disease A ctivity State 
The Lupus Low Disease Activity  State (LLDAS) incorporate s multiple measures of 
disease activity , specifically :
SLEDAI -2K 4, with no activity  in major organ sy stems (renal, CNS, 
cardiopulmonary , vasculitis, fever) and no hemol ytic anemia or gastrointestinal 
activity
No new features of lupus disease activity  com pared with the previous assessment
PGA (scale 0 -3) 1
Current prednisolone (or equivalent) dose 7.5 mg daily
Well tolerated standard maintenance doses of immunosuppressive drugs and 
approved biological agents, excluding investigational drugs.
9.6.1. Patient -Repo rted Outcomes A ssessments
Patient-Reported Outcome (PRO) questionnaires will be completed b y participants at 
clinic visits on the schedule outlined in the SoA (Section 2). PRO questionnaires should 
be completed b y participants, whenever possible before the investigator ’s safet y
evaluation and efficacy assessment (e.g., SLEDAI- 2K)at a clinic visit, in the order 
specified in the SRM. Patient interviews (post -treatment and exit interviews) will be 
conducted in a subgroup of partic ipants, as described below.
Patient Global A ssessment
The Patient Global Assessment (PtGA) asks participants to rate the severity of their SL E 
between 0 ( ) and 10 ( ) that best represents their current level of 
disease activity . (“Consider ing all of the way s your sy stemic lupus ery thematosus (lupus) 
affects y ou, how do y ou feel y our lupus is today ?”)
CCI
CCI
2016N272781_11 CONFIDENTIA L
205646
83FACIT-Fatigue
The Functional Assessment of Chronic Illness Therap y -Fatigue Scale (FACI T-Fatigue) 
version 4.0 includes 13 fatigue -related it ems that ask patients to rate fatigue during the 
previous 7 day s, yielding an overall score from 0 to 52 , with lower scores representing 
worse fatigue (www.facit.org). The use of the FACI T-fatigue scale in SLE patients has 
been validated by  [CONTACT_509470] [Lai, 2011] and together with results from other studies 
including Cella and colleagues [ Cella , 2005] , anMCI D of ≥4 was concluded [Lai, 2011].
LupusQoL
The LupusQoL is a valid SL E-specific health related qualify  of life (HRQOL) instrument 
with 34 questions across 8 domains. Questions are related to the patient experience in the 
prior 4 we eks, and a 5- point L ikert response format is used, ranging from 0 (
 to 4 ( ) . A LupusQoL  summary  score for each domain is reported on a 0 to 100 
scale, with greater values indicating better HRQOL [ McElhone , 2007].
WPA I: Lupus
The Work Productivity  and Activity  Impairment Questionnaire (WPAI) is a measure of 
overall work impairment that discerns time missed from work and impairment of work 
and regular activities due to a specific disease or health problem. WPAI  outcomes include 
work time missed, impairment while working, overall work productivity  impairment and 
activity  impairment expressed as impairment percentages with higher percentages 
imply ing greater impairment and less productivity  [Reill y, 1993]. The WPAI : Lupus 
reflects the impairments due to lupus. 
Patient Interviews
Patient interviews will provide a qualitative summary  of participants' experience of 
treatment benefits, treatment satisfaction, and experience as a stud y participant. Adverse 
events will not be solicited during the interview however, if a nSAE is described by  [CONTACT_2416], it will be collected and processed according to [COMPANY_004] required timelines and 
procedures .These interviews will be conducted in a subgroup of participants in the US at 
the Week 52 and Week 104 study  visits (or upon early  withdrawal after Week 12 ).
Interview questions designed to fully  assess a participant 's experience with a study  
medication will be administered in a sem i-structured format b y a trained interviewer. 
Participant feedback will be captured in a data collection sheet as well as being audio -
taped for subsequent transcription and qualitative anal ysis. The interview technique and 
questions will be described in th e SRM .
9.7. Adverse Events
The definitions of an AE or SAE can be found in Appendix 7 .
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment (see Section 8). 
CCI
CCI
CCI
2016N272781_11 CONFIDENTIA L
205646
849.7.1. Time Period and Frequency  for Collecting A E and SA E 
Information
All SAEs will be collected from the start of treatment until the follow -up visit at 
the time points specified in the SoA (Section 2).However, any  SAEs assessed as 
related to stud y participation (e.g., stud y treatment, protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a subject consents to participate in the 
study .
All AEs will be collected from the start of treatment until the follow -up visit at 
the time points specified in the SoA (Section 2).
Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the case report form (CRF) not the AE section.
All SAEs will be recorded and reported to the sponsor or designee immediately  
and under no circumstance sho uld this exceed 24hours, as indicated in 
Appendix 7 . The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigators are not obligated to activel y seek AEs or SAE s in study  
participants after completion of their participation in the study . However, if the 
investigator learns of an y SAE, including a death, at an y time after a participant 
has been discharged from the study , and he/she considers the event to be 
reason ably related to the study  treatment or study  participation, the investigator 
must promptly  notify  the sponsor.
The method of recording, evaluating, and assessing causality  of AEs and SAEs 
and the procedures for completing and transmitting SAE reports are p rovided in 
Appendix 7 .
9.7.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method t o inquire about 
AEoccurrence. 
9.7.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs and non -serious and serious AEs of 
special interest (AESI ) (i.e., infections, malignancies, and depression/suicidality /self-
injury ) will be followed until the event is resolved, stabilized, otherwise explained, or the 
participant is lost to follow -up (as defined in Section 8.5). Further information on follow -
up procedures is given in Appendix 7 .
9.7.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so 
that legal obl igations and ethical responsibilities towards the safet y of 
2016N272781_11 CONFIDENTIA L
205646
85participants and the safety  of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety  reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy  and forwarded to investigators as necessary .
An inves tigator who receives an investigator safety report describing a SAE or 
other specific safet y information e.g., summary  or listing of SAE sfrom the 
sponsor will review and then file it along with the IB and will notify  the 
IRB/IEC, if appropriate according to local requirements.
9.7.5. Cardiovascular and Death Events
For an y cardiovascular events detailed in Appendix 7 and all deaths , whether or not they  
are considered SAEs, specific Cardiovascular (CV) and Death sections of t he CRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non -cardiovascular death. 
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the CRF within one week of receipt of a CV Event data query  prompting its completion.
The Death CRF is provided immediately  after the occurrence or outcome of death is 
reported. I nitial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
9.7.6. Pregnancy
Details of all pregnancies in female participants will be collected after the start of 
study  treatment and until [ADDRESS_658677] dose of belimumab or 12 months
(i.e., Week 58) after the last dose of rituximab/rituximab -placebo, whichever is later.
If a pregnancy  is reported, the investigator should inform [COMPANY_004] within 24 hours of 
learning of the pregnancy  and should follow the proced ures outlined in Appendix 3 .
Abnormal pregnancy  outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAEs.
9.7.7. Medical Device Incidents
Medical devices (i.e., belimumab autoinjector) are provided for use in this study  for the 
purposes of self -administration of study  treatment. I n order to fulfill regulatory  reporting 
obligations worldwide, the investigator is responsible for the detection and 
2016N272781_11 CONFIDENTIA L
205646
86documentation o f events meeting the definitions of incident or malfunction that occur 
during the stud y with such devices. 
The definition of a Medical Device Incident can be found in Appendix 8 .
NOTE: Incidents fulfilling the defini tion of an AE/SAE will also follow the processes 
outlined in Section 9.7.1 and Appendix 7 of the protocol. 
Also see Section 7.6regarding instructions to subjects in the event of a device 
malfunction .  
[IP_ADDRESS]. Time Period for Detecting Medical Device Incidents
Medical device incidents or malfunctions of the device that result in an incident 
will be detected, documented, and reported dur ing all periods of the study  in 
which the medical device is used. 
If the investigator learns of an y incident at an y time after a participant has been 
discharged from the study, and such incident is considered reasonabl y related to 
a medical device provide d for the stud y, the investigator will promptl y notify the 
sponsor.
The method of documenting Medical Device Incidents is provided in Appendix 
8.
[IP_ADDRESS]. Follo w-up of Medical Device Incidents
All medical device incidents invo lving an AE or SAE will be followed and 
reported in the same manner as other AEs (see Section 9.7.1 ). This applies to all 
participants, including those who discontinue study treatment or the stud y.
The investiga tor is responsible for ensuring that follow -up includes an y 
supplemental investigations as indicated to elucidate the nature and/or causality  
of the incident.
New or updated information will be recorded on the originally  completed form 
with all changes sig ned and dated b y the investigator.
[IP_ADDRESS]. Prompt Reporting of Medical Device Incidents to Sponsor
Medical device incidents will be reported to the sponsor within 24 hours after 
the investigator determines that the event meets the protocol definition of a 
medical device incident.
The Medical Device Incident Report Form will be sent to the sponsor by  [CONTACT_509471] -coordinator .Regulatory  Reporting Requirements for Medical Device 
Incidents .
The Device Malfun ction/Failure Reporting Form will be sent to the sponsor 
along with the Medical Device Incident Form ( see Section 9.7.8 ).
The investigator will promptly  report all incidents occurring with any  medical 
device provided for use in the study  in order for the sponsor to fulfil l the legal 
2016N272781_11 CONFIDENTIA L
205646
87responsibility  to notify  appropriate regulatory  authorities and other entities about 
certain safet y information relating to medical devices being used in clinical 
studies.
The investigator, or responsible person according to local requirements (e.g., the 
head of the medical institution), will comply  with the applicable local regulatory  
requirements relating to the reporting of incidents to the I RB/IEC.
9.7.8. Device Malfunction
Medical devices (Belimumab Autoinjector) that are provided for use in this study  for the 
purposes of self -administration of study  treatment may  malfunction during use (e.g., parts 
missing, device leaking, needle bent). The i nformation provided in this section applies to 
occurrence and reporting of device malfunctions that are NOT associated with an 
AE/SAE.
If when using an autoinjector ,the subject experiences a device malfunction, the 
participant should stop using the device and SKIP additional attempts and not re -inject 
for that week’s belimumab dose. (See N OTE -1in Section 7.6for additional instruction 
regarding administration of study  treatment following a device malfunction). 
The subject should record the malfunction in the Smartphone and contact [CONTACT_509472] a spossible to report the device malfunction. The study  site sh ould 
record the malfunction on the Device Malfunction /Failure Reporting Form (see form in 
the SRM ) and forward the information to [COMPANY_004] as described on the form by [CONTACT_509473] . The subje ct should retur nthatmalfunctioned device to the study  site at the 
next scheduled visit for shipment back to [COMPANY_004] for evaluation.
9.8. Treatment of Overdose
For this study , any  dose of belimumab greater than [ADDRESS_658678] been consistent with those expected for 
belimumab.
Two doses up to 20 mg/kg administered [ADDRESS_658679] been give n to 
humans with no increase in incidence or severit y of adverse reactions compared with 
doses of 1, 4, or 10 mg/kg.
[COMPANY_004] does not recommend specific treatment for an overdose of belimumab.
For this study , any  dose of rituximab in excess of 1000 mg IV withi n a 24 hour period 
will be considered an overdose. There has been no experience of overdosage with 
rituximab. [COMPANY_004] does not recommend specific treatment for an overdose of rituximab.
In the event of a belimumab and/or rituximab overdose, the investigator sh ould:
1.Contact [CONTACT_27465] .
2016N272781_11 CONFIDENTIA L
205646
882.Closely  monitor the participant for AEs/SAEs
3.Document the quantit y of the excess dose as well as the duration of the overdosing.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_509474].
9.9. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA (Section 2).
9.9.1. Physical Examinations
The full phy sical examination at screening will include complete assessment of 
all organ s ystems including assessments of the head and neck (including eyes, 
ears, nose, throat, and thy roid gland), skin, musculoskeletal (including 
evaluation of both small and large joints), neurological, respi[INVESTIGATOR_696] , and 
cardiovascular s ystems, gastrointestinal s ystem, and abdomen (including liver 
and spleen), l ymph nodes and extremities.
A symptom -driven phy sical examination at the scheduled and unscheduled 
clinic visits w ill include, at a minimum, assessments of eyes, mouth, skin, lungs, 
cardiovascular s ystem, abdomen and extremities (including joints).
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.9.2. Vital Signs
Blood pre ssure and pulse measurements will be assessed with a completel y 
automated device. Manual techniques will be used only  if an automated device 
is not available.
Blood pressure and pulse measurements should be preceded b y at least 
5minutes of rest for the pa rticipant in a quiet setting without distractions (e.g., 
television, cell phones).
Vital signs will be measured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_658680] and 
will include temperature, sy stolic and diastolic blood pressure, and pulse. 
9.9.3. Electrocardiogra ms
A single 12 -lead ECG will be obtained during screening using an ECG machine 
that automatically  calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals.
9.9.4. Clinical Safety  Laboratory  Assessments
Refer to Appendix [ADDRESS_658681] of clinical laboratory  tests to be performed and 
to the SoA for the timing and frequency . 
2016N272781_11 CONFIDENTIA L
205646
89The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stu dy in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be mor e severe than expected for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within [ADDRESS_658682] dose of study  
treatment should be repeated until the va lues return to normal or baseline or are 
no longer considered significantly  abnormal by  [CONTACT_43210]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as defined in Appendix [ADDRESS_658683] any  signs or s ymptoms 
consistent with the diagnosis of Progressive Multifocal Leukoencephalopathy  (PML) will 
be conducted b y the investigator or designated site staff at each visit. If a question is 
answere d 'yes' and the reason for the s ymptom is unknown (i.e., is not definitively  
explained by  [CONTACT_509475]), the participant will be referred to a neurologist for 
evaluation and the medical monitor contact[CONTACT_11252] 24 hours. An MRI  with gadolinium 
enhance ment (pending renal function evaluation) and/or cerebrospi[INVESTIGATOR_872] (CSF) JCV 
PCR is recommended to be performed to confirm the diagnosis of PML, if suspected . 
9.9.6. Suicidal Risk Monitoring
There have been some reports of suicidal ideation or behavior s ymptoms , as reported in 
the product label in some patients being treated with belimumab for SL E. [COMPANY_004] considers 
it important to monitor for such events before and during clinical studies with compounds 
such as this.
Participants being treated with belimumab should be monitored appropriately  and 
observed closely  for suicidal ideation and behavior or any  other unusual changes in 
behavior. Consideration should be given to discontinuing belimumab in participants who 
experience signs of suicidal ideation or behavior. 
Families and caregivers (where appropriate and at the discretion of the participant) of 
participants being treated with belimumab should be alerted about the need to monitor 
participants for the emergence of unusual changes in behavior, as well as the emerg ence 
of suicidal ideation and behavior and to report such sy mptoms immediately to the study  
investigator.
Baseline assessment of suicidal ideation and behavior AND treatment emergent suicidal 
ideation and behavior will be assessed during Study  205646 using C-SSRS. I t is 
2016N272781_11 CONFIDENTIA L
205646
90recommended that the Investigator consider mental health consultation or referral for 
subjects who experience signs of suicidal ideation or behavior. The Medical Monitor 
should be notified when these events occur. In addition, a “y es” to any suicidal behavior 
or ideation question on the C -SSRS prompts the completion of the Possible Suicidality  
Related Questionnaire (PSR Q).Details of the C -SSRS and PSRQquestionnaires will be 
provided in the SRM .
9.10. Pharmacokinetics
Blood samples of approximatel y 2mLeach will be collected for measurement of 
serum concentrations of belimumab or rituximab, respectivel y, as specified in the 
SoA. Instructions for the collection and handling of biological samples will be 
provided b y the sponsor. The actual date and time (24 -hour clock time) of each 
sample will be recorded.
Samples will be used to evaluate the pharmacokinetics ( PK)of belimumab or 
rituximab. For each belimumab and rituximab PK sample collection the following 
is required: collect 2 mL whole blood into a 2 mL serum blood collection tube. 
Specimen will be allowed to clot and the tube then centrifuged at approximately  
1600 g for 15 minutes at room temperature to separate the clot from the serum. 
The resultant serum will be transferred to appropriately  labe led 1.8 mL 
polypropylene tubes.
Samples collected for analy ses of belimumab or rituximab serum concentrations 
may also be used to evaluate safety  or efficacy  aspects related to concerns arising 
during or after the study .
Genetic anal yses will not be perfor med on these serum samples.
Drug concentration information that would unblind the study  will not be reported to 
investigative sites or blinded personnel until the study  has been unblinded.
9.11. Pharmacody namics
Blood Leukocy te Analysis
Blood sample sfor B cell analysis will be collected as indicated in the SoA (Section 2). B
cell flow cy tometry  panels will be used to measure changes over the course of therapy in 
blood cells, B cells and B cell subsets including but no t limited to: the transitional, naive, 
memory , activated and plasma B cell compartments. For subsets of interest, absolute 
numbers of cells and proportions relative to all B cells will be determined.
Further Research
Further research samples are optional a nd will be reported separate from the Clinical 
Study  Report (CSR) including but not limited to:
Additional blood samples for further B cell research will be collected from subjects at 
select European study  sites as indicated in the SoA (Section 2).
2016N272781_11 CONFIDENTIA L
205646
91Peripheral blood mononuclear cells (PBMCs) may be collected only at US study  sites to 
allow for examination of additional selected leukocyte populations to support further 
evaluation of the mechanisms of action of stu dy treatment.
9.12. Genetics
A 6mL blood sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analy sis component of the study . Participation is 
optional. Participants who do not wish to participate in th e genetic research may  still 
participate in the stud y.
In the event of DNA extraction failure, a replacement genetic blood sample may  be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was i ncluded in the original consent.
See Appendix 10 for information regarding genetic research. Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM . 
9.13. Biomarkers
Biom arker anal yses are specified in the following sections. 
Biomarker assessments designated as “further research” require an additional further 
research consent and will be reported separate from the CSR.
Remaining aliquots of any biomarker samples collected as part of this protocol may  be 
utilized for future anal yses as permitted b y consent and local regulations.
9.13.1. Immunogenicity  Assessments
Serum samples will be collected for belimumab (Arms A, B, and C) and rituximab 
(Arms A and B) immunogenicity  assessment sas indicated in the SoA ( Section 2).
9.13.2. RNA
Blood samples will be drawn before dosing on Day 1 (Baseline) for anal ysis of interferon 
signature.
9.13.3. B Cell Receptors
Blood sample sfor further research B cell receptor analysis will be drawn as indicated in 
the SoA (Section 2). Blood samples for B cell receptor anal ysis will also be drawn if the 
participant experiences a suspected SLE Flare, as defined b y the SLE Flare I ndex.
9.13.4. BLyS Protein
Blood samples will be collected for quantification of BLy S protein levels as indicated in 
the SoA ( Section 2).
2016N272781_11 CONFIDENTIA L
205646
929.14. Medical Resource Utilization and Health Economics
Health care resource utilization (HCRU ) data will be collected for all participants 
throughout the stud y. Participants will be asked to record medical encounters each week
(see SoA, Section 2). Protocol -mandated medical resource utilization is exclu ded. The 
investigator and clinical site staff will review the reported HCRU at each visit . The data 
will be used to conduct exploratory  economic analy ses and will include:
Number of outpatient/hospi[INVESTIGATOR_509424]
Number of emergency  room /urgent care fac ilityvisits
Number and duration of in -patient hospi[INVESTIGATOR_602] (total nights, including 
duration by  [CONTACT_54006] [intensive care unit vs. general ward])
Use of over the counter (non -prescription) medication.
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
The primary  obje ctive of the study  is to demonstrate superiority  (improvement in 
response rate) of co -administration of belimumab plus rituximab (Arm B: Combination) 
over belimumab monotherap y (Arm A: Control), when comparing the primary  efficacy  
endpoint at Week 52 in su bjects with SL E. An exploratory  assessment of the relative 
performance of Arm A (control) and Arm B (combination) vs. standard SLE therapy  
(Arm C) will also be conducted.
The primary  efficacy  endpoint is defined as: the proportion of participants with a st ate of 
disease control defined as a SL EDAI -2K score 2, achieved without 
immunosuppressants and with corticosteroids at a prednisone equivalent dose of 
5mg/day  at Week 52.
Null Hypothesis (H 0): There is no difference between Arm B 
(combination) and Arm A (control) in terms of the 
primary  endpoint at Week 52.
Alternative Hypothesis (H 1): There is a difference between Arm B (combination) 
and Arm A (control) in terms of the primary  
endpoint at Week 52.
A step -down sequential testing procedure will be used to control the overall ty pe 1 error 
rate for comparing Arm B (combination) vs Arm A (control). With this procedure, the 
primary  endpoint will be evaluated first and then the two major secondary  endpoints (i.e., 
Clinical SLEDAI 2K score =0 at Week 64 next a nd then SL EDAI -2K score 2 at Week 
104) for statistical significance based on the pre -specified sequence for interpretation. 
Specificall y, endpoints will be tested in the sequence above (2 -sided alpha=0.05) 
provided that statistical significance is achieve d by [CONTACT_509476]. If at any  point in the 
2016N272781_11 CONFIDENTIA L
[ADDRESS_658684] completed 52 weeks of 
the study , if feasible .If the Week 52 database freeze is delay ed due to COVID -19 
pandemic ,the ti ming of the Week 52 reporting may be reviewed and changes will be 
documented in the RAP.
End of Study  Analysis
After the initial 52 week double -blind phase, participants in Arms A and B will enter into 
the 52 -week double blind treatment -free, observational phase of the stud y (Weeks 53 
through 104). Participants in Arm C will continue to receive belimumab SC and standard 
therap y, which may include their stable immunosuppressants, during Weeks [ADDRESS_658685] 9 8% power (for the comparison of Arm B to Arm A at Week 52) at the 
5% level of significance assuming the un derly ing response in the control arm is 10% and 
the true population effect is 25% with treatment Arm B (combination assumed response 
rate of 35%). The primary  endpoint will be based on assuming study  dropouts = 
treatment failures, and so the assumed respo nder rates for treatment Arms A and B 
alread y account for participant dropout rates. However , the sample size may  be increased 
up to a maximum of [ADDRESS_658686]. No inferential tests are planned between Arm C and Arm A or Arm 
B; therefore no adjustment for multiplici ty is required. 
There are limited clinical data with therapi[INVESTIGATOR_509425]. 
Based on elicitation of opi[INVESTIGATOR_509426], as well as the rarit y of remission or 
disease control seen in published external studies and inte rnal [COMPANY_004] review of previous 
belimumab data, a rate of 35% achieving a state of disease control (i.e., Arm B) is 
considered to be highl y significant in SLE care. The assumed 10% responder rate in 
Arm A (control) at 52 weeks was estimated based on exploratio n of historical data from 
three comparable belimumab Phase 3 trials (IV: C1056 [BLISS -76] and C1057 
[BLISS -52] and SC: BEL112341) in patients with SL E, albeit with some significant 
differences from this study  in protocol inclusion criteria, control of back ground therap y 
for SL E, SLEDAI -2K derivation and treatment failure rules. The estimated Arm A 
2016N272781_11 CONFIDENTIA L
205646
94(control) response rates based on data from previous belimumab Phase 3 studies ranged 
from 3.3% (C1056), 7.3% (C1057), and 8.3% (BEL 112341). It is appreciated tha t these 
rates are derived from studies that did not include a forced steroid or immunosuppressant 
taper. Due to the limitations of the historical data and therefore the likel y imprecision of 
the estimated responder rates, a more conservative estimate of th e assumed belimumab 
monotherap y arm of 10% is being used for sample size calculations.
Assuming a 10% control responder rate and [ADDRESS_658687] (MDE) at p -value <0.05 is a 
11% improveme nt (i.e., an observed improvement with the combination of 1 1% or more 
would give a p -value <0.05).
Sample Size Sensitivity
A sample size sensitivity  anal ysis was conducted on the primary  endpoint, to investigate 
the impact on power if the assumed underly ing control response rate deviates from 10% 
or the treatment difference deviates from 25%. The results of these anal yses are display ed 
in Table 5. 
Table 5 Power if the Underly ing Response Rat es Vary from 10% (Control) 
and 35% (Combination)a
Control Rate (Arm A) Combination Rate (Arm B) Power
5% 30% 99%
15% 40% 97%
10% 25% 75%
10% 30% 93%
10% 40% 99%
a. All calculations assume a 5 % level of significance, N= 70 (control), N=1 40 (combination).
10.3. Populations for A nalyses
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF.
Randomized All participants who are randomized. This population will be comprised of 
participan ts according to the treatment that a participant was randomized to 
receive, regardless of the actual treatment received.
Intent -To-Treat 
(ITT)All randomized participants who received at least one dose of study treatment. 
This population will be comprised of participants according to the treatment that 
a participant was randomized to receive, regardless of the actual treatment 
received.
Modified Intent - Arm A&B: All randomized participants who received at least one dose of study 
2016N272781_11 CONFIDENTIA L
205646
95Population Description
To-Treat (MITT) treatment will be included.
Arm C: All randomized participants who received at least one dose of study 
treatment and for whom their independent blinded assessor was not potentially 
unblinded (i.e. ,enrolled after 07SEPT 2018) will be included.
This population will be comprised of participants according to the treatment that 
a participant was randomized to receive, regardless of the actual treatment
received.
Per-Protocol 
(PP)All randomized participants who receive at least one dose of study treatment 
excluding par ticipants with major protocol deviations with potential to impact 
efficacy assessments.
All further populations to be used for the assessment of health outcomes, biomarkers and 
pharmacokinetics data will be defined in the RAP.
10.4. Statistical A nalyses
Follow ing an assessment of the impact of COVID -19 on the planned estimands, it may  be 
necessary  to update existing estimands or add new estimands. Where required, details of 
these anal yses will be included in the RAP.
10.4.1. Efficacy  Analyses
Unless otherwise stated, t he primary  and key  secondary  efficacy  endpoints will be 
conducted using the:
MITT population
Blinded independent assessors SL EDAI -2K data
Endpoint Statistical Analysis Methods
Primary Endpoint: The proportion of participants with a state of disease contro l defined 
as a SLEDAI 2K -score ≤2, achieved without immunosuppressants and with 
corticosteroids at a prednisone equivalent dose of 5mg/day at Week 52. (Arm B: 
combination vs Arm A control)
Analysis: The proportion of subjects achieving a treatment respon se (as defined 
for the primary endpoint) at Week 52 will be compared between Arm B 
(combination) vs Arm A (control) using a logistic regression model. The 
independent variables in the model will include treatment group, baseline 
SLEDAI -2K score ( 9 vs. 10mg/day), immunosuppressant use at baseline 
(immunosuppressant use vs. no use), and baseline corticosteroid dose 
2016N272781_11 CONFIDENTIA L
205646
96Endpoint Statistical Analysis Methods
(prednisone equivalent 10 mg/day vs. 10 mg/day). If any factor fails to 
converge it will be removed from the logistic model. If the logistic model fails to 
converge, e.g., due to a small number of responders, the primary endpoint will be 
analyzed using a Fishers exact test. 
Missing data for the primary endpoint will be handled as follows:
The study is designed to continue to collect data for p articipants who 
prematurely discontinue from their randomized treatment. All data on the 
primary endpoint collected for these participants will be included in the 
primary analysis, irrespective of whether they are classified as ‘on -treatment ‘ 
or not. For participants who withdraw prematurely from study treatment and 
for whom subsequent collection of data is not possible, it will be assumed for 
the primary analysis that they are treatment failures. A dropout/treatment 
failure = non -responder (DO/TF=NR) anal ysis will be used, therefore no 
missing data will be assumed as all participants will be classed as either a 
non-responder or responder. The basic premise of the DO/TF=NR analysis is 
that a participant meeting any of treatment failure criteria defined belo w (prior 
to Week 52), will be considered a treatment failure and thus counted as a 
non-responder in the statistical analysis:
Received protocol prohibited medication, including non -study rituximab, 
prior to Week 52;
Received immunosuppressants after Week 4 ;
Received a prednisone equivalent corticosteroid dose of >5 mg/day after 
Week 26;
Withdrew from the study prior to Week 52.
Sensitivity Analysis: Sensitivity analyses will be defined in the RAP and will 
explore the impact of missing data and treatment fa ilure imputation. 
Secondary
(First Major)Endpoint :The proportion of participants with a state of clinical remission defined 
as a Clinical SLEDAI -2K score =0, achieved without immunosuppressants and 
corticosteroids at a prednisone equivalent dose of 0 m g/day at Week 64. (Arm B: 
combination vs Arm A control)
Note: For purposes of theMajor Secondary Endpoint, Clinical SLEDAI -2K is 
scored similar to the SLEDAI -2K but exclud esserological activity scores , i.e., anti -
dsDNA positivity and/or hypocomplementemi a.
Analysis: The proposed statistical analyses planned for the primary endpoint will 
be repeated for the first major secondary endpoint. The following treatment failure 
criteria (prior to Week 64) will be used:
1. Received protocol prohibited medication, inc luding non -study rituximab, prior 
to Week 64;
2. Received immunosuppressants after Week 4;
2016N272781_11 CONFIDENTIA L
205646
97Endpoint Statistical Analysis Methods
3. Received a prednisone equivalent corticosteroid dose of >5 mg/day after 
Week 26;
4. Received open -label belimumab in the Week 52 to Week 64 period;
5. Withdrew from the study prior to Week 64.
Secondary
(Second 
Major)Endpoint: The proportion of participants with a state of disease control defined 
as a SLEDAI -2K score 2, achieved without immunosuppressants and with 
corticosteroids at a prednisone equivalent dose of 5mg/day at Week 104.
Analysis: The proposed statistical analyses planned for the primary endpoint will 
be repeated. The following treatment failure criteria will be used:
1. Received protocol prohibited medication, including non -study rituximab, prior 
to Week 104;
2. Received immunosuppressants after Week 4;
3. Received a prednisone equivalent corticosteroid dose of >5 mg/day after 
Week 26;
4. Received open -label belimumab after Week 52;
5. Withdrew from the study prior to Week 104;
Exploratory An exploratory assessment, using descriptive statistics ,ofthe relative 
performance of Arm A (control) vs standard SLE therapy (Arm C) and Arm B 
(combination) vs. standard SLE therapy (Arm C) will also be conducted using the 
primary and key secondary endpoints. Details, including treat ment failure rules for 
Arm C, will be described in the RAP.
10.4.2. Safety  Analyses
All safet y anal yses will be performed on the ITT Population. 
Endpoint Statistical Analysis Methods
Secondary Descriptive statistics will be used to summarize AEs, SAEs, AEs of special 
interest (AESI), changes in laboratory parameters, and immunogenicity (both anti -
belimumab and anti -rituximab antibodies will be assessed). The frequency of 
laboratory abnormalities will be tabulated by [CONTACT_1570]. The frequency of 
AEs will be tabulated by [CONTACT_11189] (SOC) and preferred term 
and compared between treatment arms.
10.4.3. Other A nalyses
Secondary  Efficacy  (Other), PK, pharmacod ynamic, biomarker ,and PRO exploratory  
analyses will be described in the RAP. 
2016N272781_11 CONFIDENTIA L
[PHONE_10563].4.4. Interim A nalyses
There are no formal planned interim anal yses.
An independent data monitoring committee (IDMC) will review unblinded safet y data on 
an ongoing basis until all participants have completed the 104 week study (after which 
monitoring may  be assumed by  [CONTACT_509477]). The IDMC will include 
physicians with relevant clinical expertise and a statistician, none of whom is affiliated 
with the sponsor. The 1st IDMC data review meeting will occur after approximately  
60participants have been randomized (appr oximately  15 in each of Arms A and C and 
approximately  30 in Arm B) and completed [ADDRESS_658688] participant, whichever is earlier .
After the initial review, the IDMC will review the dat a approximately  every  6 months . 
For coordination with other ongoing IDMC activities, the initial meeting may  be 
scheduled prior this milestone, and then will resume the above described schedule 
(approximately  every  6 months). Ad hoc meetings of the IDMC ca n also be requested as 
needed to review urgent safet y information or AEs. Events to be monitored during the 
safet y review will include at a minimum all SAEs (including deaths, serious psychiatric 
events, and serious infections), Grade 3 and Grade 4 laborat ory abnormalities, 
opportunistic infections (serious and nonserious), malignancies, and 
hypersensitivity /anaph ylactic reactions during the double -blind treatment phase (Year 1) 
and double -blind observational phase (Year 2) for Arms A & B and open -label tre atment 
phase (Years 1 and2) for Arm C . Investigators and I RBs/IECs will be notified of the 
outcome of each IDMC meeting. In addition, the IDMC will receive information within 
72 hours of all SAEs that are life threatening or result in death. Other SAEs , all 
opportunistic infections, irrespective of relationship to study  treatment , and protocol 
specified events (i.e., IgG <250 mg/dL) will be provided to the IDMC bi-weekl y for 
review.
2016N272781_11 CONFIDENTIA L
[PHONE_10564]. REFERENCES
Boumans MJH, Thurlings RM, Gerlag DM, Vos K, Tak PP. Response t o rituximab in 
patients with rheumatoid arthritis in different compartments of the immune sy stem. 
Arthritis Rheum 2011;63(11):3187 -94.
Carubbi F, Alunno A, Cipriani P, Bartoloni E, Ciccia F, Triolo G, et al. Rituximab in 
primary  Sjögren's s yndrome: a ten -year journey . Lupus 2014;23(13):1337 -49.
Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J . Validation of the 
Functional Assessment of Chronic Illness Therapy  Fatigue Scale relative to other 
instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005: 32(5): 811 -9.
Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345(5):340 -50.
De Vita S, Quartuccio L, Salvin S, Pi[INVESTIGATOR_509427] L , Scott CA, Rupolo M, et al. Sequential therap y 
with belimumab followed by  [CONTACT_509478]ögren's s yndrom e associated with B -cell 
lymphoproliferation and overexpression of BAFF: evidence for long -term efficacy . Clin 
Exp Rheumatol 2014;32(4):490 -4.
Frankl yn K, Lau CS, Navarra SV, Louthrenoo W, L ateef A, Hamijoy o L, et al for the 
Asia-Pacific Lupus Collaboratio n. Definition and initial validation of a L upus L ow 
Disease Activity  State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615 -21.
GlaxoSmithKline Document Number 2011N128591_ 04.Belimumab Investigator’s 
Brochure. 12 June 2017.
Gong Q, Ou Q, Ye S, Lee WP, Corneliu s J, Diehl L, et al. Importance of cellular 
microenvironment and circulatory  dynamics in B cell immunotherapy . J Immunol 
2005;174:817 -26. 
Hochberg MC. Updating the American College of Rheumatology  revised criteria for the 
classification of s ystemic lupus e rythematosus. Arthritis Rheum. 1997;40(9):1725.
Kraaij T, Huizinga TW, Rabelink TJ, Teng YK. Belimumab after rituximab as 
maintenance therap y in lupus nephritis. Rheumatology  (Oxford) 2014;53(11):2122 -4.
Lai J -S, Beaumont JL , Ogale S, Brunetta P, Cella D. Validation of the Functional 
Assessment of Chronic Illness Therap y-Fatigue Scale in patients with moderatel y to 
severel y active s ystemic lupus ery thematosus, participating in a clinical trial. J 
Rheumatol 2011;38:672 -9.
Lin W, Seshasay ee D, Lee WP, Caplazi P, McVay S, Suto E, et al. Dual B cell 
immunotherapy  is superior to individual anti -CD20 depletion or BAFF blockade in 
murine models of spontaneous or accelerated lupus. Arthritis Rheum 2015;67(1) 215 -24.
McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahm ad Y, Gordon C, et al. 
Development and validation of a disease -specific health -related quality  of life measure, 
2016N272781_11 CONFIDENTIA L
205646
100the L upusQol, for adults with sy stemic lupus ery thematosus. Arthritis Rheum 2007: 
15;57(6): 972 -9.
Meijer JM, Meiners PM, Vissink A, Spi[INVESTIGATOR_327130], Abdulahad W, Kamminga N, et al. 
Effectiveness of rituximab treatment in primary  Sjögren’s s yndrome: a randomized, 
double -blind, placebo -controlled trial. Arthritis Rheum 2010:62(4):960 -8.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, L atinis KM, Oat es JC, et al. Efficacy  
and safet y of rituximab in moderatel y-to-severely active s ystemic lupus ery thematosus: 
the randomized, double -blind, phase II/III s ystemic lupus ery thematosus evaluation of 
rituximab trial. Arthritis Rheum 2010;62(1):222 -33.
Reilly  MC, Zbrozek AS, Dukes EM. The validit y and reproducibility  of a work 
productivity  and activity  impairment instrument. PharmacoEconomics 1993; 4(5):353 -65.
Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; 2016.
Simonetta F, Allali D, Roux -Lombard P, Chizzolini C . Successful treatment of refractory  
lupus nephritis by  [CONTACT_509479]. Joint Bone Spi[INVESTIGATOR_050]. 
2016: pii: S1297 -319X(16)[ZIP_CODE] -3. doi: 10.1016/j.jbspin.2016.01.008. [Epub ahead of 
print].
Stohl W, Hiepe F, L atinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab 
reduces autoantibodies, normalizes low complement levels, and reduces select B cell 
populations in patients with sy stemic lupus ery thematosus. Arthritis Rheum 
2012;64(7):2328 -37.
Tan EM, Cohen A S, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 
revised criteria for the classification of s ystemic lupus ery thematosus. Arthritis Rheum. 
1982;25(11):1271 -7.
Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of
disease burden over five y ears in a multicenter inception sy stemic lupus erythematosus 
cohort. Arthritis Care Res 2012;64:132 -7.
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Key stone E , et al. Safet y of 
the selective costimulation modulator abata cept in rheumatoid arthritis patients receiving 
background biologic and nonbiologic disease -modify ing antirheumatic drugs: A one -year 
randomized, placebo -controlled study . Arthritis Rheum 2006;54(9):2807 -16.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE]. APPENDICES
12.1. Appendix 1 :Abbreviations and Trademar ks
ACR American College Of Rheumatology
ADA Anti-Drug Antibody
AE Adverse Event
AESI Adverse Event of Special I nterest
ANA Anti-Nuclear Antibody
APRIL AProliferation -Inducing Ligand
BAFF B-cell Activating Factor Of The TNF Ligand Family
BLyS B-Lym phocy te Stimulator
BR3 BLySReceptor 3
CNS Central Nervous S ystem
CONSORT Consolidated Standards of Reporting Trials
C-SSRS Columbia -Suicide Severity  Rating Scale
CV Cardiovascular
DBL Data Base Lock
DMC Data Monitoring Committee
dsDNA Double Strand ed Deoxy ribonucleic Acid
eCRF Electronic Case Report Form
FDA US Food and Drug Administration
GLP Good Laboratory  Practice
[COMPANY_004] GlaxoSmithKline
HBC Hepatitis C Virus
HBV Hepatitis B Virus
HCRU Health care resource utilization
HGS Human Genome Scienc es
HSR Hypersensitivity  Reaction
IB Investigator's Brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committees
Ig Immunoglobulin
IgA Immunoglobulin A
IgG Immunoglobulin G
IgM Immunoglobulin M
IM Intramascular
IP Investigational Product
IRB Institutional Review Boards
ITT Intent -to-Treat
IV Intravenous(l y)
IWRS Interactiv e We bResponse Sy stem
mAb Monoclonal Antibody
MAL T Mucosa Associated Lym phoid Tissue
MDE Minimum detectable effect
2016N272781_11 CONFIDENTIA L
205646
102MedDRA Medical Dictionary  for Regulatory  Activities
MITT Modified Intent -to-Treat
MTX Methotrexate
MZ Marginal Zone
NSAID Non-Steroid Anti-Inflammatory  Drug
OI Opportunistic I nfection
PBMC Peripheral Blood Mononuclear Cell
PK Pharmacokinetic(s)
PML Progressive Multifocal Leukoencephalopath y
PP Per-Protocol
PRES Posterior Reversible Encephalopath y Syndrome
PRO Patient Reported Out comes
pSS Primary  Sjögren’s Sy ndrome
PT Prothrombin Time
PTT Partial Thromboplastin Time
RA Rheumatoid Arthritis
RAP Reporting And Anal ysis Plan
RPLS Reversible Posterior Leukoencephalopath y Syndrome
SC Subcutaneous(l y)
SELENA Safety  of Estrogen in Lupus National Assessment Trial
SHL Scandinavian Health L imited
SLE Systemic Lupus Ery thematosus
SLEDAI Systemic Lupus Ery thematosus Disease Activity  Index
SLEDAI -2K Systemic Lupus Ery thematosus Disease Activity  Index [ADDRESS_658689] Characteristics
SOC System Organ Class
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TNF Tumor Necrosis Factor
US [LOCATION_002]
WOCBP Woman of Childbearing Potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_509480] -TB Gold or QuantiFERON -
TB Gold Plus
Rituxan
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].2. Appendix 2:Recommended Corticosteroid Taper Schedule
A two-phase corticosteroid taper will be emplo yed in the study . 
Taper Phase 1 will occur under the direction of the investigator between study  Weeks 12 
and 26 with a target prednisone equivalent corticosteroid dose of 5 mg/day  by [CONTACT_509481] 26. Participants who cannot tolerate prednisone equivalent corticosteroid dose of 
5mg/day  after Week [ADDRESS_658690] 
all efficacy  and safet y assessments. The recommended corticosteroid taper schedule for 
Phase 1 is outlined in Table 6. Common corticosteroid doses and prednisone equivalents 
are presented in Table 7. Adjus tments may  be made for tolerability  at the investigator’s 
discretion.
Table 6 Recommended Oral Corticosteroid Taper 
(Prednisone equivalent dosing)
Study Week Prednisone equivalent dose 
(mg/day)
[ADDRESS_658691] been successfully  
tapered to prednisone equivalent corticosteroid dose of 5 mg/day . In order to attempt to 
discontinu e participants’ corticosteroids a prolonged prespecified taper will be employ ed. 
A decrease of 1 mg/day  on one day  per week is recommended until a participant is 
decreased to 0 mg/day. For example, the first week of this taper a participant who was 
receivi ng a prednisone equivalent corticosteroid dose of 5 mg/day  will receive 4 mg on 
Monday  and 5 mg/day  from Tuesday  through Sunday . In the second week of the taper the 
participant will receive 4 mg on Monday  and Tuesday  and then 5 mg/day  from 
Wednesday  throug h Sunday , etc until the participant is on 0 mg/day . Thus, the 
discontinuation of 5 mg/day  would take 35 weeks to accomplish.
2016N272781_11 CONFIDENTIA L
205646
104Table 7 Common Corticosteroid Equivalent A pproximate Dose (mg) and 
Prednisone -Equivalent Multipl ierFactor
Corticosteroids Equivalent Dose (mg) Prednisone -Equivalent 
Multipl ierFactor
Prednisone 5 NA
Prednisolone 5 1
Triamcinolone 4 1.25
Cortisone 25 0.2
Hydrocortisone 20 0.25
Methy lprednisolone 4 1.25
Betamethasone 0.6 -0.75 8.3 –6.7
Dexamethasone 0.75 6.7
References:
Dixon JS (ed). Second -line agents in the treatment of rheumatic diseases . Informa Health Care, 1991. (456).
Meikle AW , Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and 
dexametha sone on human pi[INVESTIGATOR_2117] -adrenal function. Am J Med 1977;63;[ADDRESS_658692] Handbook of Critical Care . 2nd ed . [LOCATION_001]: Oxford University Press, 2005 .
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].3. Appendix 3: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below)
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female w ith ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s review of participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female part icipants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly  effective method of contraception consistently  and correctly  as described in
Table 8.
2016N272781_11 CONFIDENTIA L
205646
106Table 8 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibition of ovulation b
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulation b
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contra ception associated with inhibition of 
ovulation b
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the part ner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used. 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and 
the preferred and usual lifesty le of the participant.
NOTES: 
a. Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants in clinical studies. 
b. Hormonal contraception may be susceptible to interaction with the standard of care medications, which may 
reduce the efficacy of the contraceptive method. In this case two highly effective methods of contraception should 
be utilized during the treatment period and for at least [ADDRESS_658693] dose of belimumab and/or monthly 
until [ADDRESS_658694] dose of rituximab or placebo, whichever is later. If stricter female or male 
contraception requirements are specified in the country -specific label for in duction and/or maintenance standard of 
care medications, they must be followed.
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highl y sensitive serum pregnancy test.
2016N272781_11 CONFIDENTIA L
205646
107Additional pregnancy  testing during t he treatment period per the SoA and at 
16weeks after the last dose of belimumab and/or monthly  until [ADDRESS_658695] dose of rituximab or placebo, whichever is later, and as required locally .
Pregnancy  testing will be performed whenever a menstru al cy cle is missed or when 
pregnancy  is otherwise suspected.
Pregnancy  testing using a serum sample, with a sensitivity  of 5 mIU/mL will be 
performed and assay ed in the central laboratory  at the Screening Visit. Urine 
pregnancy  test kits provided by  [CONTACT_509482].
Collection of Pregnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  inform ation on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to d etermine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] Generall y, follow -up will not be required for longer than 6 to 
8weeks bey ond the estimated delivery  date.
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy  will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004]
as described in Appendix 4 . While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontan eous reporting. 
Any participant who becomes pregnant while participating will discontinue study  
treatment or be withdrawn from the study . Participants who discontinue study  treatment 
should be encouraged to continue to participate in study  visits in accor dance with the 
SoA (Section 2), especially  all remaining safet y evaluations.
Breast -feeding ([LOCATION_013] only) :Whether rituximab is excreted in human milk is not 
known. However, because maternal IgG is excreted in human milk, and rituximab was 
detectable in milk from lactating monkey s, women should not breastfeed while treated 
with rituximab and for 12 months following rituximab treatment.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].4. Appendix 4:Study  Governance Considerations
Regulatory  and Ethical Considerati ons
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an I RB/IEC by  
[CONTACT_20003] b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to elim inate an immediate hazard to study  participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and p rocedures established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as req uested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study  and for 1 y ear after completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study . 
Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
2016N272781_11 CONFIDENTIA L
[ADDRESS_658696] (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was e nrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the s tudy. 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be inform ed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be e xamined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
Committees Structure
An Independent Data Monitoring Committee (IDMC) will conduct periodic reviews of 
unblinded data to ensure external objective and/or statistical review of safety issues. The 
composition, remit, and procedures of the IDMC are provided in the IDMC Charter (see 
Section 10.4.4 ).
An Independent Adjudication Team , including representatives from Clinical, 
Biostatistics, and Data Management ,will be established before the Week 52data are 
unblinded. This team will participate in the review and adjudicat ion of treatment fail ures, 
AEs of special interest, and protocol deviations in preparation for the Week 52and end of 
study  data base locks (DBLs). After unblinding, only  members of the Independent 
Adjudication Team will continue to participate in the review and adjudication o f 
treatment failures, AEs of special interest, and protocol deviations in preparation for the 
end of study  DBL (unblinded team members will no longer participate in adjudication).
Members of t he Independent Adjudication Team remain blinded until the End of Study
Data Base Freeze (DBF).
2016N272781_11 CONFIDENTIA L
[ADDRESS_658697] the 
opportunity  to review the complete stu dy results at a [COMPANY_004] site or other mutually -
agreeable location. 
[COMPANY_004] will also provide the investigator with the full summary  of the stud y results. The 
investigator is encouraged to share the summary  results with the study  participants, as 
appropriate. [COMPANY_004] will provide the investigator with the randomization codes for their site 
only after completion of the full statistical anal ysis. 
The procedures and timing for public disclosure of the results summary  and for 
development of a manuscript for publication wi ll be in accordance with [COMPANY_004] Policy . 
Data Quality  Assurance
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (e.g., 
laboratory  data). The investigator is responsible for verify ing that data entries 
are accurate and correct by  [CONTACT_227569]. 
The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator m ust permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of t he data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study  is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduc t of this 
study  must be retained by  [CONTACT_1732] 25 yearsfrom the issue of the final 
Clinical Study  Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may  be 
destroy ed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or part y without 
written notification to the sponsor. 
2016N272781_11 CONFIDENTIA L
205646
111Source Documents
Source documents provide evidence for the existence of the pa rticipant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents o r the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, depending on the study . Also, current 
medical records must be available.
Definition of what constitutes source data can be found in th e SRM .
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered close d when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advan ce of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health author ities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  [CONTACT_093]
Discontinuation of further study  treatment development
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].5. Appendix 5:Liver Safety : Required A ctions and Follow -up 
Assessments
Phase III -IV liver chem istry stoppi[INVESTIGATOR_90565] y and evaluate liver event etiology 
Phase III -IV liver chemistry stoppi[INVESTIGATOR_509428]-absolute ALT 8xULN
ALT Increase ALT 5xULN but <8xULN persists for 2 weeks
ALT 3xULN but <5xULN persists for 4 weeks
Bilirubin 1, 2ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) 
INR2ALT 3xULN andINR>1.5, if INR measured
Cannot 
MonitorALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks
ALT 3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic 3ALT 3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hype rsensitivity
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
Immediately discontinue study treatment
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete 
an SAE data collection tool if the event als o 
meets the criteria for an SAE 2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries 
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart participant with study 
treatment unless allow ed per protocol and 
[COMPANY_004] Medical Governance approval is 
granted (refer to Appendix 6 )
If restart is not granted , permanently 
discontinue study treatment and continue Viral hepatitis serology 4
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
Only in those with underlying chronic 
Hepatitis B at study entry (identified by 
[CONTACT_18098] B surface antigen) 
quantitative Hepatitis B DNA and Hepatitis 
delta antibody 5.
Belimumab and rituximab pharmacokinetic 
(PK) within [ADDRESS_658698] dose 6
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
2016N272781_11 CONFIDENTIA L
205646
113participant in the study for any protocol 
specified follow up assessments
MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within 24 
hrs
Monitor participants twice weekly until liver 
chemi stries resolve, stabilize or return to 
within baseline
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessment s within 24-
72 hrs 
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to 
within baselinebilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury , or 
hypersensitivity, on the AE report form
Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal 
remedies, other over the counter 
medications .
Record alcohol use on the liver event 
alcohol intake case report form (CRF) 
page
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.
Serum acetaminophen adduct hi gh 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver injury 
in participants with definite or likely 
acetaminophen use in the preceding week 
[James, 2009]). NOTE: not required in 
China 
Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver 
disease ; complete Liver Imaging and/or 
Liver Biopsy CRF forms.
1.Serum bilirubin fractionation should be performed if te sting is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2.All events of ALT 3xULN andbilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3.New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
2016N272781_11 CONFIDENTIA L
[PHONE_10565].Includes : Hepatitis A IgM antibody ; Hepatitis B surface antigen (HbsAg) and Hepatitis B Core Antibody (IgM); 
Hepatitis C RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, 
obtain heterophile antibody or monospot testing); Hepatitis E IgM a ntibody 
5.If Hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of Hepatitis D RNA virus 
(where needed) [ Le Gal , 2005].
6.PK sample may not be required for participants known to be receiving placebo or non -[COMPANY_004] comparator 
treatments. Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
partici pant’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shippi[INVESTIGATOR_42253].
Phase III -IV liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria –Liver Monitoring Event
Criteria Actions
ALT 5xULN and <8xULN andbilirubin 
<2xULN without symptoms believed to 
be related to liver inj ury or 
hypersensitivity, andwho can be 
monitored weekly for 2 weeks.
OR
ALT 3xULN and <5xULN andbilirubin 
<2xULN without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeks.Notify the [COMPANY_004] me dical monitor within 24 hours of 
learning of the abnormality to discuss participant 
safety. 
Participant can continue study treatment 
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolv e, stabilise or return to 
within baseline 
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If ALT decreases from ALT 5xULN and <8xULN to 
≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of acetaminophen -adduct in adults with acetaminophen overdose 
and acute liver failure. Drug Metab Dispos 2009; 37:1779 -84.
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény  P, Gault E. Quantification of 
hepatitis delta virus RNA in serum by  [CONTACT_90644] -time PCR indicates different 
patterns of virological response to interferon therapy  in chronicall y infected patients. J 
Clin Microbiol. 2005;43(5) :2363 –69. 
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].6. Appendix 6 :Liver Safety  Study  Treatment Restart Guidelines
Restart Following Transient Resolving Liver Stoppi[INVESTIGATOR_509429] y treatment following liver stoppi[INVESTIGATOR_90570] a clear underl ying cause (other than DILI) of the liver event (e.g., biliary  obstruction, 
pancreatic events, hy potension, acute viral hepatitis). Furthermore, restart is not permitted 
following liver stoppi[INVESTIGATOR_509430] .
Approval b y [COMPANY_004] for study treatment restart can be considered where:
Investigator requests consideration for stud y treatment restart if liver chemistries 
have a clear underl ying cause (e.g., biliary  obstruction, hy potension and liver 
chemistries ha ve improved to normal or are within 1.5 x baseline and AL T 
<3xUL N).
Possible study  treatment -induced liver injury  has been excluded by  [CONTACT_90653]. This includes the absence of markers of h ypersensitivity  
(otherwise unexplained feve r, rash, eosinophilia). Where a study  treatment has a 
confirmed genetic marker associated with liver injury , the presence of the marker 
should be excluded. 
There is no evidence of alcoholic hepatitis.
IRB/IEC approval of study  treatment restart has been o btained.
If restart of study treatment is approved by [CONTACT_42388]: 
The participant must be provided with a clear description of the possible benefits and 
risks of study  treatment administration including the possibility  of recurrent, more 
severe liver injury  or death. 
The participant must also provide signed informed consent specifically  for the restart 
of study  treatment. Documentation of informed consent must be recorded in the 
study  file. 
Study  treatment must be administered at the dose specified by [CONTACT_23983]
Participants approved b y [COMPANY_004] for restart of stud y treatment must return to the clinic 
twice a week for liver function tests until stable liver function tests have been 
demonstrated and then standard laboratory  monitoring may  resume as per protocol.
If the participant meets protocol -defined liver function stoppi[INVESTIGATOR_509431], study  treatment should be permanently  discontinued. 
[COMPANY_004] Medical Monitor, and the I RB/IEC, must be informed of the outcome for the 
participant followi ng study  treatment restart. 
[COMPANY_004] must be notified of any  adverse events, as per Appendix 7 . 
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].7. Appendix 7 :Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unin tended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemis try, or urinaly sis) 
or other safet y assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (i.e., not re lated 
to progression of underl ying disease).
Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administra tion even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concom itant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_192682] r to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
2016N272781_11 CONFIDENTIA L
205646
117the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medic al or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hosp italization for signs/sy mptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” oc curred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  mea ns a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and a ccidental trauma (e.g., sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
2016N272781_11 CONFIDENTIA L
205646
118f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_509432] i ntervention to prevent 
one of the other outcomes listed in the above definition. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for aller gic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill o ut the specific CV event page of the CRF for the 
following AEs and SAEs:
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral a rterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascularization
Recording A E and SA E
AE and SAE Recording
 When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of c ompletion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_509433] 
2016N272781_11 CONFIDENTIA L
205646
119requested b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be docu mented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assess ed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as desc ribed in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
 The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying dis ease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Produc t 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has o ccurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  
2016N272781_11 CONFIDENTIA L
205646
120assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting r equirements.
Follow -up of AE and SAE
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully  as possible. This may  
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized f ollow -
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
findings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to [COMPANY_004] withi n 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
 The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailabl e, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours .
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualifi ed sub -investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
entry  into the eCRF.
After the stud y iscompleted at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the SAE coordinator b y telephone.
2016N272781_11 CONFIDENTIA L
205646
121SAE Reporting to [COMPANY_004] via Paper CRF
 If the electroni c system is unavailable for more than 24 hours, then facsimile 
transmission of the SAE paper CRF is the preferred method to transmit this 
information to the SAE coordinator .
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated rep orting time frames.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].8. Appendix 8 :Medical Device Incidents: Definition and 
Procedures for Recording, Evaluating, Follow -up, and 
Reporting
Definition and Documentation of Medical Device Incidents
Definitions of a Medical Device Incident
The detection and doc umentation procedures described in this protocol apply  to all [COMPANY_004] 
medical devices provided for use in the stud y (see Section 7.1.[ADDRESS_658699] of [COMPANY_004] 
medical devices). 
Medical Device Incident Definition
A med ical device incident is any  malfunction or deterioration in the characteristics 
and/or performance of a device as well as an y inadequacy in the labeling or the 
instructions for use which, directly  or indirectl y, might lead to or might have led to 
the death of a participant/user/other person or to a serious deterioration in his/her 
state of health.
Not all incidents lead to death or serious deterioration in health. The nonoccurrence 
of such a result might have been due to other fortunate circumstances or to the 
intervention of health care personnel.
It is sufficient that:
An incident associated with a device happened and
The incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health.
A serious deterioration in st ate of health can include an y of the following:
Life-threatening illness
Permanent impairment of body  function or permanent damage to bod y structure
Condition necessitating medical or surgical intervention to prevent one of the 
above 
Fetal distress, fetal death, or an y congenital abnormality  or birth defects
2016N272781_11 CONFIDENTIA L
205646
123Examples of incidents
A participant, user, caregiver, or healthcare professional is injured as a result of a 
medical device failure or its misuse.
A participant’s stud y treatment is interrupted or com promised by  a medical device 
failure.
A misdiagnosis due to medical device failure leads to inappropriate treatment.
A participant’s health deteriorates due to medical device failure.
Documenting Medical Device Incidents
Medical Device Incident Documenti ng
Any medical device incident occurring during the study  will be documented in the 
participant’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form.
For incidents fulfilling the definition of an A E or an SAE, the appropriate AE/SAE 
CRF page will be completed as described in Appendix 7 .
The form will be completed as thoroughl y as possible and signed b y the investigator 
before transmittal to the [COMPANY_004].
It is very  important that the investigator provides his/her assessment of causality  
(relationship to the medical device provided b y [COMPANY_004]) at the time of the initial report 
and describes an y corrective or remedial actions taken to prevent recurrence of the 
incident.
A remedial action is an y action other than routine maintenance or servicing of a 
medical device where such action is necessary  to prevent recurrence of an incident. 
This includes any  amendment to the device design to prevent recurrence.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].9. Appendix 9 :Clinical Laboratory  Tests
The tests detailed in Table 9will be performed b y the central laboratory . 
Local laboratory  results are required in the event that the central laboratory 
results are not available in time for eit her stud y treatment administration and/or 
response evaluation and for those patients at select sites participating in the 
further research B-cell analy ses. In addition, local laboratory  results are 
recommended if central laboratory  results cannot be obtain ed (perhaps as a 
consequence of disruption associated with the COVID -19 pandemic) .
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 6of the protocol.
Additional tests may  be performed at an y time during the stud y as determined 
necessary  by [CONTACT_43215].
Table 9 Protocol Laboratory  Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet Count RBC Indices:
MCV
MCH
MPV
MCHC
%ReticulocytesWBC count with 
Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
RDW
Hemoglobin
Hematocrit
Clinical 
Chemistry 1BUN Potassium Aspartate 
Aminotransferase
(AST)/ Serum
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)Total and direct 
bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)Total Protein
Glucose -
NonfastingCalcium 
(corrected)Alkaline 
phosphataseeGRF
Routine
UrinalysisStandard Urinalysis Macro and Urinalysis Micro (microscopic examination if 
blood or protein is abnormal)
Specific gravity
pH, Glucose, Protein, Blood, Ketones, Occult Blood, Bilirubin, Nitrite, 
2016N272781_11 CONFIDENTIA L
205646
125Laboratory 
AssessmentsParameters
Leukocyte Esterase by [CONTACT_5230]
Spot Urine (protein :creatinine ratio)
ImmunoglobulinsSerum isotypes: IgG, IgM, IgA
AutoantibodiesANA titer
Anti-dsDNA
aCL 
Beta-2-glycoprotein
Lupus anticoagulant
Extractable nuclear antigens (ENAs)
Serum 
ComplementComplement C3
Complement C4
Urine Drug 
ScreenAmpheta mines, Barbiturates, Benzodiazepi[INVESTIGATOR_1651], Cocaine Metabolites, 
Marijuana Metabolites, Methadone, Opi[INVESTIGATOR_858], Phencyclidine, Propoxyphene, 
Ethanol
GeneticsBlood sample collection
Belimumab PKBlood sample collection
Rituximab PKBlood sample collection
RNA In terferon 
SignatureBlood sample collection
PBMCBlood sample collection
ImmunogenicityBlood sample collection
B Cell SubsetBlood sample collection
B-Cell ReceptorBlood sample collection
BLyS ProteinBlood sample collection
Other Screening 
TestsFollicle-stimulating hormone and estradiol (as needed in women of non -
childbearing potential only)
Serum human chorionic gonadotropin (hCG) pregnancy test (as needed for 
women of childbearing potential)
2016N272781_11 CONFIDENTIA L
205646
126Laboratory 
AssessmentsParameters
Serology (HIV antibody, hepatitis B surface antigen [HB sAg], and hepatitis 
C virus antibody)
PT/PPT
NOTES :
1.Details of liver chemistry stoppi[INVESTIGATOR_21357] -up assessments after liver stoppi[INVESTIGATOR_43191] 8.2and Appendix 5 . All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) >1.5, if INR 
measured, which may indicate se vere liver injury (possible Hy’s Law), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis).
Labdata that could unblind the study  will not be reported to investigative sites or other 
blinded personnel until the study  has bee n unblinded.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].10. Appendix 10 :Genetics
USE/ANALYSIS OF DNA
Genetic variation may  impact a participant’s response to therap y, susceptibility , 
severit y and progression of disease. Variable response to therap y ma y be due to 
genetic determinants that impact drug ab sorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology ; and/or molecular 
subty pe of the disease being treated. Therefore, where local regulations and I RB/IEC 
allow, a blood sample will be collected for DNA anal ysis
DNA samples may  be used for research related to belimumab, rituximab, or any  
concomitant medicines, or sy stemic lupus ery thematosus (SL E) and related diseases. 
They  may  also be used to develop tests/assay s including diagnostic tests related to 
belimum ab, rituximab, or any  concomitant medicines, and SLE. Genetic research 
may consist of the anal ysis of one or more candidate genes or the anal ysis of genetic 
markers throughout the genome [or anal ysis of the entire genome] (as appropriate)
DNA samples may  be analy zed if it is hy pothesized that this may  help further 
understand the clinical data or the disease under study . 
The samples may  be analy zed as part of a multi -study  assessment of genetic factors 
involved in the response to belimumab, rituximab, or st udy treatments of these drug 
classes. The results of genetic anal yses may  be reported in the clinical study  report or 
in a separate study  summary .
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidenti ality. 
The samples will be retained while research on belimumab, rituximab or SLE 
continues but no longer than [ADDRESS_658700] visit or other period as 
per local requirements.
2016N272781_11 CONFIDENTIA L
205646
[ZIP_CODE].11. Appendix 11: A merican College of Rheumatology  (ACR) 
Criteria for SLE
The ACR Criteria for the Classification of Systemic Lupus Erythematosus* 
[Tan, 1982 ;Hochberg, 1997]
Criterion Definition
* The proposed c lassification is based on [ADDRESS_658701] been excluded.
2016N272 781_11 CONFIDENTIA L
205646
[ZIP_CODE].12. Appendix 12:Country -specific requirements
South Korea Investigational Product Labels
Belimumab
Box
CCI - This section contained Clinical Outcome 
Assessment data collection questionnaires or 
indices, which are protected by [CONTACT_509483].
CCI - This section contained Clinical Outcome 
Assessment data collection questionnaires or indices, 
which are protected by [CONTACT_509484].
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by [CONTACT_14561].
2016N272 781_11 CONFIDENTIA L
205646
130Rituximab
Box
Vial
Korea Subjects : In regards to I nclusion criteria 1, only  adult participants as per local 
laws at the time of signing the informed consent will be eligible for inclusion in this 
study .
South Korea: 
Amendment 01/KOR -1: see GlaxoSmithKline Document Number 2016N272781_02.
German y:
Amendment 01/DEU -1: see GlaxoSmithKline Document Number 201 6N272781_03.
Amendment 01/DEU -2: see GlaxoSmithKline Document Number 2016N272781_04.
Argentina:
Amendment 01/ARG- 1: see GlaxoSmithKline Document N umber 2016N272781_05.
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, 
which are protected by [CONTACT_14561].
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or 
indices, which are protected by [CONTACT_14561].
2016N272 781_11 CONFIDENTIA L
205646
[ZIP_CODE].13. Appendix 13: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC).
Amendment 03 (Global)   15-AUG -2019
Overall r ationale for the Amendment: 1) To define dosing interruptions based on 
neutrophil count , 2) Incorporate country -specific changes f or S. Korea, [LOCATION_013]  and 
Argentina into Global Amendment 03 protocol, 3) define an MITT population for 
analysis, and 4) provide clarification of changes and updates on wording related to study  
conduct.
Section # and Name [CONTACT_509489]
2: Sch edule of Activities 
(SoA) Table 1,Table 2,Table
3 and Table 4Listed sample analysis that are 
for exploratory further researchAdd clarity for sites so as not to 
confuse protocol required 
samples with further research 
samples
2: Schedule of Ac tivities 
(SoA) Ta ble1 and Table 3Footnote a–corrected visit 
week that 7 day window begins
Footnote b–corrected early 
withdrawal only for patient who 
discontinue study
Footnote u(Table 1) and 
footnote o (Table 3) –indicated 
samples are optional an d for 
further research purposes from 
select European centersIncorrect in previous version
Incorrectly indicated thi sapplied 
to patients discontinuing IP as 
well in previous version
Clarification for sites regarding 
sample collection for further 
resear ch
2: Schedule of Act ivities 
(SOA), Table 1,Table 2,
Table 3, and Table 4Footnotes n and q (Table 1) 
and footnotes g and I (Table 2), 
footnotes j and l (Table 3) and 
footnotes f and h (Table 4) 
updated text to “suspected “ 
SLE flareClarification to sit es that B -cell 
samples should be collected any 
time flare is suspected.
2SoA Table 2 and Table 4 Footnote d (Table 2) and 
footnote f (Table 4) Include 
Argentina specific r equirement 
for monthly pregnancy testing 
during study year 2 testing
Footnote n (T able 2) indicated 
samples are optional and for 
further research purposes from Incorporation of country specific 
amendments into Amendment 
03 Global Protocol
Clarification for sites regarding 
sample collection for further 
resea rch
2016N272 781_11 CONFIDENTIA L
205646
132Section # and Name [CONTACT_509490]
2 Table 2: SoA Add Further Research 
collection of B -cell subsets at 
Year 2 Unschedued VisitAllow for further research 
sample collection for patients 
who restart belimumab in Year 2
3: Benefit/Risk Assessment Removed text indicating there 
are no publis hed clinical 
research data on use of 
belimumab and rituximabPublished literature is available
3.3.1: Risk Assessment: 
InfectionsIncluded [LOCATION_013] specific 
change: for subjects with 
hypogammaglobulinemia -
changed from IgG <250 mg/dL 
to IgG <400 mg/dL
Neutropenia language updated 
to reflect new value for 
interrupting belimumab 
treatment and potential for 
continued dosingIncorporation of country specific 
amendments into Amendment 
03 Global Protocol
To allow flexibility to continue 
dosing with belimumab in 
instances of neutropenia if 
clinically appropriate
4and Study Synopsis:
Objectives and EndpointsAdded two additional 
secondary efficacy (Other) 
endpoints added based on 
principal investigator 
[INVESTIGATOR_509434] -2KChanged to aid assessment of 
difference between the blinded 
assessor and principal 
investigator
5.1: Overall Design Removed text indicating 
participants who discontinued 
IP but remained in the study 
may have to perform 
unscheduled visitCorrected error in text
5.3: Participant and Stud y 
CompletionRemoved text indicating 
participants who discontinued 
IP but remained in the study 
may have to perform 
unscheduled visitCorrected error in text
6.1:Inclusion criteria Included [LOCATION_013] specific 
change that oral 
cyclophosphamide is not an 
allowed medication in the list of 
concomitant medicationsIncorporation of country specific 
amendments into Amendment 
03 Global Protocol
6.2:Exclusion Criteria Included [LOCATION_013] specific 
changes:Incorporation of country specific 
amendments into Amendment 
2016N272 781_11 CONFIDENTIA L
205646
133Section # and Name [CONTACT_509491] -
changed fr om IgG <250 mg/dL 
to IgG <400 mg/dL added to 
the relevant prior/concomitant 
therapy exclusion criterion 
and
exclusion of subjects who had 
oral cyclophosphamide within 
60days of Day 1 03 G lobal Protocol
[IP_ADDRESS]: Other 
Immunosuppressant AgentsIncluded [LOCATION_013] specific 
change: Deleted oral 
cyclophosphamide, 
2.5mg/kg/day from the list of 
common allowable maximum 
doses at baseline and during 
the studyIncorporation of country specific 
amendments i nto Amendment 
03 G lobal Protocol
7.7.2: Prohibited Medications 
and Non -Drug Therapi[INVESTIGATOR_509435] .
Included [LOCATION_013] specific 
change: Added oral 
cyclophosphamide to list of 
medications prohibited at any 
time during the studyStatement added for clarity.
Incorporation of country specific 
amendments into Amendment 
03 G lobal Protocol
7.7.4 Additional SLE Therapy Added that rescue medications 
should be documented.Ensure collection of this 
information in the source 
documentation.
8.2: Discontinuation of Study 
Treatment and 12.3 
Appendix 3: Contraception 
Guidance and Collection of 
Pregnancy InformationIncluded [LOCATION_013] specific 
change:  Clarification that 
women should not breastfeed 
while treated with rituxim ab 
and for 12 months following 
rituximab treatment.Incorporation of country specific 
amendments into Amendment 
03 G lobal Protocol
8.3: Temporary 
Discontinuation and Restart 
of BelimumabLanguage regarding temporary 
belimumab discontinuation and 
potential restart due to 
neutropenia addedTo describe action to be taken in 
instances of neutropenia 
9.1: Screening Assessment -
Pregnancy TestIncluded Argentina specific 
change: reference to additional  
pregnancy tests during study 
year 2.Incorporation of country specific 
amendments into Amendment 
03 G lobal Protocol
2016N272 781_11 CONFIDENTIA L
205646
134Section # and Name [CONTACT_509492].Statement added for clarity.
9.4: Assessments at 
Unscheduled VisitsRemoved text indicating 
participants who discontinued 
IP but remained i n the study 
may have to perform 
unscheduled visitCorrected error in text
9.6.1 Patient -Reported 
Outcomes Assessments –
Patient InterviewsRemoved reference to the 
Patient Interview 
Communication Plan as plan is 
not implemented by [CONTACT_779].Corrected text .
9.9.[ADDRESS_658702] of future B 
cell research in newly enrolled 
participants at selected sites.
9.13 Biomarkers Added statement on remaining 
sample useAligned with further research 
intent in ICF
9.13.3: B Cell Receptors Added “ further research” Highlight these analyses are 
part of further research
10.3 Populations for 
AnalysesModified Intent -to-Treat 
population added Additional population excluding 
subjects for whom their 
independent blinded assessor 
was potentially unblinde d, to 
facilitate analysis excluding 
these subjects.
12.1 Trademarks Added trademarks. Added trademarks
12.4 Appendix 4: Study 
Governance ConsiderationsChanged wording to clarify the 
adjudication process Corrected text.
12.9 Appendix 9: Clinical 
Labora tory testsAdded wording indicating local 
labs are required for 
participants consented into 
exploratory further B cell 
researchInadvertenly not included in 
previous version .
12.12 Appendix 12: Country -
specifc requirements Korea specific label and 
enrolm ent criteria language 
addedIncorporation of country specific 
amendments into Amendment 
03 G lobal Protocol
Throughout protocol Minor editorial revisions Corrections of typographical 
errors and minor revisions for 
2016N272 781_11 CONFIDENTIA L
205646
135Section # and Name [CONTACT_509493].
Amendment 02 ( KOR -1)  02-FEB-2019
Overall Rationale for the Amendment: To add changes specific for South Korea from 
previously  approved KOR -1 (shown in the table below) to the Global Amendment 02 
Protocol.
Section # and Name [CONTACT_268340] 12: Country -
Specific requirments, 
following addition of new 
appendix in Amendment 02 
(Global), the country -specific 
requirements previously 
found in Appendix 11 in 
Amendment 01/KOR -1 are 
now located in Appendix 12.Include IP label, additional 
clarification about the in clusion 
criteria age as per local 
regulations, provide details of 
IPs supplied for South KoreaCountry specific requirement for 
South Korea
Amendment 02 ( ARG -1)  11-DEC -2018
Overall Rationale for the Amendment: To add changes specific for Argentina from 
previously  approved ARG -1 (shown in the table below) to the Global Amendment 02 
Protocol:
Section # and Name [CONTACT_19523] 2: Schedule of 
Activities (SoA), Table 2 and 
Table 4Include requirement for 
monthly pregnancy testi ng 
during study year 2.Country specific requirement for 
Argentina
Section 9.1: Screening 
Assessment -Pregnancy 
TestInclude reference to additional  
pregnancy tests during study 
year 2.Country specific requirement for 
Argentina
Amendment 02 ( DEU -2)  28-NOV -2018
Overall Rationale for the Amendment: To add changes specific for [LOCATION_013]  from 
previously  approved DEU -1 and DEU -2 (shown in the table below) to the Global 
Amendment 02 Protocol:
Section # and Name [CONTACT_23688]
3.3.1 Ri sk Assessment, 
Mitigation StrategyExclusion criterion for subjects 
with hypogammaglobulinemia Country specific requirement for 
[LOCATION_013]
2016N272 781_11 CONFIDENTIA L
205646
136Section # and Name [CONTACT_23688]
6.2 Exclusion criteria changed from IgG <250 mg/dL 
to IgG <400 mg/dL
8.[ADDRESS_658703] of 
concomitant medicationsCountry specific requirement for 
[LOCATION_013]
[IP_ADDRESS] Other 
Immunosuppresant AgentsDeleted oral 
cyclophosphamide, 
2.5mg/kg/day from the list of 
common a llowable maximum 
doses at baseline and during 
the study
6.2 Exclusion criteria Added oral cyclophosphamide 
within 60 days of Day 1 to the 
relevant prior/concomitant 
therapy exclusion criterion Country specific requirement for 
[LOCATION_013]
7.7.[ADDRESS_658704] of medications prohibited 
at any time during the study
Amendment 02 (Global)   17-NOV -2018
Rationale for the Amendment: 1) To change the timing of the initial analy sis from 
Study  Week 64 to Study  Week 52 to support an earlier submission to regulatory  
authorities, 2) Recruit additional 80 participants into the study  to ensure adequate number 
of evaluable participants, and 3) provide clarification of changes and updates on wording 
related to study  conduct.
Section # and Name [CONTACT_23688]
1 Synopsis
1)Objectives and 
Endpoints;
2)Number of 
Participants1)Removed reference to 
timing of analysis from 
this section.
2)Changed the number 
of participants  Changed for consisten cy.
2016N272 781_11 CONFIDENTIA L
205646
137Section # and Name [CONTACT_23688]
1, Synopsis; 3.3.1 Risk 
Management; 5.1 Overall 
Design; 5.4.1, Selection of 
Controls; 6.1 Inclusion 
Criteria IC #5, Removed reference to “oral” 
antihistamine Increase flexibility to administer 
pre-medication for 
rituximab/rituximab placebo 
treatment arms A or B)
2 Schedule of Activities 
(Table 1 -Table 4)1)Added a new row “Vital 
Signs” for Screening phase
2)Deleted select sample 
collection times for “B Cell 
Receptor”
3)Added new footnote for 
Dispense Belimumab for 
weekly dosing (SC)” 
advising that if Week 4 and 
6 belimumab dosing 
should happen to be 
scheduled for the day of 
the rituximab/rituximab 
placebo infusions, 
whenever possible, the day 
of belimumab dosing 
should be altered within 
the dosing window to occur 
on a day other than that of 
the infusion.
4)Added information to 
monitor subjects including 
vital signs during IV 
Rituximab/ rituximab 
placebo infusion.
5)Updated footnote for “Urine 
Pregnancy Test (WCBP)” 
6)Added footnote to 
“SLEDAI -2K: Blinded 
Assessor” row to 1) clarify 
the need to perform 
Symptom -driven physical 
exam, vital signs same as 
primary or sub investigator 
and 2) indicate the need to 
maintain source 
documentation for the 
physical exam and lab 
report analysis supporting Added for clarity and 
consistency with study 
procedures, added missing 
information. 
Rationale for #2: These samples 
were not part of c entral lab 
sample collection procedures. 
Samples at the deleted time 
points for B Cell Receptor have 
not been collected since the 
sites were informed of this 
change at study start.
2016N272 781_11 CONFIDENTIA L
205646
138Section # and Name [CONTACT_509494] S2K scoring.
7)Added clarification to 
footnotes regarding PBMC 
blood sa mple collection 
and SLE flares
8)Added footnote regarding 
future B cell research
9)Remove additional text at 
end of Table 4.Rationale for #9: This text 
applies only to [COMPANY_004] early phase/ 
Pharmacokinetic studies and 
was not applicable to this study.
4 Objectives and Endpoints Removed reference to timing of 
analysis from this section.Changed for consistency.
5.1 Overall Design, Figure 1 Updated number of participants 
in study schematic Changed for consistency.
5.2 Number of Participants 1) Changed number of 
participants screened: 400 to 
560;
Changes number of 
participants randomized: 200 to 
280
2) Changed number of added 
due to dropout/missing 
data/major protocol dev iations: 
[ADDRESS_658705] of the 
study some participants in Arm 
C (n=29) were inappropriately 
identified on the lab report which 
could have unblinded the 
independent blinded assessors. 
Blinding of Arms A and B was 
not compromised. The in crease 
in the overall sample size from 
200 to 280 randomized 
participants under the same 
randomization ratio (1:2:1) 
increases the number of 
participants enrolled in Arm C 
from [ADDRESS_658706] treatment 
effects and assessment of 
safety.
Assumes approx. 10% -15% 
dropout rate.
6.1 Inclusion criteria IC #2 -Added minimum 
number of criteria required for 
SLE diagnosis (4 or more of Added for clarity and 
consistency with study 
procedures, add missing 
2016N272 781_11 CONFIDENTIA L
205646
139Section # and Name [CONTACT_23688]
11)
IC #3 –Added clarification on 
presence and scoring of 
serological activity
IC #4 –Removed “key on 
historical lab report” that 
explaines positive/negative lab 
results.information.
Note to IC #4: Use serum 
antibody threshold described in 
IC #4 (i.e., ANA titer ≥1:80 and 
anti-dsDNA ≥30 IU/mL) 
6.2 Exclusion Criteria EC #2 -Revised text
EC #2 –Replaced 
Quanti FERON -TB Gold with 
QuantiFERON -TB Gold Plus 
assay
EC #4 –Revised text 
EC #24 –Added examplesAdded for clarity and 
consistency; 
Qiagen has recently developed 
an improved version of its 
Quantiferon -TB Gold assay and 
as a result this assay is being 
disco ntinued. Quantiferon -TB 
Gold assay is being r eplaced by 
“Quantiferon -TB Gold Plus” 
assay that is more specific and 
sensitive. 
7.3 Method of Treatment 
Assignment1)Changed ≥10 mg/day 
to >10 mg/day
2)Changed the number 
of participants1)Corrected information
2)Updated for consistency
7.[ADDRESS_658707] did 
not administer the full dose of 
belimumab due to autoinjector 
malfunction.
Revised text on missed Added for clarity and 
consistency
2016N272 781_11 CONFIDENTIA L
205646
140Section # and Name [CONTACT_23688]
4doses of belimumab.
[IP_ADDRESS] Corticosteroids Added inf ormation about 
corticosteroid dose=0 mg/day 
at study Day 1Added for clarity and 
consistency
8.1 Withdrawal from the 
StudyChanged 52 weeks to 12 
monthsChanged for consistency
8.2 Discontinuation of Study 
TreatmentChanged 52 weeks to 12 
months
Remove D uplicate pregnancy 
language Changed for clarity and 
consistency
9.3 Assessment of 
Scheduled VisitsAdded “deemed treatment 
failure”Added for clarity and 
consistency
9.6.1 Patient -Reported 
Outcomes Assessments
And
Patient InterviewsAdded information on timing of 
PRO assessments
Added information on 
managing SAEs described 
during “Patient Interview”Added for clarity and 
consistency
9.7.6 Pregnancy Added “e.g., Week 58” Added for clarity
9.7.7. Medical Device 
Incidents (Including 
Malfunctions) Added “autoinjector” 
Added cross -reference to 
Section 7.6 Patient ComplianceAdded for clarity and 
consistency
[IP_ADDRESS] Prompt Reporting of 
Medical Device Incidents to 
SponsorAdded information regarding 
formsAdded for clarity
9.7.8 Device Malfunction 
(NEW)Added a new section for 
reporting Device MalfunctionAdded to align with [COMPANY_004] 
procedures.
9.9.6 Suicidal Risk 
MonitoringRemoved “Adverse Event” and 
changed PSRAE to PSRQChanged for consistency
9.[ADDRESS_658708] of future B 
cell research in newly enrolled 
participants at selected sites.
10.1.1 Analysis for Marketing 
ApplicationInitial database lock (DBL) has 
been changed to after Week 
52. The first DB L will include the 
initial 52 week double -blind 
phase (Primary Endpoint)
10.[ADDRESS_658709] changes 
in the sample populationChanged for consistency
11 References Added references for new Added new references
2016N272 781_11 CONFIDENTIA L
205646
141Section # and Name [CONTACT_509495] 
12 Appendices Removed text in Table 7 in 
Appendix: Recommended 
Corticosteroid Taper Schedule 
Updated timing from Week 64 
to Week 52 in Appendix: Study 
Goverance, Committee 
Structure
Added ACR Criteria for SLE 
Update appendix for Country -
specific Requirem ents. Removed text added in error
Changed for consistency
Added new appendix for clarity.
Adedd cross -reference for 
country -specific amendments for 
Korea, [LOCATION_013], and Argentina.
Throughtout protocol Minor editorial and document 
formatting revisionsAdded for clarity
Amendment 01 /ARG -1 -02-JUL-2018
Overall Rationale for the Amendment: The purpose of this amendment is to support 
country -specific requirements and amendments for Argentina.
Section # and Name [CONTACT_19523] 2: Schedule of 
Activities (SoA), Table 2 and 
Table 4Include requirement for 
monthly pregnancy testing 
during study year 2.Country specific requirement for 
Argentina
Section 9.1: Screening 
Assessment -Pregnancy 
TestInclude reference to additional  
pregnancy tests during study 
year 2.Country specific requirement for 
Argentina
Amendment 01/DEU -227-NOV -2017
Overall Rationale for the Amendment: The purpose of this amendment is to support 
country -specific requirements for [LOCATION_013] .
Section # and Name [CONTACT_23688]
6.[ADDRESS_658710] of 
concomitant medicationsCountry specific requirement for 
[LOCATION_013]
[IP_ADDRESS] Other 
Immunosuppresant AgentsDeleted oral 
cyclo phosphamide, 
2.5mg/kg/day from the list of 
common allowable maximum 
2016N272 781_11 CONFIDENTIA L
205646
142Section # and Name [CONTACT_509496]
6.2 Exclusion criteria Added oral cyclophosphamide 
within 60 days of Day 1 to the 
relevant prior/concomitant 
therapy exclusion criterion Country specific requirement for 
[LOCATION_013]
7.7.[ADDRESS_658711] of medications prohibited 
at any time during the study
Amendment 01 /DEU -[ADDRESS_658712] -2017
Overall Rationale for the Amendment: The purp ose of this amendment is to support 
country -specific requirements for [LOCATION_013] .
Section # and Name [CONTACT_23688]
3.3.1 Risk Assessment, 
Mitigation Strategy
6.2 Exclusion criteriaExclusion criterion for subjects 
with hypogammaglobu linemia 
changed from IgG <250 mg/dL 
to IgG <400 mg/dLCountry specific requirement for 
[LOCATION_013]
8.2 Discontinuation of Study 
Treatment
Appendix 3, Contraceptive 
Guidance and Collection of 
Pregnancy InformationClarification that women should 
not breastfeed while treated 
with rituximab and for 
12months following rituximab 
treatment.Consistent with recommendation 
from rituximab EU SmPC
Amendment 01 /KOR -1 22-JUN-2017
Overall Rationale for the Amendment: The purpose of this amendment is to support 
country -specific requirements and amendments for South Korea.
Section # and Name [CONTACT_268340] 11 Include IP label, additional 
clarification about the inclusion 
criteria age as per local 
regulations, provide details of 
IPs supplied for South KoreaCountry specific requirement for 
South Korea
Amendment 01 (Global) 17-APR -2017
2016N272 781_11 CONFIDENTIA L
205646
143Overall Rationale for the Amendment: [COMPANY_004] received additional c omments and 
feedback from EMA and FDA and incorporated the recommendations in
Amendment 1. In ad dition, further changes and updates were identified by [CONTACT_509485] 1 .
Section # and Name [CONTACT_23688]
1 Synopsis Number of 
Participants
5.2 Number of ParticipantsAdding language to allow for 
rando mization of additional 
subjectsAccount for early dropout rate 
and provide sufficient exposure 
in Arms A and B for safety 
assessment
6.2 Exclusion Criteria New criterion: History of 
anaphylactic reaction to 
parenteral administration of 
contrast agents, hu man or 
murine proteins or monoclonal 
antibodies Consistent criteria in subjects 
receiving biological products
7.4 Blinding Updated text for unblinding by 
[CONTACT_509486]
7.4 Blinding 
10.1.1 Analysi s for Marketing 
ApplicationInitial database lock (DBL) has 
been changed to week [ADDRESS_658713] by [CONTACT_16096]. DBL will 
include the initial 52 week 
double -blind phase (Primary 
Endpoint)
8.[ADDRESS_658714] bullet –
Pregnancy will require study 
treatment withdrawal and 
requirement for pregnancy 
testing for rituximab [ADDRESS_658715] dose.  Clarification
[IP_ADDRESS] Corticosteroids for 
Reasons Other Than SLE 
Disease ActivityChange corticosteroid dose 
from 100 mg/day to 60 mg/day 
for 2-3 days FDA recommendation to 
minimize confounding effects of 
high dose corticosteroids
2 Schedule of Activities 
(Table 1 -Table 4)Update definition and 
organization of the tablesAdd clarity and consistency with 
study proced ures, add missing 
information
9.6.1 Patient -Reported 
Outcomes AssessmentsUpdate information about the 
assessment scales.Add clarifying information 
regarding the scales
9.13.3 B Cell Receptors Add more blood sample 
collection times to match those 
for th e B Cell analysisRequired in order to obtain 
absolute numbers of B Cell 
subsets and relative values to all 
B Cells.
10.4.1 Efficacy Analyses Definition of Clinical SLEDAI -
2KClarification
2016N272 781_11 CONFIDENTIA L
205646
144Section # and Name [CONTACT_23688]
10.4.3 Other Analyses Reference to Efficacy Analysis 
(Other)Add missing information
10.4.4 Interim Analyses Update safety review timeline 
and processesReview processes consistent 
with other belimumab studies 
and per changes approved by 
[CONTACT_184160]
12 Appendices Common corticosteroid dose 
and prednisone -equivalent 
multiplie r tableAdd supporting information 
Liver safety study treatment 
restart text updated as per 
updates to [COMPANY_004] guidelinesChange made as per updates to 
[COMPANY_004] guidelines
11 Reference References for new appendix Add new references
Global changes Change namin g convention of 
‘Exit’ visit to ‘Early Withdrawal’ 
visit; 
Replace rituximab 
premedication “analgesia” with 
“acetaminophen or equivalent”;  More accurate description